Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page iv
1600 John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899 CLINICAL REPRODUCTIVE MEDICINE AND SURGERY Copyright © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Health Sciences Rights Department in Philadelphia, PA, USA: phone: (+1) 215 239 3804, fax: (+1) 215 239 3805, e-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://www.elsevier.com), by selecting “Customer Support” and then “Obtaining Permissions.”
Notice Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on his or her own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors/Authors assume any liability for any injury and/or damage to persons or property arising out or related to any use of the material contained in this book.
Library of Congress Cataloging-in-Publication Data Clinical and reproductive medicine and surgery/[edited by] Tommaso Falcone, William W. Hurd p.; cm. ISBN-10: 0-323-03309-1 ISBN-13: 978-0-323-03309-1 1. Generative organs—Diseases. 2. Generative organs, Female—Diseases. 3. Infertility. 4. Human reproduction. I. Falcone, Tommaso. II. Hurd, William W. [DNLM: 1. Genital Diseases, Female. 2. Genital Diseases, Female–surgery. 3. Gynecologic Surgical Procedures–methods. 4. Reproductive Medicine–methods. WP 140 C6403 2007] RC875.C555 2007 616.65—dc22 2006048168
Acquisitions Editor: Rebecca Schmidt Gaertner Developmental Editors: Jennifer Ehlers and Christine Oberle Project Manager: Mary B. Stermel Design Direction: Louis Forgione Marketing Manager: Matt Latuchie Printed in Hong Kong Last digit is the print number: 9
8
7
6
5
4
3
2
1
ISBN-13: ISBN-10:
978-0-323-03309-1 0-323-03309-1
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page v
Contributors Cynthia Abacan, MD Fellow Department of Endocrinology, Diabetes, and Metabolism Cleveland Clinic Cleveland, Ohio Ashok Agarwal, PhD, HCLD Director Andrology Laboratory and Reproductive Tissue Bank; Director Reproductive Research Center; Professor Cleveland Clinic Lerner College of Medicine Case Western Reserve University; Glickman Urological Institute and Departments of Obstetrics and Gynecology, Anatomic Pathology, and Immunology Cleveland Clinic Cleveland, Ohio Raedah Al-Fadhli, MD Fellow Reproductive Endocrinology and Infertility McGill University Montreal, Quebec, Canada Shyam S.R. Allamaneni, MD Resident Department of General Surgery Saint Vincent Catholic Medical Center Jamaica, New York
Marjan Attaran, MD Head Section of Pediatric Gynecology Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio Cynthia Austin, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio Jaswant S. Bal, MD, FRCOG, FACOG Assistant Clinical Professor Department of Obstetrics and Gynecology SUNY Health Science Center Syracuse, New York Sheela Barhan, MD Department of Obstetrics and Gynecology Wright State University School of Medicine Dayton, Ohio Kurt Barnhart, MD, MSCE Associate Professor of Obstetrics and Gynecology and Epidemiology Penn Fertility Care University of Pennsylvania Philadelphia, Pennsylvania
Lawrence S. Amesse, MD, PhD Department of Obstetrics and Gynecology Wright State University School of Medicine Dayton, Ohio
Kshonija Batchu, MD Research Assistant Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology Stanford University School of Medicine Stanford, California
Aydin Arici, MD Professor Department of Obstetrics and Gynecology Yale University School of Medicine New Haven, Connecticut
Mohamed A Bedaiwy, MD Fellow Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
Francisco Arredondo, MD, MPH Department of Obstetrics and Gynecology University Hospitals of Cleveland Cleveland, Ohio
Sarah L. Berga, MD Professor and Chair Department of Obstetrics and Gynecology Emory University School of Medicine Atlanta, Georgia
Khalid Ataya, MD Professor Department of Obstetrics and Gynecology MetroHealth Medical Center Cleveland, Ohio
Charles V. Biscotti, MD Department of Anatomic Pathology Cleveland Clinic Cleveland, Ohio
v
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page vi
Contributors
Linda D. Bradley, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
Miriam Delaney, MD Department of Rheumatic and Immunologic Disease Cleveland Clinic Cleveland, Ohio
Ronald T. Burkman, MD Chairman Department of Obstetrics and Gynecology Baystate Medical Center Springfield, Massachusetts; Deputy Chair and Professor Department of Obstetrics and Gynecology Tufts University School of Medicine Boston, Massachusetts
Nina Desai, PhD Assistant Professor Director In Vitro Fertilization Laboratories Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
John Carey, MD Department of Rheumatic and Immunologic Disease Cleveland Clinic Cleveland, Ohio Allison M. Case, MD Department of Obstetrics and Gynecology Royal University Hospital Saskatoon, Saskatchewan, Canada Robert F. Casper, MD Professor Toronto Center for A.R.T. Toronto, Ontario, Canada SuYnn Chia, MD Department of Endocrinology Cleveland Clinic Cleveland, Ohio Gregory M. Christman, MD Associate Professor of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility University of Michigan Medical School; Associate Professor Reproductive Sciences Program Department of Obstetrics and Gynecology University of Michigan Health System Ann Arbor, Michigan Brian Clark, MD, PhD Professor Department of Obstetrics and Gynecology Magee-Womens Hospital Center for Medical Genetics Pittsburgh, Pennsylvania Damon Davis, MD Resident Department of Urology University of Michigan Medical School Ann Arbor, Michigan
vi
Anne S. Devi Wold, MD Reproductive Research Center Lexington, Massachusetts Michael P. Diamond, MD Associate Chair and Kamran S. Moghissi Professor of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology Wayne State University Detroit, Michigan Richard L. Drake, PhD Professor Department of Education Cleveland Clinic Cleveland, Ohio Janice Duke, MD Department of Obstetrics and Gynecology Wright State University School of Medicine Dayton, Ohio Kristin A. Englund, MD Department of Infectious Disease Cleveland Clinic Cleveland, Ohio Navid Esfandiari, DVM, PhD, ELD, HCLD Director IVF, Andrology and Research Laboratories Toronto Center for A.R.T. Toronto, Ontario, Canada Charles Faiman, MD Department of Endocrinology Cleveland Clinic Cleveland, Ohio Tommaso Falcone, MD Professor and Chairman Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page vii
Contributors
Stephanie Fisher MD, FRCS(C) Assistant Professor Department of Obstetrics and Gynecology University of British Columbia Vancouver, British Columbia, Canada
Gary M. Horowitz, MD Associate Professor Department of Obstetrics and Gynecology Southern Illinois School of Medicine Springfield, Illinois
Maria Fleseriu, MD Assistant Professor Division of Endocrinology, Diabetes, and Clinical Nutrition Oregon Health and Sciences University Portland, Oregon
Elizabeth M. Hurd, RN, BSN Lactation Consultant Miami Valley Hospital Dayton, Ohio
Margo Fluker MD, FRCS(C) Co-Director Genesis Fertility Center; Clinical Professor Department of Obstetrics and Gynecology University of British Columbia Vancouver, British Columbia, Canada Gita Gidwani, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio Jeffrey M. Goldberg, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio James Goldfarb, MD, MBA Clinical Professor Beachwood Family Health Center Cleveland Clinic Beachwood, Ohio Dorothy Greenfeld, MSW, LCSW Associate Professor Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University Fertility Center Yale University School of Medicine New Haven, Connecticut
William W. Hurd, MD, MS Professor of Obstetrics and Gynecology and Community Health Department of Obstetrics and Gynecology Wright State University School of Medicine Dayton, Ohio Shahryar K. Kavoussi, MD, MPH Fellow Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology University of Michigan Health System Ann Arbor, Michigan Elizabeth Ann Kennard, MD Ohio Reproductive Medicine Columbus, Ohio Harry J. Khamis, PhD Director and Professor Statistical Consulting Center Wright State University Dayton, Ohio Peter N. Kolettis, MD Division of Urology University of Alabama at Birmingham Birmingham, Alabama Layne Kumetz, MD House Officer Department of Obstetrics and Gynecology Cedars-Sinai Medical Center Los Angeles, California
Manjula K. Gupta, PhD Department of Clinical Pathology Cleveland Clinic Cleveland, Ohio
William H. Kutteh, MD, PhD, HCLD Division of Reproductive Endocrinology University of Tennessee Memphis, Tennessee
Robert Hemmings, MD OVO Clinic Montreal, Quebec, Canada
Steven R. Lindheim, MD Department of Obstetrics and Gynecology University of Wisconsin Madison, Wisconsin
Melissa Hiner, BS Embryologist Department of Obstetrics and Gynecology University of Michigan Medical School Ann Arbor, Michigan
Hanna Lisbona, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
vii
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page viii
Contributors
James H. Liu, MD Arthur H. Bill Professor and Chair Department of Obstetrics and Gynecology University Hospitals/MacDonald Women’s Hospital; Department of Reproductive Biology Case School of Medicine Cleveland, Ohio J. Ricardo Loret de Mola, MD Department of Obstetrics and Gynecology University Hospitals of Cleveland Cleveland, Ohio Tammy L. Loucks, MPH Director of Clinical Research Department of Obstetrics and Gynecology Emory University School of Medicine Atlanta, Georgia Andrea Magen, MD Department of Radiology Cleveland Clinic Cleveland, Ohio
Pasquale Patrizio, MD, MBe Yale Fertility Center Yale University New Haven, Connecticut Teresa Pfaff-Amesse, MD Assistant Professor, Departments of Pathology and Neuroscience, Cell Biology, and Physiology Wright State University School of Medicine Dayton, Ohio Barry Peskin, MD Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio
Neal Gregory Mahutte, MD Assistant Professor Reproductive Endocrinology and Infertility Dartmouth Medical School Lebanon, New Hampshire
Susanne A. Quallich, NP Nurse Practitioner Division of Andrology and Microsurgery Department of Urology University of Michigan Ann Arbor, Michigan
Beth A. Malizia, MD Fellow Reproductive Endocrinology and Fertility Beth Israel Deaconess Medical Center Boston, Massachusetts
S. Sethu K. Reddy, MD Department of Endocrinology, Diabetes, and Metabolism Cleveland Clinic Cleveland, Ohio
Mohamed F. Mitwally, MD Clinical Assistant Professor Department of Obstetrics and Gynecology Wayne State University Detroit, Michigan
Robert L. Reid, MD Department of Obstetrics and Gynecology Queen’s University Kingston General Hospital Kingston, Ontario, Canada
Dana A. Ohl, MD Professor of Urology Department of Urology Head Division of Andrology and Microsurgery University of Michigan Ann Arbor, Michigan
Ellen S. Rome, MD Department of Pediatric and Adolescent Medicine Cleveland Clinic Cleveland, Ohio
Sophia Ouhilal, MD Assistant Professor Reproductive Endocrinology and Infertility Dartmouth Medical School Lebanon, New Hampshire
viii
John K. Park, MD Division of Reproductive Endocrinology and Fertility Department of Obstetrics and Gynecology Emory University School of Medicine Atlanta, Georgia
Kelly Pagidas, MD Department of Reproductive Medicine Women and Infants Hospital Providence, Rhode Island
Jonathan Ross, MD Glickman Urological Institute Cleveland Clinic Cleveland, Ohio Joseph S. Sanfilippo, MD, MBA Professor, Obstetrics-Gynecology and Reproductive Sciences University of Pittsburgh School of Medicine; Vice Chairman, Reproductive Sciences Division Director, Reproductive Endocrinology Residency Program Director Magee-Womens Hospital Pittsburgh, Pennsylvania
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page ix
Contributors
Erin J. Saunders, MD Clinical Professor Department of Obstetrics and Gynecology Vanderbilt University Nashville, Tennessee Timothy G. Schuster, MD Assistant Professor Department of Urology Division of Andrology and Microsurgery University of Michigan Ann Arbor, Michigan Beata Seeber, MD Department of Obstetrics and Gynecology University of Pennsylvania Philadelphia, Pennsylvania; Department of Gynecologic Endocrinology and Reproductive Medicine Medical University of Innsbruck Innsbruck, Austria Rakesh K. Sharma, PhD Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function Glickman Urological Institute Department of Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio Howard T. Sharp, MD Department of Obstetrics and Gynecology University of Utah Medical Center Salt Lake City, Utah Cristine Silva, BS Embryologist Department of Obstetrics and Gynecology University of Michigan Medical School Ann Arbor, Michigan Gary D. Smith, MD Department of Obstetrics and Gynecology University of Michigan Medical School Ann Arbor, Michigan Jonathon M. Solnik, MD Director Minimally Invasive Gynecologic Surgery Department of Obstetrics and Gynecology Cedars-Sinai Medical Center; Assistant Professor Department of Obstetrics and Gynecology The David Geffen School of Medicine at UCLA Los Angeles, California Michael P. Steinkampf, MD Director Alabama Fertility Specialists Birmingham, Alabama
Thomas G. Stovall, MD Women’s Health Specialists Germantown, Tennessee Holly L. Thacker, MD, FACP Director Women’s Health Center Departments of Internal Medicine and Obstetrics and Gynecology Cleveland Clinic Cleveland, Ohio Geoffrey D. Towers, MD Assistant Professor Department of Obstetrics and Gynecology Wright State University Dayton, Ohio Togas Tulandi, MD, MHCM Professor and Chief of Obstetrics and Gynecology, JGH Department of Obstetrics and Gynecology Milton Leong Chair in Reproductive Medicine McGill University Montreal, Quebec, Canada Meike L. Uhler, MD Clinical Associate Professor Department of Obstetrics and Gynecology Loyola University School of Medicine Maywood, Illinois; Fertility Centers of Illinois Chicago, Illinois Joseph C. Veniero, MD Department of Radiology Cleveland Clinic Cleveland, Ohio Gary Ventolini, MD Associate Professor Department of Obstetrics and Gynecology Wright State University Dayton, Ohio James L. Whiteside, MD Department of Obstetrics and Gynecology Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Mylene W. M. Yao, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology Stanford University School of Medicine Stanford, California
ix
Frontmatter-A03309.qxd
1/29/07
2:44 PM
Page xi
Preface Reproductive medicine and surgery have together evolved into a distinctive field of modern gynecology. The focus of this field is on the identification and restoration of medical and anatomic abnormalities affecting the human reproductive system. Replacement therapy and more extensive surgery are now used only when required, since natural reproductive function is often more effective and safer than the best artificial replacement techniques. The knowledge gained in reproductive sciences over the last half of the 20th century is truly remarkable, and encyclopedic volumes have been written as a result. These distinguished works, however, deal primarily with the medical aspects of reproduction, and little has been written about the surgical aspects. This book is unique in that it includes both medical and surgical treatments, an approach we believe to be more reflective of the clinical practice of reproductive medicine. When compiling this text, we focused on two goals. The first was to provide a comprehensive review of all facets of clinical reproductive medicine and surgery. This review encompasses basic science and pathophysiology, clinical diagnosis and imaging, and medical and surgical treatment approaches. The second, and perhaps more challenging goal, was to create a book designed to be read rather than a reference work to be reserved for consultation. To this end, we diligently organized information provided
by many experts into 53 understandable and consistent chapters. We hope this book serves as a concise knowledge base for those in training and in the early years of practice, especially those planning to take comprehensive examinations on this information. With these goals in mind, we divided the book into seven parts. The first deals with basic science, covering the classic topics of neurophysiology, gametogenesis, fertilization and genetics, as well as anatomy, histology, statistics, and bioethics. The clinical medicine section has three parts that cover pediatric, adolescent and adult clinical reproductive medicine and infertility for both men and women. There are separate sections that cover the broad areas of female contraception and imaging. The final section deals with reproductive surgery performed to maintain fertility. Since visualization is an important part of learning surgery, a number of instructive video presentations on compact disk are included to reinforce the text. We hope that this book weaves together the elements of basic, clinical, and surgical science in such a way that the reader emerges with both a broad understanding of the basic science of reproductive medicine and a comprehensive approach to the reproductive patient. TOMMASO FALCONE BILL HURD
xi
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 1
Section 1 Basic Science Chapter
1
The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle Neal Gregory Mahutte and Sophia Ouhilal
INTRODUCTION The hypothalamus and pituitary gland form a unit that exerts control over a wide range of endocrine organs, including the gonads. This chapter describes the hypothalamic-pituitary-ovarian axis and control of the menstrual cycle, which is modulated by the central nervous system, other endocrine systems, and the environment. Key hormones in the hypothalamic-pituitary-ovarian axis include gonadotropin-releasing hormone (GnRH), folliclestimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone (Table 1-1). Supporting roles are also played by inhibin, activin, follistatin, and endorphins.
THE HYPOTHALAMUS The hypothalamus forms the lower part of the lateral wall and the floor of the third ventricle, and weighs approximately 10 grams. The hypothalamus is typically divided into eight specific nuclei (consistently clustered groups of neurons) and three areas (less clustered, less distinctly demarcated neurons), as illustrated in Figure 1-1. From a reproductive standpoint, the most important of these are the arcuate nucleus and the preoptic area, the principal sites of GnRH-producing neurons.1 The arcuate nucleus is located in the medial basal hypothalamus and is the most proximal of all the hypothalamic nuclei to the optic chiasm and the pituitary stalk. The arcuate nucleus is also the site of dopamine-secreting neurons that function to inhibit pituitary prolactin secretion and neurons that secrete growth hormone-releasing hormone.
Neurosecretory cell products from the hypothalamus, including GnRH, are released into the portal system from the median eminence, a prominence in the pituitary stalk at the floor of the third ventricle. The portal system serves as the major route of communication between the hypothalamus and the anterior pituitary. In contrast, the pituitary stalk (infundibulum) directly connects neuronal cell bodies in the hypothalamus to the posterior pituitary. The pituitary stalk lies immediately posterior to the optic chiasm.
GnRH GnRH is the primary hypothalamic regulator of pituitary reproductive function. Two human forms of GnRH (GnRH-I and GnRH-II) have been identified.2,3 Both are decapeptides and are the products of different genes. At least 20 other types of GnRH have been identified in fish, amphibians and protochordates, but none of these are believed to be present in humans.4,5 GnRH-I was first characterized and synthesized in 1971 by Andrew Schally and Roger Guillemin, an accomplishment for which both men ultimately received the Nobel prize.6–9 The structure of GnRH-I is common to all mammals, and its action is similar in males and females (Fig. 1-2). GnRH-I is synthesized from a much larger, 92-amino acid precursor peptide that contains GnRH-associated peptide.10 GnRH-I then travels along an axonal pathway called the tuberoinfundibular tract to the median eminence of the hypothalamus, where it is released into
Table 1-1 Major Hormones of the Hypothalamic-pituitary-ovarian Axis Hormone
Structure
Gene Location
Major Site(s) of Production
Half-Life
Serum Concentration
GnRH
Decapeptide
8p21-8p11.2
Arcuate nucleus of hypothalamus
2–4 min
N/A
FSH
Glycoprotein with α and β subunits
α: 6q12.2 β: 11p13
Gonadotrophs of anterior pituitary
1.5–4 hr
5–25 mIU/mL
LH
Glycoprotein with α and β subunits
α: 6q12.21 β: 19q12.32
Gonadotrophs of anterior pituitary
20–30 min
5–25 mIU/mL
Estradiol
18-carbon steroid
N/A
Granulosa cells
2–3 hr
20–400 pg/mL
Progesterone
21-carbon steroid
N/A
Theca-lutein cells
5 min
0.1–30 ng/mL
Inhibin
Peptide with α and β subunits Inhibin A= α + βA Inhibin B= α + βB
α: 2q33 βA: 2q13 βB: 7p15
Granulosa cells
30–60 min
A: 10–60 pg/mL B: 10–150 pg/mL
GnRH = gonadotropin-releasing hormone; FSH = follicle-stimulating hormone; LH = luteinizing hormone; N/A = not available
1
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 2
Section 1 Basic Science
DH
PV
DM
PA
AH
VM
Hypothalamus PH
PM LM
MM
SO SC
Arcuate nucleus
Superior hypophyseal artery Optic chiasm Median eminence Middle hypophyseal artery Portal circulation
Inferior hypophyseal artery
Internal carotid artery Anterior pituitary
Sphenoid sinus
Posterior pituitary
Sella turcica
Figure 1-1 Illustration of the hypothalamus, pituitary, sella turcica, and portal system. The arcuate nucleus is the primary site of neurons that produce gonadotropin-releasing hormone (GnRH). GnRH is released from the median eminence into the portal system. The blood supply of the pituitary gland derives from the internal carotid arteries. In addition to the arcuate nucleus, the other hypothalamic nuclei are SO, supraoptic nucleus; SC, suprachiasmatic nucleus; PV, paraventricular nucleus; DM, dorsal medial nucleus; VM, ventromedial nucleus; PH, posterior hypothalamic nucleus; PM, premammillary nucleus; LM, lateral mammillary nucleus; MM, medial mammillary nucleus. The three hypothalamic areas are PA, preoptic area; AH, anterior hypothalamic area; DH, dorsal hypothalamic area.
pyro
Glu 1
Hi
s2 p Tr
3
7
Ser 4
Figure 1-2
2
6
Tyr5
Gly
Leu
Arg8
Pro9
Gly10
NH2
Structure of GnRH-I.
the portal circulation in a pulsatile fashion. The half-life of GnRH-I is very short (2 to 4 minutes) because it is rapidly cleaved between amino acids 5 and 6, 6 and 7, and 9 and 10. Because of its short half-life and rapid dilution in the peripheral
circulation, serum GnRH-I levels are difficult to measure and do not correlate with pituitary action. GnRH-I has three principal actions on anterior pituitary gonadotrophs: (1) synthesis and storage of gonadotropins, (2) movement of gonadotropins from the reserve pool to a point where they can be readily released, and (3) direct secretion of gonadotropins. GnRH-I pulses occur in response to intrinsic rhythmic activity within GnRH neurons in the arcuate nucleus. Pulsatile release of GnRH-I from the median eminence within a critical frequency and amplitude results in normal gonadotropin secretion.11,12 Continuous, rather than pulsatile, exposure to GnRH-I results in suppression of FSH and LH secretion and suppression of gonadotropin gene transcription.13,14
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 3
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle Table 1-2 Menstrual Cycle Variation in LH Pulse Frequency and Amplitude Cycle Phase
Mean Frequency (minutes)
Early follicular
90
Mean Amplitude (mIU/mL) 6.5
Mid-follicular
50
5
Late follicular
60–70
7
Early luteal
100
15
Mid-luteal
150
12
Late luteal
200
8
Table 1-3 Neurotransmitter Effects on GnRH Release Neurotransmitter
Effect
Dopamine
Inhibits GnRH release
Endorphin
Inhibits GnRH release
Serotonin
Inhibits GnRH release
Norepinephrine, epinephrine
Stimulates GnRH release
In the absence of gonadal feedback, the GnRH pulse frequency is approximately once per hour.15 During the menstrual cycle the frequency and amplitude of GnRH pulses vary in response to hypothalamic feedback (Table 1-2).16 In general, the follicular phase is characterized by high-frequency, low-amplitude pulses, and the luteal phase is characterized by lower-frequency, higheramplitude pulses.17,18 However, considerable variability exists both between and within individuals.19 In humans, GnRH-I pulse frequency and amplitude are best approximated by measuring LH pulse frequency and amplitude. GnRH-II is most highly expressed outside of the brain, in tissues that include kidneys, bone marrow, and prostate. This is in contrast to GnRH-I, which is not expressed in high levels outside the brain. Although GnRH-II can induce release of both FSH and LH, it appears to have a wide array of physiologic functions outside the brain including regulation of cellular proliferation and mediation of ovarian and placental hormone secretion.20 Initial attempts in the mid-1990s to identify estrogen receptors in GnRH neurons were unsuccessful.21,22 However, subsequent use of more sophisticated techniques identified estrogen receptors α and β in the arcuate nucleus.23–26 Both receptors mediate estrogen action on GnRH neurons in vivo.27,28 The GnRH gene contains a hormone response element for the estrogen–estrogen receptor complex.29 Transcription of GnRH-I and GnRH-II is differentially regulated by estrogen.30 The regulatory role of estradiol on GnRH is complex. Estrogen inhibits GnRH gene expression/biosynthesis, but secretion of GnRH may be increased, decreased, or unaffected.31,32 The activity of the hypothalamus is further modulated by nervous stimuli from higher brain centers. GnRH neurons exhibit many connections to each other and to other neurons. Some of the neurotransmitters that modulate GnRH secretion are outlined in Table 1-3. The effects of these neurotransmitters help explain the mechanism by which certain physical or clinical conditions may affect the menstrual cycle (Table 1-4).
Table 1-4 Mechanisms for Oligo/amenorrhea in Various Clinical Conditions Hyperprolactinemia
Elevated dopamine suppresses GnRH
Hypothyroidism
Elevated TRH increases prolactin, which in turn increases dopamine which, then suppresses GnRH
Stress
Increased corticotropin (ACTH) results in increased endorphins (both are derived from the same peptide precursor); endorphins suppress GnRH
Exercise
Increased endorphins suppress GnRH
TRH = thyrotropin-releasing hormone; GnRH = gonadotropin-releasing hormone.
Cells that produce GnRH originate embryologically from the olfactory area.33 GnRH neurons, like olfactory epithelial cells of the nasal cavity, have cilia.34 During embryogenesis GnRH neurons migrate from the medial olfactory placode to the arcuate nucleus of the hypothalamus.35 The common origin of GnRH and olfactory neurons is demonstrated by Kallmann’s syndrome, where GnRH deficiency is associated with anosmia. Kallmann’s syndrome is believed to be caused by a variety of gene defects that affect neuronal cell migration.36 The common origin of GnRH and olfactory neurons is also suggestive of the relationship between pheromones and menstrual cyclicity. Pheromones are small airborne chemicals that when secreted externally by one individual may be perceived by other individuals of the same species, producing a change in sexual or social behavior. It is well recognized that women who work or live together often develop synchrony of their menstrual cycles.37 Moreover, it has been shown that odorless compounds from the axillae of cycling women can alter the cycle characteristics of recipient women.38 Presumably, these alterations occur through olfactory GnRH-mediated mechanisms.
The GnRH Receptor The GnRH-I receptor is a G-protein receptor that utilizes inositol triphosphate and diacylglycerol as second messengers to stimulate protein kinase, release of calcium ions, and cyclic adenosine monophosphate (cAMP) activity. The GnRH-I receptor is encoded by a gene on chromosome 14q21.1 and is expressed in many parts of the body outside of the brain, including ovarian follicles and the placenta. In humans it appears that GnRH-II signaling occurs through the GnRH-I receptor.5 Although a GnRH-II receptor is present in many mammalian species, its functional capacity is limited due to a frame shift and a stop codon. GnRH receptors are regulated by many substances, including GnRH itself, inhibin, activin, estrogen, and progesterone. Changes to the amino acid sequence of GnRH can extend its half-life to hours or days and can change its biologic activity from an agonist to an antagonist. All of the GnRH agonists currently available extend their half-life by substitutions at amino acid 6 and sometimes amino acid 10 of native GnRH (Table 1-5). Continuous activation of the GnRH receptor results in desensitization due to phosphorylation and conformational change of the receptor, uncoupling from G proteins, internalization of the receptor via endocytosis, and decreased receptor synthesis.39,40 On administration all GnRH agonists increase gonadotropin secretion (the flare effect). However, after 7 to 14 days GnRH receptor desensitization occurs and pituitary suppression is achieved.
3
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 4
Section 1 Basic Science Table 1-5 Properties of Commercially Available GnRH Agonists
Agonist
Structure and Substitutions at Position 6 and 10
Half-Life
Relative Potency
Route of Administration
GnRH
Native decapeptide
2–4 min
1
IV, SC
Naferelin
Decapeptide 6: Nal for Gly
3–4 hr
200
Intranasal
Triptorelin
Decapeptide 6: Trp for Gly
3–4 hr
36–144
SC, IM depot
Leuprolide
Nonapeptide 6: Leu for Gly 10: NHEt for Gly
1.5 hr
50–80
SC, IM depot
Buserelin
Nonapeptide 6: Ser(OtBu) for Gly 10: NHEt for Gly
1.5 hr
20–40
SC, intranasal
Goserelin
Decapeptide 6: Ser(OtBu) for Gly 10: AzaGly for Gly
4.5 hr
50–100
SC implant
Histrelin
Decapeptide 6: DHis for Gly 10: AzaGly for Gly
50 min
100
SC
that recombines in long portal veins draining down the pituitary stalk to the anterior pituitary, where they break up into another capillary network. The blood supply of the posterior pituitary (neurohypophysis) comes from the middle and inferior hypophyseal arteries. Veins from these arteries drain into the cavernous sinuses, from which they ultimately reach the petrosal sinuses and then the jugular veins. The posterior pituitary is best understood as a continuation of the hypothalamus. The posterior pituitary is a direct downgrowth of nervous tissue from the hypothalamus through the pituitary stalk. The posterior pituitary is composed of glial tissue and axonal termini that secrete oxytocin and arginine vasopressin (AVP, also known as antidiuretic hormone). Oxytocin is synthesized in the paraventricular nucleus of the hypothalamus, whereas AVP is synthesized in the supraoptic nucleus, just above the arcuate nucleus. Oxytocin and AVP pass down the length of the pituitary stalk and are stored in terminal parts of axons in the posterior pituitary. Both oxytocin and AVP consist of nine amino acid residues (nonapeptides). Release of oxytocin and AVP is controlled directly by nervous impulses passing down the axons from the hypothalamus.
The Anterior Pituitary In contrast, GnRH antagonists directly inhibit gonadotropin secretion. Structurally, GnRH antagonists are characterized by multiple amino acid substitutions to the natural GnRH decapeptide. The commercially available GnRH antagonists cetrorelix and ganirelix have large amino acid additions to position 1 of native GnRH. GnRH antagonists compete for and occupy pituitary GnRH receptors, thus competitively blocking endogenous GnRH–GnRH receptor binding. In contrast to GnRH agonists, there is no flare effect with GnRH antagonists. Because receptor loss does not occur, a constant supply of antagonist is necessary to ensure that all GnRH receptors are continuously occupied. Thus, the therapeutic dosage range for antagonists is typically higher than that for agonists (mg versus μg).
THE PITUITARY
4
The pituitary gland measures approximately 15 × 10 × 6 mm and weighs approximately 500 to 900 mg. The pituitary gland lies immediately beneath the third ventricle and just above the sphenoidal sinus in a bony cavity called the sella turcica (Turkish saddle). It consists of anterior and posterior lobes, each having different embryologic origins, functions, and control mechanisms (Fig. 1-3). The secretion of pituitary hormones is controlled primarily by the hypothalamus. However, the activity of the hypothalamus and pituitary are modulated by nervous stimuli from higher brain centers and feedback from circulating hormones. There is no direct nervous connection between the hypothalamus and the anterior pituitary gland. Instead, communication occurs via the hypothalamic-pituitary portal system. The arterial blood supply of the pituitary is derived from branches of the internal carotid artery. The anterior pituitary gland is the most richly vascularized of all mammalian tissues. The blood supply of the anterior pituitary comes from the superior hypophyseal artery. The superior hypophyseal artery forms a capillary network in the median eminence of the hypothalamus
The anterior pituitary arises from an epithelial upgrowth from the roof of the primitive oral cavity (Rathke’s pouch). The anterior pituitary wraps around the posterior pituitary and constitutes two thirds of the volume of the pituitary gland. The portion of Rathke’s pouch in direct contact with the posterior pituitary develops less extensively than the rest of the anterior pituitary and is termed the pars intermedia. The major cell types of the anterior pituitary are outlined in Table 1-6. The anterior pituitary is a classic endocrine gland in that it is composed of secretory cells of epithelial origin supported by connective tissue rich in blood and lymphatic capillaries. In accordance with their active synthetic function the endocrine cells are characterized by prominent nuclei and prolific mitochondria, endoplasmic reticulum, Golgi bodies, and secretory vesicles. Synthesis of gonadotropins takes place in the rough endoplasmic reticulum, after which the hormones are packaged within the Golgi apparatus and stored as secretory granules. In response to GnRH the secretory granules are extruded from the cell membrane. The endothelial lining of capillary sinusoids is fenestrated, facilitating the passage of pituitary hormones into the sinusoids.
Gonadotropins The anterior pituitary secretes two hormones that stimulate the growth and activity of the gonads, FSH and LH. These glycoprotein hormones, termed gonadotropins, work in conjunction to stimulate secretion of steroid hormones from the ovary. FSH
FSH is a glycoprotein with a molecular weight of approximately 29,000 daltons. It consists of both an α and β subunit. The α subunit consists of 92 amino acids stabilized by 5 disulfide bonds and is identical to the α subunit of LH, thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (hCG). The β subunit contains 118 amino acids and 5 sialic acid residues. Neither subunit has any intrinsic biologic activity by itself.
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 5
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle
A D
B
E Figure 1-3 X-ray and T1-weighted magnetic resonance images (MRI) of the pituitary gland. A, Lateral skull film with the sphenoidal sinus and sella turcica. B, Sagittal section demonstrating the relationship between the sphenoidal sinus and the pituitary gland. The normal posterior pituitary is brighter on MRI compared to the anterior pituitary. The sella turcica is not well seen on MRI. C, Sagittal section after administration of gadolinium contrast. Because the pituitary lies outside the blood-brain barrier, both the anterior and posterior pituitary are illuminated with the contrast. D, Coronal section demonstrating the relationship of the pituitary to the optic chiasm and the pituitary stalk. E, Coronal section after gadolinium contrast demonstrating the close proximity of the pituitary to the internal carotid arteries.
C
5
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 6
Section 1 Basic Science Table 1-6 Major Cell Types of the Anterior Pituitary Gland
Cell Type
Appearance on Light Microscopy
Cellular Frequency
Hormone Products
Somatotrophs
Acidophilic
50%
Growth hormone
Lactotrophs
Acidophilic
20%
Prolactin
Corticotrophs
Basophilic
20%
Corticotropin
Thyrotrophs
Basophilic
5%
Thyroid-stimulating hormone (TSH) and free α subunit
Gonadotrophs
Basophilic
5%
Follicle-stimulating hormone (FSH), luteinizing hormone (LH) and free α subunit
The sialic acid content of FSH, LH, TSH, and hCG varies, and these differences are largely responsible for variations in half-life of the glycoprotein hormones. The liver is the major site of clearance for gonadotropins. Sialic acid prevents hepatic clearance; thus, the greater the sialic acid content, the longer the half-life.41 hCG, with 20 sialic acid residues, has the longest half-life (about 24 hours), whereas LH (1 to 2 sialic acid residues) has the shortest half-life (20 to 30 minutes). Addition of sialic acid residues in urinary-derived commercially available gonadotropins (e.g., hMG) is responsible for their longer half-life (30 hours). In gonadotrophs of the anterior pituitary, GnRH signaling leads to transcription of the α and β subunits for both FSH and LH. The GnRH-dependent availability of the β subunits is the rate-limiting step in gonadotropin synthesis. Although both FSH and LH require GnRH stimulation, synthesis of the FSH β subunit also requires the presence of activin.42,43 Follicle-stimulating hormone plays a crucial role in follicle recruitment and selection of the dominant follicle. FSH has a trophic effect on granulosa cells in antral follicles, including the induction of aromatase activity, inhibin synthesis, and expression of LH receptors. A certain amount of FSH (the FSH threshold) is required to induce these changes in a given follicle. FSH must then remain above that threshold for folliculogenesis to continue. In the normal menstrual cycle serum concentrations of FSH begin to rise a few days before the onset of menstruation. FSH levels plateau in the midfollicular phase and decline in the late follicular phase in response to the rise in estrogen and inhibin B. This decline contributes to the dominance of selected follicles over others. FSH levels then peak briefly during the ovulatory gonadotropin surge, after which they decline to their nadir in the luteal phase. LH
6
LH is a glycoprotein with a molecular weight of 29,000 daltons. Like FSH, TSH, and hCG, it consists of both an α and β subunit. The α subunit is identical to the α subunit of FSH, TSH, and hCG. The β subunit of LH has 121 amino acids and 1 to 2 sialic acid residues. Luteinizing hormone is synthesized in gonadotrophs of the anterior pituitary gland. Because it contains fewer sialic acid residues than FSH, LH is rapidly cleared from the circulation by the liver and kidney. For this reason LH is rapidly biosynthesized,
and LH pulses occur at higher amplitude than those of FSH. It is believed that the pituitary content of LH is turned over 1 to 2 times per day. Serum LH levels begin to rise a few days before the onset of menstruation. They increase very gradually during the follicular phase. Unlike FSH, serum LH values rise in the late follicular phase, surpassing FSH values around cycle day 9 or 10. The LH surge at midcycle is followed by a steady decline to their nadir in the midluteal phase.
FSH and LH Receptors The actions of both LH and FSH are mediated by G protein receptors on the cell membrane. LH receptors are found exclusively on theca cells in the ovary. Stimulation of these receptors by increased cytochrome P450c17 enzyme activity (17-hydroxylase and 17,20-lyase) in theca cells, resulting in activation of both adenylate cyclase and cAMP-dependent protein kinases and leading to increased production of androstenedione and testosterone. In contrast, FSH receptors are found exclusively on granulosa cells in the ovary. FSH binds to receptors on the cell surface of granulosa cells in antral follicles. Like LH, FSH acts via the cAMP-dependent protein kinase pathway.44 In response to FSH the androgens produced as a result of LH stimulation are then aromatized to estrogens in granulosa cells.
Opioid Modulation of Pituitary Hormones Opioids (i.e., endogenous opiates) are natural occurring sedative narcotics produced in the brain whose structure and function are similar to opium. Opioids include enkephalins, endorphins, and dynorphins; they modulate every pituitary hormone by acting on the hypothalamus. An important action of opioids is to inhibit gonadotropin secretion by suppressing GnRH release.45 Opioid tone is an important regulator of menstrual cyclicity.46-49 Endorphins are at a nadir in the early follicular phase (menstruation) and gradually rise to peak levels in the luteal phase in response to the rise in estrogen and progesterone. It is believed that opioids mediate the negative feedback of ovarian steroids on gonadotropin release, particularly in the luteal phase.50 Endogenous opioids appear to play a central role in hypothalamic amenorrhea. Treatment of women suffering from this condition with an opioid receptor antagonist (e.g., naltrexone) results in the return to ovulatory menstrual patterns and even conception in some cases.51,52 Women with stress-related amenorrhea demonstrate increased hypothalamic corticotropinreleasing hormone and pituitary corticotropin, which manifests as hypercortisolism.53 The corticotropin precursor peptide, proopiomelanocortin, is also the precursor for endorphin synthesis. It is hypothesized that stress-related amenorrhea is the result of GnRH inhibition secondary to increased production of endogenous opioids. Opioids also rise during exercise (“runners’ high”), and this may contribute to hypothalamic amenorrhea in athletes.54,55
Ovarian Peptide Hormone Feedback on Gonadotropin Secretion The ovary secrets two polypeptide hormones that inhibit or stimulate FSH secretion by the anterior pituitary. Inhibin and activin act as opposing nonsteroidal gonadal hormones that
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 7
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle
Inhibin and activin are members of the transforming growth factor-β (TGF-β) superfamily of ligands, which includes müllerian inhibiting substance (MIS; see Chapter 2). Like the gonadotropins, inhibin and activin are comprised of two subunits. Inhibin is comprised of an α and β subunit and has been isolated in two forms containing different β subunits, Inhibin-A and Inhibin-B. Activin is comprised of two beta subunits identical to those found in inhibin. Inhibin is secreted by granulosa cells in response to FSH.56 However, mRNA for inhibin has also been found in pituitary gonadotrophs. Inhibin selectively inhibits FSH but not LH secretion.57 Thus, a negative feedback loop is created where FSH stimulates inhibin and in turn inhibin suppresses FSH. Inhibin B is predominantly secreted in the follicular phase of the menstrual cycle, whereas inhibin A is predominantly secreted in the luteal phase.58 Peak levels of inhibin B in the follicular phase are in the range of 50 to 100 pg/mL. Peak levels of inhibin A in the luteal phase are between 40 and 60 pg/mL. Activin is also secreted by granulosa cells. Activin augments the secretion of FSH by the pituitary by enhancing GnRH receptor formation. Activin is also required for synthesis of the FSH β subunit. In the ovary, activin augments FSH action and stimulates production of follistatin by a paracrine effect. These effects of activin are blocked by both inhibin and follistatin. With increased GnRH stimulation, activin is increasingly antagonized by inhibin and bound by follistatin.
Cell Type
Major Steroid Hormone Products
Theca cells
Androgens (androstenedione, DHEA, testosterone)*
Granulosa cells
Estrogens (estradiol, estrone)
Theca-lutein cells
Progestogens (progesterone, 17-hydroxyprogesterone)**
Granulosa-lutein cells
Estrogens (estradiol, estrone)
*Mostly via Δ5 pathway **Via Δ4 pathway
Cholesterol C27 P450scc 3βHSD Pregnenolone C21
Progesterone C21 P450c17
Δ4 pathway
Inhibin and Activin
Table 1-7 Site of Synthesis of Major Steroidogenic Products of the Ovary
17 hydroxypregnenolone C21
Δ5 pathway
regulate FSH synthesis and secretion by the pituitary. They also have paracrine effects within the ovary, where they modulate follicle growth and steroidogenesis. Follistatin is a binding protein that modulates the effects of activin but not inhibin.
17 hydroxyprogesterone C21 P450c17 3βHSD DHEA C19
Androstenedione C19 17βHSD
Aromatase
Follistatin
Follistatin is an activin-binding protein that sequesters activin. Follistatin is produced in the same tissues as activin, including the pituitary, and regulates activin’s local paracrine and autocrine actions. In the circulation, follistatin binds the majority of activin, thereby inhibiting FSH secretion. This suggests that activin’s primary actions are paracrine in nature. Follistatin does not bind inhibin, thus allowing it to act as a conventional endocrine hormone between the ovary and the pituitary in addition to its local ovarian effects.
OVARIAN STEROIDOGENESIS DURING THE MENSTRUAL CYCLE Ovarian steroidogenesis during the menstrual cycle occurs in granulosa and theca cells (Table 1-7 and Fig. 1-4). Before ovulation, theca cells are separated from granulosa cells in the same follicle by a basal membrane. Thus, granulosa cells of preovulatory follicles do not have a blood supply. However, at the time of the LH surge the preovulatory follicle undergoes luteinization with disappearance of the basal membrane and capillary invasion of the granulosa cells. Theca cells become theca-lutein cells, and granulosa cells become granulosa-lutein cells. If pregnancy does not occur, the lifespan of the corpus luteum is fixed at approximately 14 days. After 12to 14 days luteolysis and apoptosis are initiated. The corpus luteum involutes, and
Estrone C18 17βHSD
Testosterone C19
Aromatase
Estradiol C18 Figure 1-4 The Δ5 and Δ4 pathways. The rate-limiting step in steroidogenesis is the conversion of cholesterol to pregnenolone via side chain cleavage (P450scc). In the follicular phase pregnenolone is preferentially converted to androstenedione via the Δ5 pathway involving 17-hydroxypregnenolone and dehydroepiandrosterone (DHEA). In contrast, the corpus luteum preferentially converts pregnenolone to progesterone (Δ4 pathway) via 3β-hydroxysteroid dehydrogenase (3βHSD).
menstruation occurs. Ovarian steroidogenesis then shifts to a new cohort of follicles with their granulosa and theca cells.
Two-Cell Theory The two-cell, two-gonadotropin theory of ovarian steroidogenesis holds that follicular estrogen/androgen production is compartmentalized.59 Ovarian theca cells produce androgens in response to LH. These androgens may then be aromatized to estrogens in
7
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 8
Section 1 Basic Science Table 1-8 Location Specificity of P450c17 and Aromatase Enzyme
Location
Function
P450c17
Theca cells only
Converts 21-carbon steroids (progesterone/pregnenolone) to 19-carbon steroids (androstenedione, DHEA)
Aromatase
Granulosa cells only
FSH
LH Cholesterol
Theca cell
Cholesterol
+
Converts 19-carbon steroids (androstenedione/testosterone) to 18-carbon steroids (estrone, estradiol)
Estrogens Estrogens are 18-carbon steroids that include estradiol (i.e., 17β-estradiol), estrone, and estriol. The most potent estrogen, estradiol, is predominantly secreted by the ovary. Estrone, which is one twelfth as potent as estradiol, is also secreted by the ovary. However, the principal source of estrone is from peripheral conversion from androstenedione. Estriol, which is one eightieth as potent as estradiol, is the principal estrogen formed by the placenta during pregnancy. Estriol is also formed by metabolism of estradiol and estrone by the liver and is the most abundant estrogen found in urine. Estrogen is largely bound to carrier proteins in serum. Approximately 60% of estradiol is bound to albumin, 38% is bound to sex hormone-binding globulin (SHBG), and 2% to 3% is free. It had previously been thought that only the free hormone was active and could enter cells, but recent evidence suggests that hormone transport and hormone availability may be more complex.62 Estrogen Receptors
8
There are two known estrogen receptors, ERα and ERβ. Both contain a steroid-binding domain, a DNA-binding domain, a hinge region, and a transcription-activation functional domain. The negative feedback of estradiol on FSH secretion is a direct effect of estradiol coupled to its receptor repressing transcription of the FSH β subunit.63 Negative feedback of estradiol on FSH may also be modulated by the estrogen-associated decline in pituitary expression of activin.64 Estrogens can enter any cell, but only cells with estrogen receptors will respond to its presence. When estrogens enter susceptible cells, estrogen associates with its receptor in the cell nucleus. This binding then activates the receptor. The DNAbinding domain of the estrogen–ER complex then associates with
P450scc Pregnenolone
LH-R
granulosa cells appropriately stimulated by FSH. FSH receptors are present only on granulosa cells, and early in the follicular phase LH receptors are present only on theca cells.60 The enzyme P450c17 (17-hydroxylase and 17,20-lyase) is only present in theca cells. Thus, only theca cells have the ability to convert 21-carbon steroids to 19-carbon steroids. In contrast, aromatase is only present in granulosa cells. Thus, in the ovary only granulosa cells have the ability to aromatize androgens to estrogens (Table 1-8 and Fig. 1-5). Supporting evidence for the two-cell theory includes the fact that women with hypogonadotropic hypogonadism may develop follicles in response to treatment with recombinant FSH, but do not significantly elevate androgen or estrogen levels unless LH is added to the stimulation regimen.61
StAR
+
P450c17
cAMP
17 hydroxypregnenolone
+
P450c17 DHEA 3βHSD
+
Androstenedione Basement membrane Granulosa cell cAMP
Androstenedione
+
Aromatase Estrone
FSH-R 17βHSD
Estradiol Figure 1-5 The two-cell theory and follicular phase steroidogenesis. Binding of luteinizing hormone (LH) to LH receptors on ovarian theca cells stimulates conversion of cholesterol to androstenedione. Binding of folliclestimulating hormone (FSH) to FSH receptors on granulosa cells then stimulates the aromatization of androgens to estrogens. StAR, steroidogenic acute regulatory protein; scc, side chain cleavage; HSD, hydroxysteroid dehydrogenase.
specific promoter sequences (DNA response elements) and activates gene transcription. Estrogen Metabolism
Serum concentrations of estradiol are less than 50 pg/mL in the early follicular phase. In response to follicle development estradiol levels rise, typically peaking at 200 to 300 pg/mL just before ovulation. Estradiol levels drop at the time of ovulation, then rise again, with a second peak in the midluteal phase reflecting estrogen secretion from the corpus luteum. The liver conjugates estrogens to form glucuronides and sulfates, about 80% of which are then excreted into the urine and 20% of which are excreted in the bile. In the liver, circulating estradiol is rapidly converted to estrone by 17β-hydroxysteroid dehydrogenase. Estrone may then be further metabolized in the
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 9
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle liver to 16α-hydroxyestrone and then estriol. Estriol is then converted to estriol 3-sulfate-16-glucuronide before excretion by the kidney. Some 16α-hydroxyestrone may also be converted to catechol estrogens (i.e., 2-hydroxy or 4-hydroxyestrone). Biologically active catechol estrogens may then be converted to 2-methoxy and 4-methoxy compounds. Catechol estrogens are important because they have been implicated in carcinogenesis. Metabolism of catechol estrogens may generate oxygen free radicals.
Progesterone Progesterone, a 21-carbon steroid, is the principle secretory steroid of the corpus luteum. Progesterone is responsible for the induction of secretory changes that prepare estrogen-primed endometrium for implantation. If implantation occurs, continued progesterone production is necessary for maintenance of the pregnancy. The release of FSH and LH require the continuous pulsatile release of GnRH. The coordinated secretion of FSH and LH control follicle growth, ovulation, and maintenance of the corpus luteum. The release of FSH and LH is both positively and negatively influenced by estrogen and progesterone. Whether estrogen and progesterone stimulate or inhibit gonadotropin release depends on the quantity and duration of exposure to the steroid. At high concentrations progesterone inhibits both FSH and LH secretion by negative feedback on both the hypothalamus and pituitary.65 Progesterone also slows the GnRH pulse generator; hence the decline in GnRH pulse frequency in the luteal phase. However, at low concentrations, and only after previous exposure to estrogen, progesterone stimulates LH release.66 Progesterone Receptors
Progesterone receptors are similar to estrogen receptors in that they contain a steroid-binding domain, a DNA-binding domain, a hinge region, and a transcription-activation functional domain. There are two progesterone receptors, A and B. Receptor B is the positive regulator of progesterone-responsive genes. Binding of progesterone to progesterone receptor A inhibits activity of receptor B. Progesterone causes a depletion of estrogen receptors. This is the mechanism by which progestins protect against endometrial hyperplasia.
Progesterone is rapidly cleared from the circulation by the liver. The liver converts progesterone to pregnanediol. Pregnanediol is then conjugated to glucuronic acid, and pregnanediol glucuronide is excreted in the urine. Measurement of urinary pregnanediol glucuronide can be used as an index of progesterone production.
Androgens Ovarian theca cells secrete a variety of androgens (i.e., 19-carbon steroids), including androstenedione, testosterone, and dehydroepiandrosterone (DHEA). Androstenedione is the principal androgen secreted by ovarian theca cells. Theca cells also possess the enzyme 17β-hydroxysteroid dehydrogenase, which may convert androstenedione to testosterone. In premenopausal women, at least 60% of circulating testosterone is derived from the ovary, by either this conversion or direct secretion. Androstenedione and testosterone can then be aromatized to estrogens in granulosa cells under the influence of FSH. Androstenedione can also be converted to estrone or testosterone in peripheral tissues. Unlike testosterone and dihydrotestosterone, androstenedione does not have high affinity for the androgen receptor. Side chain cleavage of cholesterol to pregnenolone is the starting point and rate-limiting step in steroidogenesis. In the ovary cholesterol side chain cleavage is regulated by LH. Lowdensity lipoprotein (LDL) cholesterol is the principal source of cholesterol for steroidogenesis in the human ovary.67 Increased cAMP production due to LH stimulation of adenylate cyclase increases transcription of LDL receptor mRNA and LDL uptake. cAMP-activated steroidogenic acute regulatory protein then increases the intracellular transport of cholesterol to the inner mitochondrial membrane, where side chain cleavage occurs.68 In the preovulatory follicle the preferred pathway for androgen/ estrogen synthesis involves conversion of pregnenolone to 17-hydroxypregnenolone, the so-called Δ5 pathway (see Fig. 1-4). Ovarian theca cells have the enzymatic capability to convert pregnenolone to androgens, but lack the ability to aromatize androstenedione or testosterone into estrogens. Only granulosa cells, under the influence of FSH, can aromatize androgens to estrogens. In contrast to the preovulatory follicle, the corpus luteum prefers the Δ4 pathway, the initial conversion of pregnenolone to progesterone. Androgen Receptors
Progesterone Metabolism
Throughout the follicular phase serum progesterone concentrations are less than 1 ng/mL. Much of this progesterone is believed to result from adrenal production of pregnenolone and progesterone as a by-product of cortisol and aldosterone synthesis. In the late follicular phase progesterone levels begin to rise as the ovary starts to contribute to progesterone production. The rise in progesterone accelerates markedly after ovulation, and progesterone levels reach 10 to 20 ng/mL in the midluteal phase. If pregnancy does not occur, progesterone levels fall in the late luteal phase and return to levels below 1 ng/mL just before the onset of menstruation. In the circulation, approximately 80% of progesterone is bound to albumin. Another 18% is bound to corticosteroidbinding globulin. About 2.5% is freely circulating, and only about 0.5% is bound to SHBG.
The androgen receptor is similar to the estrogen receptor. It activates target gene expression via a similar sequence of ligand binding, nuclear translocation, DNA binding, and complex formation with coregulators and general transcription factors. Although the androgen receptor is known to play a central role in the development of male sex organs and secondary sexual characteristics, its physiologic roles in female reproduction remain unclear. Recent studies in androgen-deficient animals suggest that androgen receptors play an important role in granulosa cell development.69 These animals also exhibit reduced fertility with defective folliculogenesis, reduced corpus luteum formation, and reduced uterine response to gonadotropins. Androgen Metabolism
Androstenedione is produced in equal amounts by the ovaries and adrenal glands. The serum concentrations mirror estradiol
9
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 10
Section 1 Basic Science levels and range from 0.5 to 3 ng/mL. Androstenedione levels increase in the mid- to late follicular phase and are maximal just before the LH surge. They decline at the time of ovulation, reach a second peak in the midluteal phase, and are lowest around the time of menstruation. Serum testosterone concentrations, in contrast, vary to a much lesser extent during the menstrual cycle and exhibit only a transient periovulatory increase. Testosterone concentrations range from 1.5 to 60 ng/dL.
CONTROL OF THE MENSTRUAL CYCLE Normal menstrual cycles, termed eumenorrhea, normally range in length between 24 to 35 days, with menstrual bleeding lasting 3 to 7 days. The average amount of blood loss is approximately 30 mL.70 Heavy, prolonged, or irregular menses are referred to as abnormal uterine bleeding and are considered in length in Chapter 21. Normal menstrual cycles result from a relatively precise interaction of the hypothalamus, pituitary, and ovaries. Under the influence of pituitary gonadotropins, the ovary undergoes cyclic changes providing for the development and release of a mature oocyte and production of ovarian hormones that prepare the endometrial lining for implantation. LH stimulates androgen production in theca cells; FSH promotes follicle development and aromatization of androgens to estrogens in granulosa cells (see Fig. 1-5). In turn, estrogens lead to proliferation of the endometrial lining and the induction of endometrial receptors for both estrogen and progesterone.71 To understand the menstrual cycle it is helpful to divide it into four phases: the follicular phase, the ovulatory phase, the luteal phase, and the luteal–follicular transition. We concentrate on changes in pituitary and ovarian hormones and the effects that these hormones have on the hypothalamus, pituitary, and ovary.
Follicular Phase The purpose of the follicular phase is to develop a single mature follicle to release a mature oocyte at ovulation. The presence of sufficient FSH also leads to expression of LH receptors on mature granulosa cells of preovulatory follicles. Thus, in the late follicular phase LH can sustain follicular endocrine activity, even in the absence of FSH.72 The follicular phase is variable in duration, but the other three phases are relatively constant, averaging 14 ± 2 days.
granulosa cells can cause upregulation or downregulation of granulosa cell FSH receptors.75 Without functional FSH follicle growth and ovarian estrogen production cannot occur.76 The steady decline in FSH beginning in the midfollicular phase serves to inhibit development of all but the dominant follicle. The dominant follicle remains dependent on FSH and must complete its development in spite of declining FSH levels. Because it has the largest cohort of granulosa cells, it has the largest cohort of FSH receptors and thus is able to grow in the face of insufficient FSH for smaller follicles. Luteinizing hormone levels are stable in the first half of the follicular phase. However, in the second half LH levels rise in response to positive feedback from increasing estrogen. Ovarian Hormones
Estradiol levels rise as the dominant follicle emerges. FSH and estrogen synergistically exert a mitogenic effect on granulosa cells, stimulating their proliferation. This in turn increases the FSH receptor content of the follicle, enhancing the ability of the follicle to respond to FSH and produce estrogen. Curiously, not every granulosa cell must express FSH receptors to respond to the gonadotropin signal. Gap junctions between cells allow cells with receptors to transmit protein kinase activation to their neighbors.77
LH FSH
A Estradiol Inhibin B Inhibin A
B
GnRH
Progesterone
Throughout most of the follicular phase GnRH pulses occur every 60 to 90 minutes. Just before the onset of the LH surge both GnRH pulse frequency and amplitude increase. Gonadotropins
10
FSH levels rise in the early follicular phase due to the lack of negative inhibition from estradiol and inhibin (Fig. 1-6). FSH stimulates follicle growth and estrogen production.73 Through binding of FSH to its receptor, granulosa cells in developing follicles attain the ability to aromatize androstenedione to estrone and testosterone to estradiol. Importantly, receptors for FSH are not detected on granulosa cells until the preantral stage.74 Moreover, both in vitro and in vivo administration of FSH to
2
C
4
6
8
10
12
14 16 18 Cycle day
20
22
24
26
28
30
Figure 1-6 Hormone fluctuations during the menstrual cycle. A, Mean values of follicle-stimulating hormone and luteinizing hormone throughout the cycle. B, Mean values of estradiol and inhibin. C, Mean values of progesterone during the menstrual cycle.
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 11
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle Within the follicular fluid of follicles greater than 8 mm in diameter, the concentration of FSH, estradiol, and progesterone are all extremely high. Within smaller antral follicles, androgens predominate in the follicular fluid. The role of androgens in the follicle is dose-dependent. At low levels androgens provide a substrate for aromatization. However, at higher levels androgens are converted in granulosa cells by 5α-reductase to more active forms such as dihydrotestosterone (DHT) that cannot be aromatized to estrogens.78,79 Granulosa cells have androgen receptors.80 Activation of granulosa cell androgen receptors inhibits aromatase activity and also inhibits FSH induction of granulosa LH receptors.81 Follicles exposed to excessive androgens eventually become atretic.82,83 In contrast, follicles with the highest estrogen-to-androgen ratios and the highest estrogen concentrations are most likely to contain a competent oocyte.84 Rising estradiol levels have a dual role for the follicle. Within the follicle, estradiol promotes granulosa cell growth, aromatization of androgens to estrogens, and, in combination with FSH, induction of development of LH receptors on granulosa cells. However, outside the follicle rising serum estradiol levels have an inhibitory effect on FSH secretion. The resulting decline in FSH levels in the mid- to late follicular phase limits aromatase activity in smaller follicles, leading to higher androgen levels and follicular atresia. Indeed, a reduction in granulosa cell expression of FSH receptors is one of the first signs of follicular atresia. Inhibin B levels begin to rise almost immediately after the rise in FSH levels. By the midfollicular phase the rise in estradiol and inhibin B levels causes FSH levels to decline. Inhibin B levels peak approximately 4 days after the FSH peak.47 In the late follicular phase inhibin B levels fall, mirroring the decline in FSH levels. Progesterone and inhibin A levels are low throughout most of the follicular phase, but both begin to rise in the days immediately preceding ovulation. The rise in progesterone in the late follicular phase mirrors the rise in LH.
Ovulatory Phase The ovulatory phase begins with the midcycle LH surge, which disrupts contacts between granulosa cells and the cumulus oophorus (specialized granulosa cells surrounding the oocyte), causing the oocyte to detach from the follicle wall. The LH surge also induces the resumption of meiosis within the oocyte and release of the oocyte–cumulus complex from the follicle (ovulation). GnRH
GnRH plays a supporting role for the midcycle gonadotropin surge, but it does not trigger the surge.85 There is no change in GnRH pulse frequency during the midcycle gonadotropin surge.86 Rather, ovarian steroid feedback to the primed anterior pituitary triggers the LH surge.87 Whereas estrogen inhibits the secretion of pituitary gonadotropins, it facilitates their synthesis and storage. Estrogen also increases the expression of GnRH receptors.88,89 Thus, in the mid- to late follicular phase each pulse of GnRH is met with a greater gonadotropin response.90,91 When the estradiol level in the circulation meets a critical level for a sufficiently long period of time, the inhibitory action of estradiol on LH secretion changes to a stimulatory one. The LH surge is accompanied by a surge of GnRH in both portal and peripheral blood.92 However, as demonstrated by women with hypo-
gonadotropic hypogonadism treated with a pulsatile GnRH pump, ovulation and pregnancy may occur in the absence of any change in GnRH pulse frequency or amplitude.93 Moreover, the LH surge ends before there is a decline in the GnRH signal.94 Gonadotropins
Both FSH and LH levels peak just before ovulation. The initiation of the gonadotropin surge is dependent on attaining serum estradiol levels of at least 200 pg/mL for at least 2 days.95 In natural cycles this level of estradiol is typically not attained until the dominant follicle reaches a mean diameter of 15 mm.96 During the gonadotropin surge serum LH levels increase tenfold over a period of 2 to 3 days, while FSH levels increase fourfold. Within the dominant follicle the LH surge induces detachment of the oocyte–cumulus complex from the follicle wall. The release of the oocyte–cumulus complex from its follicular wall attachments is accompanied by the resumption of meiosis and release of the first polar body. The LH surge also induces luteinization of the periovulatory follicle. Luteinization refers to functional and morphologic changes within the theca–granulosa cell complex associated with accumulation of a yellow pigment called lutein. The function of the FSH surge is less clearly known, but it is believed to ensure an adequate number of LH receptors on the granulosa layer and to increase production of plasminogen activator, thus increasing the concentration of the proteolytic enzyme plasmin. Ovulation typically occurs from mature follicles 34 to 36 hours after the onset of the LH surge.97 The peak of LH and FSH occurs 10 to 12 hours before ovulation.98 The LH surge usually lasts 48 to 50 hours and must be maintained for at least 14 hours for full maturation of the oocyte to occur.99 The mechanism that turns off the LH surge is unknown. It may simply reflect the depletion in pituitary LH content. Ovarian Hormones
Just prior to ovulation the follicle becomes vascularized.100 Angiogenesis is mediated by LH and a variety of other factors, including vascular endothelial growth factor.101-103 Prostaglandins reach peak levels in the follicular fluid.104 Proteolytic enzymes digest collagen in the follicular wall, resulting in distensibility and thinning just before ovulation.105 Progesterone rises in the follicular fluid. FSH, LH, and progesterone all serve to increase the activity of proteolytic enzymes. There is a rapid increase in follicular fluid volume, but due to increased elasticity there is little to no change in intrafollicular pressure. Finally, a protrusion (stigma) appears on the follicular wall, and it is at this site that ovulation ultimately occurs. Interestingly, spontaneous lueteinization occurs in the absence of LH when granulosa cells are removed from follicles and cultured in vitro. Similarly, cumulus-enclosed oocytes removed from developing follicles before the LH surge will spontaneously resume meiosis.106,107 These findings have led to speculation that substances functioning as oocyte maturation inhibitors or luteinization inhibitors must exist within each follicle. Further support for this hypothesis lies in the fact that cumulus cells lack LH receptors. Estradiol levels fall beginning with the onset of the LH surge. Progesterone and inhibin A levels continue to rise at the time of ovulation. Inhibin B levels surge at the time of ovulation. Luteinization of the follicle begins.
11
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 12
Section 1 Basic Science Luteal Phase The luteal phase is the time when the ovary secrets progesterone, resulting in endometrial receptivity for embryo implantation. LH receptors on granulosa cells result in luteinization, driving the postovulatory follicle to become a corpus luteum. Granulosa cells become granulosa-lutein cells with their own blood supply and begin secretion of both estrogen and progesterone. Release of large amounts of progesterone from the corpus luteum results in secretory endometrial changes and the final development of endometrial receptivity. GnRH and Gonadotropins
GnRH pulse frequency declines but pulse amplitude increases in the luteal phase. Changes in GnRH pulse frequency correlate with the duration of exposure to progesterone; changes in pulse amplitude correlate with progesterone levels.17 Luteinizing hormone and FSH levels reach a nadir during the luteal phase in response to the elevation in estrogen, progesterone, and inhibin A. Nevertheless, function of the corpus luteum is dependent on continued low-level pituitary gonadotropin secretion throughout the luteal phase.108 LH pulses stimulate pulses of progesterone secretion from the corpus luteum.17,109 Moreover, reducing LH pulse frequency and amplitude with a GnRH agonist in the luteal phase shortens the luteal phase itself.110 Ovarian Hormones
After ovulation granulosa and theca cells of the dominant follicle are luteinized. Luteinization involves both chemical and morphologic changes. Granulosa and theca cells hypertrophy and increase steroidogenesis. Moreover, breakdown of the basal membrane that previously separated granulosa and theca cells leads to capillary invasion around granulosa-lutein cells. Granulosa-lutein cells can now make progesterone directly from LDL via side chain cleavage and 3β-hydroxysteroid dehydrogenase. Levels of mRNA for side chain cleavage and 3βhydroxysteroid dehydrogenase are maximal at the time of ovulation and in the early luteal phase.111 The induction of LDL receptor expression in granulosa cells occurs in response to the LH surge and is an early feature of luteinization.112 Progesterone secretion correlates with the number of LH receptors and adenylate cyclase activity.113 Progesterone levels peak during the midluteal phase. Granulosa-lutein cells cannot make estrogens directly from cholesterol because they lack the enzyme P450c17. However, granulosa-lutein cells continue to be able to aromatize thecalutein produced androgens to estrogens, and estrogen levels remain high throughout most of the luteal phase. In granulosa-lutein cells inhibin production switches from inhibin B to inhibin A. Thus inhibin B levels decline to their nadir during the luteal phase, whereas inhibin A levels reach their peak. Secretion of inhibin A by granulosa-lutein cells is controlled by LH.114 Inhibin A, like inhibin B, suppresses FSH levels.115
Luteal–Follicular Transition
12
As the luteal phase continues, progesterone inhibits LH release via a negative feedback loop on the anterior pituitary. During the luteal–follicular transition, subsequent decline in LH causes the
corpus luteum to involute unless the corpus luteum is rescued by production of hCG from an implanting embryo. Involution of the corpus luteum leads to a fall in both estrogen and progesterone production. The endometrium can no longer be maintained and menstruation occurs. The fall of estrogen production then reactivates FSH secretion, initiating a new cycle of follicular development with estrogen secretion and renewed proliferation of the endometrial lining. GnRH
A progressive and rapid increase in GnRH pulse frequency occurs during the luteal–follicular transition. GnRH pulse frequency, as estimated by LH pulse frequency, increases from 3 pulses per 24 hours (midluteal phase) to 14 pulses per 24 hours.18 Gonadotropins
FSH and LH levels rise from their nadir due to the decline in negative feedback from estradiol and inhibin and the rise in activin.116 The rise in FSH initiates recruitment of gonadotropinresponsive follicles for the next menstrual cycle. This recruitment of antral follicles actually begins at least 2 days before the onset of menstrual bleeding. In fact, an increase in FSH bioactivity can be measured back to the midluteal phase.117 During the luteal–follicular transition both inhibin A and B levels are at a nadir.118 In contrast, activin levels begin to increase in the late luteal phase and peak at the time of menstruation.119 Activin plays an important role as gonadotropin responses to GnRH require the presence of activin.43 Ovarian Hormones
In the absence of pregnancy corpus luteum function declines approximately 10 days after ovulation. The exact mechanisms for luteolysis are unclear. Luteolysis involves apoptosis and expression of matrix metalloproteinases.120,121 Luteolysis may also be mediated by nitric oxide.122 Nitric oxide induces apoptosis in the human corpus luteum.123 One of the final signs of luteolysis is ovarian production of prostaglandin F2α, which inhibits luteal steroidogenesis. Thus, unless the corpus luteum is rescued by the hCG of pregnancy, estrogen, progesterone, and inhibin levels fall as the luteal–follicular transition occurs.
PEARLS ●
●
●
●
GnRH-secreting neurons are found predominantly in the arcuate nucleus of the hypothalamus. GnRH is released into the portal circulation at the median eminence in a pulsatile fashion and binds to cell membrane receptors in the anterior pituitary. GnRH pulse frequency and amplitude vary during the menstrual cycle. The follicular phase is characterized by highfrequency (q60–90 minutes), low-amplitude pulses; the luteal phase is characterized by lower-frequency (q2–4 hours), higher-amplitude pulses. The activity of GnRH-releasing neurons is modified by a variety of factors, including neurotransmitters, glycoprotein hormones, and steroid hormones. GnRH has an extremely short half-life (2 to 4 minutes). GnRH agonists and antagonists are characterized by modifications to the native GnRH decapeptide structure that extend its half-life.
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 13
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle ●
●
●
●
The pituitary gland lies in the sella turcica and is connected to the hypothalamus via the pituitary stalk. The blood supply to the pituitary gland comes from the internal carotid artery. Specialized cells within the anterior pituitary (gonadotrophs) secrete FSH and LH in response to GnRH. Gonadotrophs comprise only 5% of all the cells in the anterior pituitary gland. FSH and LH are glycoproteins that share the same α subunit. The half-life of LH (20 to 30 minutes) is much shorter than that of FSH (1 to 4 hours), and LH pulse frequency/amplitude correlates closely with GnRH pulse frequency and amplitude. FSH and LH bind to cell membrane receptors that activate adenylate cyclase, thus raising intracellular cyclic AMP. FSH plays a crucial role in folliculogenesis, as well as inducing aromatization of androgens to estrogens. LH plays a crucial role in ovulation and steroidogenesis. Certain steroidogenic enzymes are specific to certain ovarian cell types. Only theca cells express P450c17, the enzyme
●
●
●
●
that allows conversion of progestins (21-carbon steroids) to androgens (19-carbon steroids). In turn, only granulosa cells, stimulated by FSH, have the ability to aromatize androgens to estrogens (18-carbon steroids). Granulosa cells of preovulatory follicles do not have a direct blood supply; they are separated from theca cells by a basal membrane. In contrast, almost immediately after ovulation capillaries invade the granulosa layer. In theca cells of the preovulatory follicle pregnenolone is preferentially converted to 17-hydroxypregnenolone (Δ5 pathway) on the way to synthesis of androstenedione. In the corpus luteum pregnenolone is preferentially converted to progesterone (Δ4 pathway). Progesterone, 17-hydroxyprogesterone, and inhibin A levels all peak in the luteal phase. The lifespan of the corpus luteum is fixed at approximately 14 days. If the corpus luteum is not rescued by hCG, luteolysis and apoptosis are initiated.
REFERENCES 1. Rance NE, Young WS 3rd, McMullen NT: Topography of neurons expressing luteinizing hormone-releasing hormone gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol 339:573–586, 1994. 2. White RB, Eisen JA, Kasten TL, Fernald RD: Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 95:305–309, 1998. 3. Cheng CK, Leung PCK: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II and their receptors in humans. Endocr Rev 26:283–306, 2005. 4. Morgan K, Millar RP: Evolution of GnRH ligand precursors and GnRH receptors in protochordate and vertebrate species. Gen Comp Endocrinol 139:191–197, 2004. 5. Millar RP, Lu ZL, Pawson AJ, et al: Gonadotropin-releasing hormone receptors. Endocr Rev 25:235–275, 2004. 6. Schally AV, Arimura A, Baba Y, et al: Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 43:393–399, 1971. 7. Schally AV, Arimura A, Kastin AJ, et al: Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science173:1036–1038, 1971. 8. Arimura A, Matsuo H, Baba Y, Schally AV: Ovulation induced by synthetic luteinizing hormone-releasing hormone in the hamster. Science 174:511–512, 1971. 9. Amoss M, Burgus R, Blackwell R, et al: Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochem Biophys Res Commun 44:205–210, 1971. 10. Nikolics K, Mason AJ, Szonyi E, et al: A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 316:511–517, 1985. 11. Knobil E: The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36:53–88, 1980. 12. Mais V, Kazer RR, Cetel NS, et al: The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. J Clin Endocrinol Metab 62:1250–1255, 1986. 13. Belchetz PE, Plant TM, Nakai Y, et al: Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropinreleasing hormone. Science 202:631–633, 1978. 14. Haisenleder DJ, Dalkin AC, Ortolano GA, et al: A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: Evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 128:509–517, 1991.
15. Marshall JC, Dalkin AC, Haisenleder DJ, et al: Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog Horm Res 47:155–189, 1991. 16. Reame N, Sauder SE, Kelch RP, Marshall JC: Pulsatile gonadotropin secretion during the human menstrual cycle: Evidence for altered frequency of gonadotropin-releasing hormone secretion. J Clin Endocrinol Metab 59:328–337, 1984. 17. Filicori M, Santoro N, Merriam GR, Crowley WF Jr: Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 62:1136–1144, 1986. 18. Hall JE, Schoenfeld DA, Martin KA, Crowley WF Jr: Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition. J Clin Endocrinol Metab 74:600–607, 1992. 19. Veldhuis JD, Evans WS, Johnson ML, et al: Physiological properties of the luteinizing hormone pulse signal: Impact of intensive and extended venous sampling paradigms on its characterization in healthy men and women. J Clin Endocrinol Metab 62:881–891, 1986. 20. Kauffman AS: Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour. J Neuroendocrinol 16:794–806, 2004. 21. Sullivan KA, Witkin JW, Ferin M, Silverman AJ: Gonadotropin-releasing hormone neurons in the rhesus macaque are not immunoreactive for the estrogen receptor. Brain Res 685:198–200, 1995. 22. Herbison AE, Horvath TL, Naftolin F, Leranth C: Distribution of estrogen receptor-immunoreactive cells in monkey hypothalamus: Relationship to neurones containing luteinizing hormone-releasing hormone and tyrosine hydroxylase. Neuroendocrinology 61:1–10, 1995. 23. Kallo I, Butler JA, Barkovics-Kallo M, et al: Oestrogen receptor betaimmunoreactivity in gonadotropin releasing hormone-expressing neurones: Regulation by oestrogen. J Neuroendocrinol 13:741–748, 2001. 24. Hrabovszky E, Steinhauser A, Barabas K, et al: Estrogen receptor-beta immunoreactivity in luteinizing hormone-releasing hormone neurons of the rat brain. Endocrinology142:3261–3264, 2001. 25. Hrabovszky E, Shughrue PJ, Merchenthaler I, et al: Detection of estrogen receptor-beta messenger ribonucleic acid and 125I-estrogen binding sites in luteinizing hormone-releasing hormone neurons of the rat brain. Endocrinology 141:3506–3509, 2000. 26. Skynner MJ, Sim JA, Herbison AE: Detection of estrogen receptor alpha and beta messenger ribonucleic acids in adult gonadotropinreleasing hormone neurons. Endocrinology 140:5195–5201, 1999. 27. Abraham IM, Han SK, Todman MG, et al: Estrogen receptor beta mediates rapid estrogen actions on gonadotropin-releasing hormone neurons in vivo. J Neurosci 23:5771–5777, 2003.
13
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 14
Section 1 Basic Science
14
28. Dorling AA, Todman MG, Korach KS, Herbison AE: Critical role for estrogen receptor alpha in negative feedback regulation of gonadotropinreleasing hormone mRNA expression in the female mouse. Neuroendocrinology 78:204–209, 2003. 29. Radovick S, Ticknor CM, Nakayama Y, et al: Evidence for direct estrogen regulation of the human gonadotropin-releasing hormone gene. J Clin Invest 88:1649–1655, 1991. 30. Chen A, Zi K, Laskar-Levy O, Koch Y: The transcription of the hGnRH-I and hGnRH-II genes in human neuronal cells is differentially regulated by estrogen. J Mol Neurosci 18:67–76, 2002. 31. Matagne V, Lebrethon MC, Gerard A, Bourguignon JP: In vitro paradigms for the study of GnRH neuron function and estrogen effects. Ann NY Acad Sci 1007:129–142, 2003. 32. Krajewski SJ, Abel TW, Voytko ML, Rance NE: Ovarian steroids differentially modulate the gene expression of gonadotropin-releasing hormone neuronal subtypes in the ovariectomized cynomolgus monkey. J Clin Endocrinol Metab 88:655–662, 2003. 33. Schwanzel-Fukuda M, Pfaff DW: Origin of luteinizing hormonereleasing hormone neurons. Nature 338:161–164, 1989. 34. Jennes L, Stumpf WE, Sheedy ME: Ultrastructural characterization of gonadotropin-releasing hormone (GnRH)-producing neurons. J Comp Neurol 232:534–547, 1985. 35. Silverman AJ, Jhamandas J, Renaud LP: Localization of luteinizing hormone-releasing hormone (LHRH) neurons that project to the median eminence. J Neurosci 7:2312–2319, 1987. 36. Waldstreicher J, Seminara SB, Jameson JL, et al: The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 81:4388–4395, 1996. 37. McClintock MK: Menstrual synchorony and suppression. Nature 229:244–245, 1971. 38. Stern K, McClintock MK: Regulation of ovulation by human pheromones. Nature 392:177–179, 1998. 39. Suarez-Quian CA, Wynn PC, Catt KJ: Receptor-mediated endocytosis of GnRH analogs: Differential processing of gold-labeled agonist and antagonist derivatives. J Steroid Biochem 24:183–192, 1986. 40. Schvartz I, Hazum E: Internalization and recycling of receptor-bound gonadotropin-releasing hormone agonist in pituitary gonadotropes. J Biol Chem 262:17046–17050, 1987. 41. Morell AG, Gregoriadis G, Scheinberg IH, et al: The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246:1461–1467, 1971. 42. Weiss J, Guendner MJ, Halvorson LM, Jameson JL: Transcriptional activation of the follicle-stimulating hormone beta-subunit gene by activin. Endocrinology 136:1885–1891, 1995. 43. Besecke LM, Guendner MJ, Schneyer AL, et al: Gonadotropinreleasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology 137:3667–3673, 1996. 44. Richards JS, Hedin L: Molecular aspects of hormone action in ovarian follicular development, ovulation, and luteinization. Annu Rev Physiol 50:441–463, 1988. 45. Goodman RL, Parfitt DB, Evans NP, et al: Endogenous opioid peptides control the amplitude and shape of gonadotropin-releasing hormone pulses in the ewe. Endocrinology 136:2412–2420, 1995. 46. Genazzani AR, Genazzani AD, Volpogni C, et al: Opioid control of gonadotrophin secretion in humans. Hum Reprod 8(Suppl 2): 151–153, 1993. 47. Whisnant SC, Havern RL, Goodman RL: Endogenous opioid suppression of luteinizing hormone pulse frequency and amplitude in the ewe: Hypothalamic sites of action. Neuroendocrinology 54:587–593, 1991. 48. Genazzani AR, Petraglia F: Opioid control of luteinizing hormone secretion in humans. J Steroid Biochem 33:751–755, 1989. 49. Ferin M: The role of endogenous opioid peptides in the regulation of the menstrual cycle. J Steroid Biochem 33(4B):683–685, 1989. 50. Maruncic M, Casper RF: The effect of luteal phase estrogen antagonism on luteinizing hormone pulsatility and luteal function in women. J Clin Endocrinol Metab 64:148–152, 1987. 51. Wildt L, Sir-Petermann T, Leyendecker G, et al: Opiate antagonist treatment of ovarian failure. Hum Reprod 8(Suppl 2):168–174, 1993.
52. Wildt L, Leyendecker G, Sir-Petermann T, Waibel-Treber S: Treatment with naltrexone in hypothalamic ovarian failure: Induction of ovulation and pregnancy. Hum Reprod 8:350–358, 1993. 53. Suh BY, Liu JH, Berga SL, et al: Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab 66:733–739, 1988. 54. De Cree C: Endogenous opioid peptides in the control of the normal menstrual cycle and their possible role in athletic menstrual irregularities. Obstet Gynecol Surv 44:720–732, 1989. 55. Harber VJ, Sutton JR: Endorphins and exercise. Sports Med 1:154–171, 1984. 56. Bicsak TA, Tucker EM, Cappel S, et al: Hormonal regulation of granulosa cell inhibin biosynthesis. Endocrinology 119:2711–2719, 1986. 57. Rivier C, Rivier J, Vale W: Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat. Science 234:205–208, 1986. 58. Groome NP, Illingworth PJ, O’Brien M, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401–1405, 1996. 59. McNatty KP, Smith DM, Makris A, et al: The intraovarian sites of androgen and estrogen formation in women with normal and hyperandrogenic ovaries as judged by in vitro experiments. J Clin Endocrinol Metab 50:755–763, 1980. 60. Kobayashi M, Nakano R, Ooshima A: Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the “two-cell, two-gonadotrophin” hypothesis of steroidogenesis in the human ovary. J Endocrinol 126:483–488, 1990. 61. Schoot DC, Coelingh Bennink HJ, Mannaerts BM, et al: Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J Clin Endocrinol Metab 74:1471–1473, 1992. 62. Mendel CM: The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl 13:107–116, 1992. 63. Miller CD, Miller WL: Transcriptional repression of the ovine folliclestimulating hormone-beta gene by 17 beta-estradiol. Endocrinology 137:3437–3446, 1996. 64. Baratta M, West LA, Turzillo AM, Nett TM: Activin modulates differential effects of estradiol on synthesis and secretion of folliclestimulating hormone in ovine pituitary cells. Biol Reprod 64:714–719, 2001. 65. Wildt L, Hutchison JS, Marshall G, et al: On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. Endocrinology 109:1293–1294, 1981. 66. Liu JH, Yen SS: Induction of midcycle gonadotropin surge by ovarian steroids in women: A critical evaluation. J Clin Endocrinol Metab 57:797–802, 1983. 67. Carr BR, MacDonald PC, Simpson ER: The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum. Fertil Steril 38:303–311, 1982. 68. Clark BJ, Soo SC, Caron KM, et al: Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Mol Endocrinol 9:1346–1355, 1995. 69. Hu YC, Wang PH, Yeh S, et al: Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA 101:11209–11214, 2004. 70. Hallberg L, Hogdahl AM, Nilsson L, Rybo G: Menstrual blood loss— a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 45:320–351, 1966. 71. Lessey BA, Killam AP, Metzger DA, et al: Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67:334–340, 1988. 72. Sullivan MW, Stewart-Akers A, Krasnow JS, et al: Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): A role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 84:228–232, 1999. 73. Yong EL, Baird DT, Hillier SG: Mediation of gonadotrophin-stimulated growth and differentiation of human granulosa cells by adenosine-
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 15
Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle
74.
75.
76.
77. 78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
3′,5′-monophosphate: One molecule, two messages. Clin Endocrinol (Oxf) 37:51–58, 1992. Oktay K, Briggs D, Gosden RG: Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 82:3748–3751, 1997. LaPolt PS, Tilly JL, Aihara T, et al: Gonadotropin-induced up- and down-regulation of ovarian follicle-stimulating hormone (FSH) receptor gene expression in immature rats: Effects of pregnant mare’s serum gonadotropin, human chorionic gonadotropin, and recombinant FSH. Endocrinology 130:1289–1295, 1992. Matthews CH, Borgato S, Beck-Peccoz P, et al: Primary amenorrhoea and infertility due to a mutation in the beta-subunit of folliclestimulating hormone. Nat Genet 5:83–86, 1993. Fletcher WH, Greenan JR: Receptor mediated action without receptor occupancy. Endocrinology 116:1660–1662, 1985. McNatty KP, Makris A, Reinhold VN, et al: Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids 34:429–443, 1979. Hillier SG, van den Boogaard AM, Reichert LE Jr, van Hall EV: Intraovarian sex steroid hormone interactions and the regulation of follicular maturation: Aromatization of androgens by human granulosa cells in vitro. J Clin Endocrinol Metab 50:640–647, 1980. Hild-Petito S, West NB, Brenner RM, Stouffer RL: Localization of androgen receptor in the follicle and corpus luteum of the primate ovary during the menstrual cycle. Biol Reprod 44:561–568, 1991. Jia XC, Kessel B, Welsh TH Jr, Hsueh AJ: Androgen inhibition of follicle-stimulating hormone-stimulated luteinizing hormone receptor formation in cultured rat granulosa cells. Endocrinology 117:13–22, 1985. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C: The ovarian androgen producing cells: A review of structure/function relationships. Endocr Rev 6:371–399, 1985. Chabab A, Hedon B, Arnal F, et al: Follicular steroids in relation to oocyte development and human ovarian stimulation protocols. Hum Reprod 1:449–454, 1986. Andersen CY: Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab 77:1227–1234, 1993. Knobil E, Plant TM, Wildt L, et al: Control of the rhesus monkey menstrual cycle: Permissive role of hypothalamic gonadotropinreleasing hormone. Science 207:1371–1373, 1980. Adams JM, Taylor AE, Schoenfeld DA, et al: The midcycle gonadotropin surge in normal women occurs in the face of an unchanging gonadotropin-releasing hormone pulse frequency. J Clin Endocrinol Metab 79:858–864, 1994. Nakai Y, Plant TM, Hess DL, et al: On the sites of the negative and positive feedback actions of estradiol in the control of gonadotropin secretion in the rhesus monkey. Endocrinology 102:1008–1014, 1978. Gregg DW, Nett TM: Direct effects of estradiol-17 β on the number of gonadotropin-releasing hormone receptors in the ovine pituitary. Biol Reprod 40:288–293, 1989. Bauer-Dantoin AC, Weiss J, Jameson JL: Roles of estrogen, progesterone, and gonadotropin-releasing hormone (GnRH) in the control of pituitary GnRH receptor gene expression at the time of the preovulatory gonadotropin surges. Endocrinology 136:1014–1019, 1995. Adams TE, Norman RL, Spies HG: Gonadotropin-releasing hormone receptor binding and pituitary responsiveness in estradiol-primed monkeys. Science 213:1388–1390, 1981. Menon M, Peegel H, Katta V: Estradiol potentiation of gonadotropinreleasing hormone responsiveness in the anterior pituitary is mediated by an increase in gonadotropin-releasing hormone receptors. Am J Obstet Gynecol 151:534–540, 1985. Xia L, Van Vugt D, Alston EJ, et al: A surge of gonadotropin-releasing hormone accompanies the estradiol-induced gonadotropin surge in the rhesus monkey. Endocrinology 131:2812–2820, 1992. Leyendecker G, Wildt L, Hansmann M: Pregnancies following chronic intermittent (pulsatile) administration of Gn-RH by means of a portable pump (“Zyklomat”)—a new approach to the treatment of infertility in hypothalamic amenorrhea. J Clin Endocrinol Metab 51:1214–1216, 1980.
94. Caraty A, Antoine C, Delaleu B, et al: Nature and bioactivity of gonadotropin-releasing hormone (GnRH) secreted during the GnRH surge. Endocrinology 136:3452–3460, 1995. 95. Young JR, Jaffe RB: Strength–duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. II. Effects of varying concentrations of estradiol. J Clin Endocrinol Metab 42:432–442, 1976. 96. Cahill DJ, Wardle PG, Harlow CR, Hull MG: Onset of the preovulatory luteinizing hormone surge: Diurnal timing and critical follicular prerequisites. Fertil Steril 70:56–59, 1998. 97. Hoff JD, Quigley ME, Yen SS: Hormonal dynamics at midcycle: A reevaluation. J Clin Endocrinol Metab 57:792–796, 1983. 98. Pauerstein CJ, Eddy CA, Croxatto HD, et al: Temporal relationships of estrogen, progesterone, and luteinizing hormone levels to ovulation in women and infrahuman primates. Am J Obstet Gynecol 130:876–886, 1978. 99. Zelinski-Wooten MB, Hutchison JS, Chandrasekher YA, et al: Administration of human luteinizing hormone (hLH) to macaques after follicular development: Further titration of LH surge requirements for ovulatory changes in primate follicles. J Clin Endocrinol Metab 75:502–507, 1992. 100. McClure N, Macpherson AM, Healy DL, et al: An immunohistochemical study of the vascularization of the human graafian follicle. Hum Reprod 9:1401–1405, 1994. 101. Wulff C, Wilson H, Wiegand SJ, et al: Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143:2797–2807, 2002. 102. Wulff C, Wilson H, Largue P, et al: Angiogenesis in the human corpus luteum: Localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J Clin Endocrinol Metab 85:4302–4309, 2000. 103. Dickson SE, Fraser HM: Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. J Clin Endocrinol Metab 85:2339–2344, 2000. 104. Lumsden MA, Kelly RW, Templeton AA, et al: Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. J Reprod Fertil 77:119–124, 1986. 105. Yoshimura Y, Santulli R, Atlas SJ, et al: The effects of proteolytic enzymes on in vitro ovulation in the rabbit. Am J Obstet Gynecol 157:468–475, 1987. 106. Edwards RG: Maturation in vitro of human ovarian oocytes. Lancet 2(7419):926–929, 1965. 107. Edwards RG: Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes. Nature 208:349–351, 1965. 108. Hutchison JS, Zeleznik AJ: The rhesus monkey corpus luteum is dependent on pituitary gonadotropin secretion throughout the luteal phase of the menstrual cycle. Endocrinology 115:1780–1786, 1984. 109. Filicori M, Butler JP, Crowley WF Jr: Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest 73:1638–1647, 1984. 110. Sheehan KL, Casper RF, Yen SS: Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: A model for fertility control. Science 215:170–172, 1982. 111. Bassett SG, Little-Ihrig LL, Mason JI, Zeleznik AJ: Expression of messenger ribonucleic acids that encode for 3 β-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage enzyme throughout the luteal phase of the macaque menstrual cycle. J Clin Endocrinol Metab 72:362–326, 1991. 112. Brannian JD, Shiigi SM, Stouffer RL: Gonadotropin surge increases fluorescent-tagged low-density lipoprotein uptake by macaque granulosa cells from preovulatory follicles. Biol Reprod 47:355–360, 1992. 113. Rojas FJ, Moretti-Rojas I, Balmaceda JP, Asch RH: Regulation of gonadotropin-stimulable adenylyl cyclase of the primate corpus luteum. J Steroid Biochem 32:175–182, 1989. 114. McLachlan RI, Cohen NL, Vale WW, et al: The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum. J Clin Endocrinol Metab 68:1078–1085, 1989.
15
Ch01-A03309.qxp
1/17/07
5:32 PM
Page 16
Section 1 Basic Science 115. Molskness TA, Woodruff TK, Hess DL, et al: Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys. J Clin Endocrinol Metab 81:4002–4006, 1996. 116. le Nestour E, Marraoui J, Lahlou N, et al: Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. J Clin Endocrinol Metab 77:439–442, 1993. 117. Christin-Maitre S, Taylor AE, Khoury RH, et al: Homologous in vitro bioassay for follicle-stimulating hormone (FSH) reveals increased FSH biological signal during the mid- to late luteal phase of the human menstrual cycle. J Clin Endocrinol Metab 81:2080–2088, 1996. 118. Roseff SJ, Bangah ML, Kettel LM, et al: Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab 69:1033–1039, 1989.
16
119. Muttukrishna S, Fowler PA, George L, et al: Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 81:3328–3334, 1996. 120. Shikone T, Yamoto M, Kokawa K, et al: Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy. J Clin Endocrinol Metab 81:2376–2380, 1996. 121. Young KA, Hennebold JD, Stouffer RL: Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. Mol Hum Reprod 8:833–840, 2002. 122. Friden BE, Runesson E, Hahlin M, Brannstrom M: Evidence for nitric oxide acting as a luteolytic factor in the human corpus luteum. Mol Hum Reprod 6:397–403, 2000. 123. Vega M, Urrutia L, Iniguez G, et al: Nitric oxide induces apoptosis in the human corpus luteum in vitro. Mol Hum Reprod 6:681–687, 2000.
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 17
Section 1 Basic Science Chapter
2
Ovarian Hormones: Structure, Biosynthesis, Function, Mechanism of Action, and Laboratory Diagnosis Manjula K. Gupta and SuYnn Chia
INTRODUCTION The main function of the ovaries, maturation and release of oocytes, is accomplished via the production of several steroidal and nonsteroidal hormones that locally modulate a series of complex events. Peripherally, these hormones act on various target organs, including the uterus, vagina, fallopian tubes, mammary glands, adipose tissue, bones, kidneys, and liver, leading to the female phenotype. The secretion of the ovarian hormones in turn is precisely regulated by the hypothalamic-pituitary axis. The complex interactions and regulations of the hypothalamic, pituitary, and ovarian hormones are collectively responsible for the regular and predictable ovulatory menstrual cycle and fertility in females.
STEROIDOGENESIS AND STEROID HORMONES OF THE OVARY The ovary contains multiple distinctive steroid-producing cells, including stromal cells, theca cells, granulosa cells, and luteinized granulosa cells. Each cell type contains all the enzymes necessary for synthesis of androgens, estrogens, and progesterone. However, the types of hormones produced vary according to the cell type and the expression of steroidogenic enzymes. Other factors that influence which steroid hormone is synthesized in a given cell include the level and expression of gonadotropin and the availability of low-density lipoprotein (LDL) cholesterol. (As discussed below, steroid hormone synthesis occurs via one of two pathways: the Δ5[3β-hydroxysteroid] pathway or the Δ4[3 ketone] pathway.)
Steroidogenesis
The Ovary as an Endocrine Organ A single ovarian follicle is regarded as the basic endocrine/ reproductive unit of the ovary. It is composed of one germ cell that is surrounded by a cluster of endocrine cells, which are organized in two layers separated by a basal membrane. The inner layer surrounding the oocyte is composed of granulosa cells, and the outer layer is composed of thecal cells. These two cell types provide the basic machinery that is responsible for producing ovarian hormones. These cells are also differentially regulated by the gonadotropins (i.e., luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) and produce distinctly different steroid hormones. The two-cell theory describes the sequence of events that occurs during ovarian follicular growth and steroidogenesis. According to this theory, LH primarily stimulates thecal cells to produce androstenedione and testosterone, both 19-carbon steroids. In contrast, FSH primarily stimulates granulosa cells to aromatize these 19-carbon steroids into estrogens.1,2 The ovarian production of steroid hormones is regulated both within the ovary, by paracrine (intercellular) and autocrine (intracellular) mechanisms, and by endocrine regulation of FSH secretion by the pituitary. Central to this regulation are several nonsteroidal hormones and factors produced by the ovary.3 This chapter focuses on these aspects of the ovary and discusses the biochemistry, biosynthesis, regulation, and actions of both steroidal and peptide ovarian hormones.
The ovary, like the adrenal gland, produces all three classes of steroid hormones from cholesterol—estrogens, progesterone, and androgens. In contrast to the adrenal gland, the ovary cannot produce glucocorticoids or mineralocorticoids because it lacks the enzymes 21-hydroxylase and 11β-hydroxylase. Steroid hormone formation in the steroid-producing endocrine glands follows the same fundamental pathway and mainly relies on exogenous (or plasma) cholesterol, with the exception of the liver and intestinal mucosa, which are capable of synthesizing cholesterol endogenously from acetyl-coA. The primary source of cholesterol for steroidogenesis in the ovary is derived from the uptake of plasma LDL.4 The rate-limiting step in steroidogenesis is transfer of cholesterol from the cytosol to the inner membrane of the mitochondria.5 This is mediated by an LH-induced mitochondrial enzyme called steroidogenic acute regulatory (StAR) protein.6 The StAR gene is located on chromosome 8p11.2 and codes for a 285-amino acid precursor protein, of which 25 amino acids are cleaved off after transport to the mitochondria.7,8 Nonsense mutations of the StAR gene that result in premature stop codons have been identified as a cause of congenital lipoid adrenal hyperplasia, which is characterized by the presence of intracellular lipid deposits that destroy steroidogenesis.7 Ovary steroid hormones are synthesized in both interstitial and follicular cells. The basic structure of cholesterol is three hexagonal carbon rings and a pentagonal carbon ring to which a side chain is attached (Fig. 2-1). Two important methyl groups are also attached at positions 18 and 19. Progestins and corticosteroids
17
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 18
Section 1 Basic Science
23
20 18 11
2
HO
1
19 10
9
5
3 4
12
8
13
C
22
21
17
14
24 16
C
26 25 27
15
7 6
Cholesterol C27
Pregnane C21
Androstane C19
Estrane C18
Progestins
Androgens
Estrogens
CH C
O
HO
O
O
O
O
Progesterone
Androstendione
Estrone
OH
O
OH
O
Testosterone
Estradiol
Figure 2-1 Structures of cholesterol (27 carbons) and of the three major classes of ovarian steroids: the progestins (21 carbons), androgens (19 carbons), and estrogens (18 carbons).
18
(pregnane series 21-carbon steroids) are produced by partial cleavage of the side chain (i.e., the desmolase reaction). Androgens (androstane series 19-carbon steroids) are produced by the total removal of the side chain. Estrogens (estrane series 18-carbon steroids) are produced by aromatization of one of the three hexagonal carbon rings to a phenolic structure with loss of the 19-methyl group. The first step in steroidogenesis is the conversion of cholesterol to pregnenolone via hydroxylation at the carbon 20 and 22 positions, which is followed by cleavage of the side chain (Fig. 2-2). From pregnenolone, steroid hormones are produced by one of two general pathways.5 The pregnenolone (Δ5) pathway produces androgens and estrogens (pregnenolone → 17OH-pregnenolone → dehydroepiandrosterone [DHEA] → testosterone → estrogen). The progesterone (Δ4) pathway produces androgens and estrogens (pregnenolone → progesterone → 17OH-progesterone → androgen → estrogen). In the adrenal gland, the Δ4 pathway produces mineralocorticoids and glucocorticoids. The enzymes involved in the intracellular synthesis of steroid hormones include five hydroxylases, two dehydrogenases, a reductase, and an aromatase. The hydroxylases and aromatase belong to the cytochrome P450 (CYP) supergene family (Table 2-1). These enzymes exist on both the mitochondria and endoplasmic reticulum.
Table 2-1 Enzyme Reaction and Cellular Location of Steroidogenic Enzymes Cellular Location/ Tissue Location
Enzyme Reaction
Gene (Enzyme)
Cholesterol side chain cleavage
CYP11A (P450scc)
Mitochondria (theca; granulosa)
17α-hydroxylase
CYP17 (P450c17)
ER (theca)
17,20-hydroxylase (lyase)
CYP17 (P450c17)
ER (theca)
Aromatase
CYP19 (P450arom)
ER (granulosa)
3β-hydroxysteroid dehydrogenase
3βHSD
ER (theca; granulosa)
17β-hydroxysteroid dehydrogenase
17βHSD
ER (granulosa)
21-hydroxylase
CYP21 (P450c21)
ER (adrenal)
11β-hydroxylase
CYP11B1 (P450c11)
Mitochondria (adrenal)
ER, endoplasmic reticulum
Of these nine enzymes, four key enzymes regulate the main steps of steroidogenesis (see Fig. 2-2): CYP11A (P450scc), a side chain cleavage enzyme that catalyzes the conversion of cholesterol to pregnenolone; 3βHSD, or 3 βa-hydroxysteroid
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 19
Chapter 2 Ovarian Hormones Theca cells Cholesterol LH Corpus luteum
Δ4 pathway
CYP11A (P450scc)
Pregnenolone
Δ5 pathway
3βHSD
CYP17 (P450c17)
Progesterone
17OH Pregnenolone
CYP17
17,20 lyase
CYP17 17OH Progesterone
DHEA 3βHSD
CYP17 CYP21
CYP21 17βHSB
11-Deoxycorticosterone CYP11
11 Deoxycortisol
Androstenedione
Testosterone
CYP19 (P450arom)
CYP11B1
FSH
CYP19
17βHSB Corticosterone
Cortisol
Estrone
Estradiol Granulosa cells
18-OH Corticosterone
Aldosterone Adrenal gland Figure 2-2 Steroid hormone biosynthesis pathways in the ovary. The Δ4 pathway converts pregnenolone to progesterone and is the main pathway in the corpus luteum. The Δ5 pathway converts pregnenolone to androgens and subsequently estrogens and is the preferred pathway in the thecal cells. Also shown are the conversion of 17OH-progesterone to aldosterone and cortisol as a result of CYP21 and CYP11, which occurs exclusively in the adrenal gland. Irreversible reactions are denoted by a single arrow, and reversible reactions are denoted by double arrows.
dehydrogenase, which converts pregnenolone to progesterone; CYP17 (P450c17), an hydroxylase that converts pregnenolone to androgens; and CYP19 (P450arom), an aromatase that converts androgens to estrogens. Most reactions are irreversible (denoted by a single arrow in Fig. 2-2). The few reversible reactions (denoted by double arrows) are dependent on cofactor availability (e.g., NADP/NADPH ratio). The kind of hormone produced depends on the nature of the cell and the presence or absence of the inherent steroidogenic enzymes in the tissue. The adrenal cortex lacks 17βHSD; hence, adrenal androgen production is limited to DHEA and androstenedione. In the testes, LH controls 17βHSD activity and testosterone production. The steroid-producing cells of the ovary (granulosa, theca, corpus luteum) contain the full enzymatic complement for steroid hormone synthesis. In the thecal cells, LH also controls 17βHSD activity and androstenedione production, whereas CYP19 (P450arom) activity in the granulosa cells is controlled by FSH and hence estradiol production.
These relationships are the basis for the two-cell, twogonadotropin system (Fig. 2-3). Aromatization occurs in the endoplasmic reticulum. In each of the two cell types, the amount of the various enzymes differs depending on the stage of follicle development. CYP11A (P450scc) and 3βHSD are expressed in both thecal and granulosa cells of antral and preovulatory follicles and in the luteinized granulosa and thecal cells of the corpus luteum. In contrast, CYP17 (P450c17) is expressed only in the thecal cells of antral and preovulatory follicles and of the corpus luteum (see Fig. 2-3).
Steroid Hormones of the Ovary On the basis of chemical structure and biologic function, the major steroid hormones synthesized and secreted by the ovaries can be classified into three major types: estrogens, progesterone, and androgens.
19
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 20
Section 1 Basic Science Pituitary gland LH
FSH
LH receptor
LH receptor
FSH receptor
Cholesterol
GTP
Gs
Cholesterol
CYP11A1
GTP
Gs
CYP11A1
GDP
GDP
Pregnenolone
Pregnenolone
CYP17 Gs
GTP
cAMP
CYP17 ATP
17α-OH pregnenolone Protein kinase A
cAMP
CYP17
Adenylate cyclase
Gs
Progesterone
3βHSD
17βHSD
CYP19
Testosterone
Androstenedione 17βHSD
Adenylate cyclase
Androstenedione
DHEA
CYP19
Testosterone
17βHSD Estradiol
Protein kinase A Estrone
Blood
Blood Thecal cell Granulosa cell Figure 2-3 Differential regulation by luteinizing hormone (LH) and follicle-stimulating hormone (FSH) of ovarian estrogen, progesterone, and androgen production, the basis of the two-cell, two-gonadotropin system. LH acts on both thecal and granulosa cells; FSH acts only on granulosa cells. FSH and LH stimulate adenylate cyclase via G protein-coupled receptors. Cyclic adenosine monophosphate (cAMP) generated from adenosine triphosphate (ATP) activates protein kinase A, which in turn stimulates steroidogenic enzymes. Gs, G protein; GDP, guanosine diphosphate; GTP, guanosine triphosphate.
Estrogens Physiologic Role
20
Estrogens are essential in the development and maintenance ofthe female phenotype, germ cell maturation, and pregnancy. In addition to their reproductive effects, estrogens also have many other nonreproductive systemic effects, such as bone metabolism/remodeling, nervous system maturation, and endothelial responsiveness.9 At puberty, estrogen stimulates breast development and enlargement and maturation of the uterus, ovaries, and vagina.10,11 Estrogen also works in concert with growth hormone and insulinlike growth factor I (IGF-I) to produce a growth spurt and stimulates the maturation of chondrocytes and osteoblasts, which ultimately leads to epiphyseal fusion.12,13 After midpuberty, estrogen begins to exert a positive feedback on gonadotropin-releasing hormone (GnRH) secretion, leading to the progressive increase of LH and FSH production, culminating in the LH surge, ovulation, and the initiation of the menstrual cycle. In the adult female, estrogen plays a critical role in maintaining the menstrual cycle.14 The cyclical changes in estradiol, progesterone, and pituitary hormones are illustrated in Figure 2-4. In the early follicular phase of the menstrual cycle, FSH stimulates granulosa cell aromatase activity, resulting in increased follicular concentrations of estrogen. The rising estrogen level further increases the sensitivity of the follicle to FSH and estrogen by increasing the number of estradiol receptors on the granulosa cells. Follicular growth and antral formation is also
promoted by estrogen. This sets up a positive feedback cycle, which culminates in one dominant follicle producing an exponential rise in estrogen levels. This exerts a negative feedback on FSH so that falling FSH levels contribute to atresia of other nondominant follicles. The dominant follicle secretes large quantities of estrogen; estradiol levels must be greater than 200 pg/mL for approximately 50 hours before a positive feedback on LH release is achieved.13,15 Once the LH surge is initiated, luteinization of the granulosa cells and progesterone production occurs. In pregnancy, estrogen augments uterine blood flow, although it is not required in itself for the maintenance of pregnancy.16 In the central nervous system, estrogen withdrawal at menopause has been associated with reduced libido, altered mood, and cognitive disturbances. These effects have been attributed to estrogen’s ability to modulate the synthesis, release, and metabolism of many neuropeptides and neurotransmitters.17 Estrogen acts as a serotoninergic agonist by increasing serotonin synthesis in the brain, which may positively influence mood.18 Although prospective observational studies in postmenopausal women have suggested that estrogen replacement therapy might protect against cognitive decline19 and the development of dementia,20 randomized trials of estrogen in the treatment of Alzheimer’s disease have shown no evidence of benefit.21–24 In the skeletal system, estrogen antagonizes the effect of parathyroid hormone by directly inhibiting the function of osteoclasts, which decreases the rate of bone resorption and diminishes bone loss. The Postmenopausal Estrogen/Progestin
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 21
Chapter 2
80
200
60
150
40
100
20
50
0
0
Inhibin B (pg/mL)
Inhibin A (pg/mL)
Ovarian Hormones
Biosynthesis and Metabolism
A 1500
Progesterone (nmol/L)
40 1000 30 20
500
Estradiol (pmol/L)
50
10 0
0
40
15
B
LH (U/L)
10 20 5 10 0 –14
C
FSH (U/L)
30
0 –7 0 7 Days relative to midcycle LH peak
disease.31 These studies led to the conviction that estrogen replacement therapy would consequently prevent the progression of atherosclerosis and coronary heart disease. However, the WHI study and the Heart and Estrogen/progestin Replacement Study (HERS), both large randomized, prospective trials designed to specifically address this issue, have not shown any benefit of estrogen for either the primary or secondary prevention of coronary artery disease, respectively.26,32
14
Figure 2-4 Plasma hormone concentrations (mean ± standard error) during the female menstrual cycle. Graph A, inhibins; Graph B, progesterone and estradiol; Graph C, LH and FSH. (Data from Groome NP, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401-1405, 1996.)
Interventions (PEPI) trial was a prospective, placebo-controlled trial designed to study the effects of hormone replacement on bone density in postmenopausal women. After 12 months of treatment with estrogen, bone mineral density increased by 1.8% at the hip and by 3% to 5% at the spine.25 The Women’s Health Initiative (WHI) showed that estrogen reduced the risk of both hip and vertebral fractures by 30% to 39%.26 In the cardiovascular system, there is strong evidence that estrogen has a natural vasoprotective role. At a cellular level, estrogen receptors are found on the smooth muscle cells of coronary arteries27 and the endothelial cells of various sites.28 Estrogen causes short-term vasodilation by increasing nitric oxide and prostacyclin release in endothelial cells.29 Several large observational studies, including the Framingham study and the Nurses Health Study, have shown that cardiovascular incidence rates are lower in premenopausal than postmenopausal women.30 There was also a significant association between a younger age at menopause and a higher risk of coronary artery
Estrogens are 18-carbon steroids derived from cholesterol (see Fig. 2-1). The three forms of naturally occurring estrogen include estrone, 17β-estradiol, and estriol. In nonpregnant females, estrone and estradiol are the main biologically active estrogens secreted by the ovary. Estradiol is almost 2 to 5 times more potent than estrone.33 The circulating levels of estradiol are 2 to 4 times higher than those of estrone in premenopausal women. Estradiol concentrations in postmenopausal women are one tenth of those in premenopausal women. Estrone concentrations do not differ with menopausal status; thus, over time, the premenopausal estradiol-to-estrone ratio is reversed.34 In contrast, estriol is not the secretory product of the ovary but is the peripheral metabolite of estrone and estradiol. The main estrogen in premenopausal women is estradiol, which is produced primarily by the granulosa cells of the ovary. Androstenedione is converted to testosterone via 17βHSD, which is rapidly demethylated at the C-19 position and aromatized to estradiol. Estradiol is also generated to some degree from androstenedione via estrone. Estrone is also a secreted product of the ovary. It constitutes the remaining circulating estrogen (40%) and is mainly derived from the extragonadal peripheral aromatization of adrenal androstenedione.35 Peripheral conversion of androgens to estrogens occurs in skin, muscle, and adipose tissue and in the endometrium.36 In the normal adult female, the production of estradiol varies according to the phase of the menstrual cycle. During the mid luteal phase, for example, the production rate is about 100 to 270 μg/day. In comparison, the production rate for androstenedione is about 3 mg/day, and with its peripheral conversion rate to estrone of about 1.5%, it accounts roughly for about 10% to 30% of estrone production per day. Secondary increases in estrone formation occur in patients with polycystic ovaries or with ovarian cancer characterized by increased androgen production. In such patients, the increased estrogen can disturb the menstrual cycle. In postmenopausal women, the ovarian contribution shrinks, leaving estrone, derived from adrenal androstenedione, as the main source of circulating estrogen.37 In the pregnant woman, the placenta becomes the main source of estrogen in the form of estriol. The placenta is unable to synthesize steroids de novo and depends on circulating precursors from both fetal and maternal steroids. Most of the placental estrogens are derived from fetal androgens (e.g., DHEA sulfate), produced by the fetal adrenal gland.38 Fetal DHEA sulfate is converted to free DHEA by placental sulfatase and then to androstenedione and testosterone before being aromatized to estrone and estradiol. Finally, it is hydroxylated to form estriol. Estradiol is rapidly converted in the liver to estrone by 17βHSD. Estrone can be further metabolized via three pathways. First, it can be hydroxylated to 16α-hydroxyestrone,
21
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 22
Section 1 Basic Science which is then converted to estriol. Estriol is further metabolized by sulfation and glucuronidation, and the conjugates are excreted into the bile or urine. Secondly, estrone can be conjugated to form estrone sulfate, which occurs primarily in the liver. Estrone sulfate is biologically inactive and is present in concentrations that are 10-fold to 20-fold higher than concentrations of estrone or estradiol.39 Estrone sulfate can be hydrolyzed by sulfatases present in various tissues to estrone and may serve as a reserve of estrogen in an inactive form. Estrone sulfate may be of some importance in assessing estrogenicity in women and can be detected in serum as well as in urine.40 Thirdly, estrone can also be metabolized by hydroxylation to form 2-hydroxyestrone and 4-hydroxyestrone, which are known as catechol estrogens. These are then converted to the 2-methoxy and 4-methoxy compounds by catechol-O-methyltransferase. Progesterone Physiologic Role
Progesterone plays a critical role in reproduction. It inhibits further endometrial proliferation mediated by estrogen and converts the endometrium into a secretory type, preparing it not only to receive the blastocyst for implantation, but also to maintain the pregnancy. It inhibits uterine contractions and increases the viscosity of cervical mucus. Progesterone also inhibits the action of prolactin so that lactation occurs only after delivery. It raises the basal body temperature by about 0.5°C (0.9°F) and increases the sensitivity of the respiratory center to carbon dioxide (CO2), leading to hyperventilation. During pregnancy, progesterone increases insulin resistance in concert with the production of the other placental counterregulatory hormones, including placental growth hormone, placental lactogens, placental corticotropin-releasing hormone, and cortisol.41 Biosynthesis and Metabolism
Progesterone is part of the group of 21-carbon steroids, which also includes pregnenolone and 17OH-progesterone. Progesterone is responsible for all the progestational effects, whereas pregnenolone is the precursor for all steroid hormones. 17OHprogesterone has little biologic activity. Progesterone and 17OH-progesterone are mainly produced by the corpus luteum in the luteal phase of the menstrual cycle and by the placenta if pregnancy occurs. Circulating levels of progesterone at concentrations greater than 4 to 5 ng/mL (12.7 to 15.9 nmol/L) are indicative of ovulation.42 Progesterone is rapidly metabolized by the liver and has a half-life of approximately 5 minutes. It is converted to pregnanediol and conjugated to glucuronic acid in the liver. Pregnanediol glucuronide is excreted in the urine. Pregnanetriol is the main urinary metabolite of 17OH-progesterone. Androgens Physiologic Role
22
In women, androgens originate as 19-carbon steroids from the adrenals and ovaries. The major androgens produced in the ovary, primarily by the thecal cells and to a lesser degree by the ovarian stroma, include DHEA, androstenedione, and a small amount of testosterone. Both DHEA and androstenedione serve as precursors to estrogen synthesis and have little, if any, androgenic activity. However, these biologically inactive androgens are
converted by extraglandular metabolism to biologically active androgens such as testosterone and dihydrotestosterone (DHT). Normally, the levels of these potent androgens are low in females and have no significant physiologic function. Excessive production of androgens by the ovary or adrenals has been implicated as the cause of hirsutism and virilization in women.43 In contrast, in the male the androgens, of which testosterone and DHT are the most crucial, are of primary importance. Biosynthesis and Metabolism
Androgens are 19-carbon steroids derived from cholesterol. The rate-limiting step in androgen synthesis is the conversion of cholesterol to pregnenolone, which is mediated by the action of LH on the ovary and testes. In a normal ovulatory woman, the ovaries secrete approximately 1 to 2 mg of androstenedione, 1 mg of DHEA, and approximately 0.1 mg of testosterone. The majority (≈0.2 mg) of circulating testosterone is derived from peripheral metabolism of DHEA and androstenedione. Overall, testosterone production in women is about 0.3 mg/day; roughly 50% of this is derived from peripheral conversion whereas the remaining 50% is secreted equally by the ovary and the adrenals.44 In the male, more than 95% of circulating testosterone is secreted by the testicular Leydig cells. The testes also secrete small amounts of DHT and the weak androgen DHEA and androstenedione. In most androgen target cells, testosterone is converted to the biologically more potent DHT by the enzyme 5α-reductase. In the female, androgens are derived either from the adrenal cortex in the form of DHEA and androstenedione or from the peripheral conversion of these androgen precursors to testosterone and DHT. Most of the circulating testosterone is metabolized in the liver into androsterone and etiocholanolone, which are conjugated with glucuronic acid or sulfuric acid and excreted in the urine as 17-ketosteroids. Of note, only 20% to 30% of urinary 17-ketosteroids are derived from testosterone metabolism; the rest originate from the metabolism of adrenal steroids.
Transport of Ovarian Steroid Hormones in Plasma Steroid hormones are not water-soluble and require transport proteins to be carried to their target tissues. The two types of transport proteins are general carrier proteins such as albumin and transthyretin and specific carrier proteins such as thyroxinebinding globulin, sex hormone-binding globulin (SHBG), and transcortin. Both types of proteins are produced in the liver. Less than 2% of ovarian steroid hormones are free in the circulation; the remainder are mostly bound to SHBG and albumin.45,46 Sex hormone-binding globulin, a β-globulin of 95 kDa, is synthesized in the liver. Its gene is localized on the short arm of chromosome 17 (p12-13).47 It is a homodimer composed of two polypeptide chains and has a single binding site for androgens and estrogens. Dimerization is a necessary step in the binding process.48 The bound and free fractions appear to exist in a steady state of equilibrium. The amount of free fraction depends on the concentration of steroid hormone and on the levels and binding affinities of the binding proteins. Of all the steroid hormones, DHT has the highest affinity for SHBG. Approximately 98% of testosterone circulates bound to SHBG (≈65%) and albumin (≈33%). Estradiol is primarily bound to albumin (≈60%) but also to SHBG (38%); about 2%
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 23
Chapter 2 Ovarian Hormones circulates as the free fraction.49 Progesterone, on the other hand, is mainly bound to albumin (≈80%) but also to transcortin (≈18%). Only approximately 0.6% of progesterone is bound to SHBG and about 2% exists in the free state. The metabolic clearance of these steroids is inversely related to their binding affinity to SHBG. Thus, conditions that affect levels of SHBG (e.g., pregnancy, oral contraceptives) directly affect the levels of free hormone. Because estrogens increase SHBG synthesis and androgens decrease its synthesis, SHBG levels are twice as high in women compared to men. Several other hormones and other factors are known to influence SHBG levels. Thyroid hormones increase its synthesis and release by the liver.46 Insulin, IGF-I, and prolactin have been shown to inhibit SHBG production in cultured cells.50,51 Furthermore, serum concentrations of SHBG are increased in many disease states, including hyperthyroidism and liver cirrhosis. Certain drugs, including estrogen, tamoxifen, and phenytoin, can also increase serum SHBG concentrations. Carrier protein levels are decreased by hypothyroidism, obesity, and acromegaly and by administration of exogenous androgens, glucocorticoids, and growth hormones. For many years, only the free fraction of testosterone was regarded as the biologically active component. However, researchers noted that steroid hormones bind with greater affinity to their specific carrier proteins and with much less affinity to albumin. In addition, studies of tissue delivery in vivo showed that the dissociation of albumin-bound testosterone can occur rapidly in a capillary bed so that the active fraction can be larger than the free fraction measured under equilibrium conditions in vitro.52 Thus, unconjugated steroids that are bound to albumin may be treated as free and biologically available.53,54 As mentioned above, SHBG levels can be influenced by numerous disease states. As such, changes in SHBG concentrations can result in large shifts in the free and SHBG-bound fractions. Hence, measurement of SHBG is of great clinical interest because it allows more accurate assessment of free hormones. SHBG is measured by a technique called saturation analysis, in which specific binding capacity of 3H-labeled testosterone is detected.55,56 With modifications, this method can also measure the non-SHBG bound fraction (bioavailable).57 Recently, specific nonisotopic two-site immunoassays for SHBG have become available and are used in most clinical laboratories.
Measurement of Steroid Hormones in Circulation The technique responsible for the accurate measurement of low concentrations of various steroid hormones and metabolites is competitive inhibition immunoassay or radioimmunoassay (RIA), which was originally described in 1960 by Yalow and Berson.58 However, the development of steroid immunoassays presented several problems. First, they are not immunogenic and have a similar structure—they all have a same cyclopentahaptene nucleus with only minor structural variations—which makes it difficult to generate specific antibodies. Steroids can be made immunogenic via chemical coupling to a carrier protein known as hapten, and antibodies can be raised by immunization with haptens.59 However, the site of the steroid where the protein is conjugated has a significant impact on the specificity of the resulting antibody.59 Antibodies raised to conjugates of BSA coupled at the 19th position show higher specificity than
those coupled at the 3rd or 17th positions.60 For accurate clinical interpretation, it is important to know the cross-reactivity data on each antibody that is selected for a given assay. Most commercial assay reagent manufacturers provide cross-reactivity data, but it may not always be reliable and must be evaluated in the clinical laboratories performing the assay.61 Second, the high-affinity binding proteins such as SHBG in the serum compete with the antibody and thus interfere with the measurement of steroid molecules by RIA. This makes direct measurement difficult and necessitates a preassay extraction procedure with organic solvents and often a chromatographic separation of the steroid. Alternatively, the use of certain chemicals, such as 8-anilinonaphthalene sulfonic acid can inhibit the binding of steroids to proteins, which allows the direct measurement of steroid hormones without the extraction step. Direct assays are fast and can be automated. Several automated platforms for measuring estradiol, progesterone, and testosterone are commercially available and are used in most clinical laboratories. These assays, however, have a low sensitivity and, when used to measure very low concentrations, have poor reliability.62 Therefore, they may not be the best choice for clinical applications that require the ability to measure very low hormone concentrations such as estradiol measurement in children and in men (<100 pg/mL),63 testosterone measurement in children and women(<1.5 ng/mL),64 or progesterone measurement during ovarian stimulation (<1 ng/mL).65 To overcome this problem, serum can be extracted with hexane-ethyl acetate (3:2 by volume), dried, and reconstituted in steroid-free serum, which can then be assayed in the automated platform.66 Gas chromatography combined with mass spectrometry (GC-MS) addresses many of the shortcomings of immunoassays and is considered more reliable and accurate than immunoassays. However, this technique requires multiple steps, including solvent extraction, chromatographic fractionation, and chemical dramatization before instrumental analysis, and it is often less sensitive than some immunoassays. This technique has now been superseded by liquid chromatography combined with tamdem mass spectrometry. This newer technique has a higher sensitivity and throughput than GC-MS and is considered a reference methodology.67,68 The technique has been used to simultaneously measure estradiol and estrone in human plasma with no cross-reactivity.69 These methods are recommended as reference methods and can be used to standardize and validate immunoassays, which provide the simplicity and rapid throughput needed for clinical use. Estrogens
Measurement of estradiol is important in the assessment of female reproductive function. It can be used as an aid in the diagnosis of infertility and oligomenorrhea and to determine menopausal status (Table 2-2). In addition, measurement of estradiol is widely used to monitor ovulation induction and in vitro fertilization protocols.70,71 Estrone levels are of limited clinical value in nonpregnant women because their levels closely parallel those of estradiol, except in the postmenopausal woman, in whom estrone becomes the main form of circulating estrogen. Also, as mentioned above, a specific RIA for the measurement of estrone sulfate has been described and made available commercially. Because estrone sulfate has a large circulating pool, it can serve as a marker of estrogenicity, especially in women on
23
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 24
Section 1 Basic Science Table 2-2 Assay Techniques and Clinical Applications of Ovarian Steroid Hormones Hormone
Assay Techniques
Clinical Application
Estradiol
Radioimmunoassay Nonisotopic immunoassays
Evaluation of ovarian function Assessment of menopausal status Monitoring ovulation induction and in vitro fertilization cycle
Estrone sulfate
Radioimmunoassay
Marker of estrogenicity in women on hormone replacement therapy
Progesterone
Radioimmunoassay Nonisotopic immunoassays
Marker for ovulation Detection of luteal phase defects Marker for threatened abortion in early pregnancy
Total testosterone
Radioimmunoassay Nonisotopic immunoassays
Evaluation of patients with hirsutism. Male infertility
Free testosterone
Equilibrium-dialysis Diafiltration
Evaluation of patients with hirsutism. Polycystic ovarian syndrome
estrogen replacement therapy, in whom estradiol measurements are of little value due to the variable cross-reactivity of conjugated estrogens in the estradiol assays.72,73 In pregnant women, estriol is the main form of estrogen produced, and the amount of estrogen secreted increases from microgram quantities to milligram quantities. Progesterone
Although GC-MS has been recommended as the reference method for the measurement of progesterone,74 immunoassays using steroid-specific antibodies are again the preferred mode of measurement in most clinical laboratories.75,76 Both RIA and nonisotopic immunoassays for progesterone are available for commercial use. Progesterone measurement is routinely used to detect ovulation and luteal phase defects (see Table 2-2).77 In the follicular phase, progesterone levels are low (<5 nmol/L or 1.5 ng/mL). In the luteal phase, they range between 9 and 79 nmol/L (3 to 25 ng/mL). As noted, progesterone is required to maintain pregnancy, and progesterone measurement in early pregnancy can be valuable in the diagnosis of defects or threatened abortion.78 Androgens
24
The measurement of androgens, including androstenedione and total testosterone or DHT, can also be accomplished using immunoassays.79–81 The one main drawback of these assays is the cross reactivity with other steroid hormones. Interference with cross-reactive testosterone in the androstenedione assay has been overcome by the use of specific testosterone antiserum to neutralize plasma testosterone.81 Direct measurement of androstenedione and testosterone without extraction is now possible with new commercial assays. However, commercial assays demonstrate high variability, which is greatest in samples from females.82 Total testosterone in hirsute women overlaps significantly with levels seen in normal women, and measurement of free testosterone correlates better with disease.83 Free testosterone has been measured by equilibrium-dialysis, which is a time-consuming and difficult technique for most clinical laboratories to perform.
An ultrafiltration technique can be used instead, which depends on MPS-1 centrifugal gel filtration devices and correlates well with the equilibrium-dialysis method83,84 as well as with GC-MS.85 Direct, single-step, nonextraction immunoassay methods using 125 I-labeled testosterone analog have been developed commercially and are used in a number of laboratories. The accuracy and validity of this direct assay has been questioned.86,87 Alternatively, an indirect parameter of free testosterone—FAI—can be calculated as a ratio of testosterone to SHBG.88 FAI is a better discriminator of hirsutism than either total testosterone or SHBG levels.87–89 When bound with albumin and transcortin, testosterone dissociates more quickly than when bound with SHBG. This loosely bound teatosterone may be biologically available through dissociation during capillary transit. Cumming and Wall provided evidence for this hypothesis and suggested that this non-SHBG bound testosterone is a marker of hyperandrogenism.57,90 Saliva Measurements
SHBG is either undetectable or minimally present in saliva. Thus, this biologic fluid may reflect the free fraction of plasma steroids. Therefore, measurement of steroid hormones in saliva has attracted considerable attention.91–93 The ease of noninvasive collection combined with the simplicity of measurement makes salivary measurement a promising and attractive alternative to measurement of steroids in plasma. In the future, salivary assays may become useful adjuncts to those performed in plasma.94–97
PEPTIDE HORMONES AND INTRAOVARIAN GROWTH FACTORS OF OVARY The role of gonadotropins and gonadal steroids in the process of folliculogenesis in the ovary is well recognized. However, multiple other phenomena within the ovary suggest the presence of other intraovarian factors that may fine-tune the effects of gonadotropins and gonadal steroids. For example, the initiation and arrest of meiosis and the different rates of follicular growth leading to the selection of a dominant follicle point toward the existence of an intraovarian modulatory system. The concept of a gonadal factor with endocrine action at the pituitary level can be traced back more than 70 years to Mottram and Cramer.98 The first moiety was identified and named inhibin for its inhibitory effect on the pituitary.99 Since then, there has been an explosion of information regarding multiple and potential intraovarian regulators and their physiology, biochemistry, and biosynthesis as well as the identification of their receptors. Some of these compounds, which have been the subject of intense investigation, include peptide hormones/growth factors, cytokines, and neuropeptides. These factors may act in either an endocrine, autocrine, or paracrine fashion.
Peptide Hormones of the Ovary: Inhibins, Activins, and Follistatins The first water-soluble peptide hormone in testicular extracts that exerted selective inhibitory activity at the pituitary level was described in 1932 and termed inhibin.99 It was not until 1985 (almost 50 years later) that inhibin was isolated and characterized.100,101 This was followed by the identification and characterization of two other related peptide factors (i.e., activin
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 25
Chapter 2 Ovarian Hormones and follistatin).102,103 With the cloning of inhibin α and β subunit genes,104 it was recognized that inhibin and activin belonged to the transforming growth factor-β (TGFβ) superfamily of growth and differentiation factors. Both inhibin and activin are of particular clinical interest and have been extensively reviewed3,105,106 in recent years. They have been found to exert numerous different regulatory functions in a wide variety of both normal and neoplastic cells. Follistatin, a glycoprotein that is structurally distinct but functionally closely linked to inhibin and activin, is also discussed here. The site of production and areas of clinical interest of these peptide hormones are listed in Table 2-3.
Precursor molecules: α subunit Proα
Inhibins Inhibin A
Inhibin B
The primary sources of inhibin production are the granulosa cells of the ovary and the Sertoli cells of the testis. Inhibin is also produced during pregnancy by the fetus, placenta, decidua, and fetal membranes. The main role of inhibin is to selectively suppress the production of FSH by the pituitary.107,108 This is achieved by modulating FSH biosynthesis through two main mechanisms: by reducing steady-state FSH mRNA in pituitary gonadotropes109 and decreasing the stability of FSH mRNA.110 Inhibin is a 32 kDa glycoprotein heterodimer consisting of 2 subunits, α and β, linked by disulfide bonds.111 There is a common α subunit but also two types of β subunits known as βA or βB. Thus, the two isoforms of inhibin are denoted inhibin A and inhibin B. As shown in Figure 2-5, each subunit derives from a separate precursor molecule called prepro-inhibin α (364 amino acid residues), prepro-inhibin βA (424 amino acid residues) and prepro-inhibin βB (407 amino acid residues). These are processed by proteolytic cleavage to yield the mature forms.104 In addition to the fully mature forms (αβ dimers, Mr~32,000), larger forms of dimeric inhibins with amino terminally extended α and/or β subunits have been identified in follicular fluid, which also possess FSH-suppressing bioactivity.112,113 Furthermore, monomeric forms of both α and β subunits and certain fragments (αN and proαN-αC) generated during subunit proTable 2-3 Role of Inhibins and Activins in Reproduction Site of Hormone Production
Circulating Levels
Inhibins Inhibin Granulosa cells A Antral/dominant follicle
↑ Luteal phase ↑ Pregnancy ↑ Ovarian tumors Inhibin Granulosa cells ↑ Follicular B Small developing phase follicle ↑ Ovarian tumors ↓ Perimenopause
Granulosa cells Pituitary/brain Adrenal cortex
Follistatin Granulosa cells Antral follicles
Clinical Areas of Interest/Applications
Reflect dominant follicle growth Prenatal screening for Down syndrome Marker for certain ovarian tumors Reflects total output of growing follicles Predict response to ovulation induction/IVF Marker for certain ovarian tumors Marker for the onset of menopause
↑In luteal phase ↑Spontaneous labor
Inhibits progesterone production by corpus luteum May prevent premature luteinization. May predict preterm delivery May relate to lack of follicle development
↓ PCOS ↑ PCOS
May relate to lack of follicle development
PCOS, polycystic ovarian syndrome
βA subunit βA Proβ
αC
βB subunit βB Proβ
Inhibins
Activins
αN
A
αC βA
Activin A
Activin AB
αC βB
Activin BB
Inhibins and activins
Follistatin
B
Activins
TGF-β
Follistatin and TGF-β
Figure 2-5 Activins, inhibins, follistatin, and TGFβ. A schematic representation of the formation of different dimeric proteins from three basic subunits, α, βA, and βB. Inhibins are heterodimers of α and β subunits (α-βA, α-βB); activins are homodimers of the β subunits (βAβA, βAβB, βBβB). Links between the units represent disulfide bridges.
cessing are present in follicular fluid (see Fig. 2-1) and have intrinsic biologic activities distinct from classical inhibin-like bioactivity.114,115 Because the circulation contains multiple molecular forms of inhibin, it can be difficult to accurately measure inhibin levels using conventional RIAs. Most lack specificity for dimeric inhibin due to the variable cross-reactivity of monomeric forms and of various fragments with the antibody used in the assay.112,116,117 Also, conventional inhibin bioassays based on FSH suppression or release by cultured pituitary cells lack specificity due to the FSH-regulating activities of follistatin and activins. In addition, bioassays lack the sensitivity necessary to measure inhibin levels in the circulation. The development of two-site immunoassays utilizing αβ dimer specific antibodies overcame these problems and allowed specific measurement of the two forms of inhibin dimers (A and B).118 Use of these novel two-site assays allows measurement of inhibin levels throughout the normal menstrual cycle.119 Synthesis of the two isoforms of inhibin differ during the various phases of the menstrual cycle (see Fig. 2-4). Inhibin B levels are highest during the luteal–follicular transition and the early follicular phase, and studies on its presence in follicular fluid and basal granulosa cell secretion suggest that it is secreted by small developing antral follicles.120 In contrast, inhibin A levels in the early and midfollicular phase reflect the sum of FSH- and LHstimulated inhibin A secretion from all antral follicles. Levels of inhibin A during the late follicular phase mainly reflect secretion from the dominant follicle. Hence, inhibin A and B levels can be used as markers of follicular development. Inhibins have also been investigated as prognostic markers for women undergoing assisted reproductive technologies. In particular, it was suggested that measuring inhibin B levels during the early stages of FSH
25
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 26
Section 1 Basic Science stimulation for ovulation induction could predict the number of oocytes retrieved and may be useful in monitoring ovarian stimulation for in vitro fertilization. However, because there is a large overlap between normal and subnormal ovarian responses in terms of inhibin B levels, it may be just as effective to obtain Day 3 FSH or perform a clomiphene challenge test.121,122 Women in early perimenopause show significant decrease in inhibin B (no significant change in inhibin A and estradiol), which correlates with a mild increase in FSH levels. This perimenopausal decrease in inhibin B precedes a decrease in inhibin A, suggesting that inhibin B may serve as a sensitive marker for the onset of menopause.123 Studies investigating the role of inhibins in the pathophysiology of polycystic ovary syndrome (PCOS) show conflicting results. Serum inhibin B levels in early follicular phase show significant increase in some studies or no change in others124,125— this awaits future studies to confirm its role in PCOS. During pregnancy, inhibin A is produced primarily by the fetoplacental unit, whereas inhibin B levels remain low throughout the pregnancy.126 Because there is a twofold elevation of circulating inhibin A levels in the second trimester of Down syndrome pregnancies, measurement of inhibin A is a clinically useful and important test.127 When measurement of inhibin A level is added to alpha-fetoprotein, maternal age, and β-hCG (quad screen), the detection rate for Down syndrome increases from 53% to 75%.128 Inhibin A has also recently been used as a tumor marker for ovarian sex cord tumors. This heterogeneous group of tumors accounts for 7% of all malignant primary ovarian neoplasms. They are composed of granulosa cells, thecal cells, Sertoli cells, Leydig cells, and other nonspecific stromal cells. It is important to distinguish this group of tumors from carcinomas and sarcomas because the former are low-grade tumors with a better prognosis. Inhibin A and its α-subunit have been found to be sensitive immunohistochemical markers of most ovarian sex cord-stromal tumors.129 Inhibin B, however, has been found to be elevated in both sex cord-stromal and epithelial tumors and hence is of limited value in differentiating between the two entities. In addition, low levels of inhibin A in the cyst fluid of epithelial ovarian tumors has recently been reported to be associated with a worse prognosis.130 Inhibin B has been found to be the predominant inhibin secreted in males and is produced by the Sertoli cells of the testes. It also has a negative feedback role on FSH from the pituitary, and its production is regulated by spermatogenesis. Inhibin B levels correlate with sperm count and testicular volume131–133 but cannot distinguish between spermatid arrest and obstructive azoospermia—a condition in which sperm counts are normal.134 As such, it is unlikely to replace testicular biopsy in the evaluation of male infertility. Activins
26
Activins are made up of dimers of the inhibin β subunit (βAβA, βAβB, or βBβB) and have a molecular weight of approximately 25 kDa (see Fig. 2-5).135 They are predominantly produced by the granulosa cells of the ovary. Activin/inhibin mRNA and protein have also been detected in extragonadal sources, including the placental trophoblast and decidua, testes, adrenal cortex, brain, spinal cord, and anterior pituitary. This implies that activin has diverse physiologic roles that are not confined to the reproductive system.
Acting either alone or with FSH, activin exerts an autocrine effect on granulosa cells to promote and maintain granulosa cell differentiation. It promotes FSH receptor expression on small undifferentiated granulosa cells136, enhances their response to FSH and LH, and hence increases aromatase activity and estrogen production.137 This may explain how small preantral follicles progress from a gonadotropin-independent to a gonadotropindependent stage of development. After the granulosa cells acquire FSH receptors, further growth and differentiation of those cells to a preovulatory stage would be driven by activin acting in concert with FSH. Activin also inhibits both spontaneous and LH/hCG-induced increases in progesterone output by human follicles,137 implying that it plays a role in delaying the onset of premature luteinization. Activin also has a paracrine effect on thecal steroidogenesis by inhibiting thecal androgen output. It has been proposed that at earlier stages of follicular development, when the androgen requirements are low, thecal androgen synthesis is kept in check due to the relative excess of activin over inhibin and follistatin. However, as dominant follicles approach preovulatory status, increasing granulosa cell expression of inhibin and follistatin upregulates thecal androgen synthesis and ensures that the granulosa cells receive an adequate supply of aromatase substrate for conversion to estradiol. Activin stimulates pituitary FSH production, acting as a functional antagonist to inhibin (Fig. 2-6).102 It achieves this effect by increasing FSH mRNA synthesis as well as by increasing the stability of produced mRNA. Its actions are intimately modulated by intrapituitary concentrations of follistatin, which bind to activin to limit its bioavailability. Free activin levels as measured by competitive protein binding assay, using follistatin as binding protein, show very little change over the menstrual cycle.138 However, activin levels were elevated throughout the cycle in older versus younger women, suggesting that activin may play an endocrine role in maintaining FSH elevation in reproductive aging.139 Lower levels of activin are detected in PCOS patients with a simultaneous increase in inhibins and follistatin, suggesting that an imbalance in these hormones may contribute to an abnormal LH/FSH ratio.125,140 Follistatin
In the ovary, follistatin is produced by the granulosa cells in antral follicles as well as by luteinized granulosa cells, which are under the positive regulation of FSH. It modulates the function of granulosa cells in favor of luteinization or atresia by neutralizing the effects of activin. It may also directly modulate progesterone metabolism by granulosa cells.141 Follistatin is a single-chain polypeptide (315 amino acids) that functions as the binding protein for activin, thereby neutralizing it. Most of its biology is explained by its antagonism with activin. Follistatin exists in two forms; as full-length follistatin (FS 315) in the circulation and as processed follistatin (FS 288) in follicular fluid142 and the pituitary. It is part of an intrapituitary negative feedback loop where activin promotes FSH biosynthesis and the increased expression of follistatin limits its bioavailability for binding to the activin receptor on target cell membranes. It has been shown that the processed isoform of follistatin (FS 288) binds to cell-surface heparan sulfate proteoglycans with a higher affinity than FS 315.143 Because proteoglycans are anchored to cell membranes, this suggests that this would limit follistatin diffusion from the site of release, leading to high local concentrations of
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 27
Chapter 2 Ovarian Hormones Table 2-4 Autocrine and Paracrine Growth Factors and Cell–cell Signaling in the Ovary
Brain
– – +
Hypothalamus
GnRH neurons
Pulsatile GnRH secretion
Pituitary
– +
LH LH FSH and FSH
+ – –
Factor/ Hormone
Site of Production
Site of Action (type)
TGFα and EGF
Theca cells
Theca (autocrine) Granulosa (paracrine)
Growth stimulation
Interleukin-1 Interleukin-6 Interleukin-8
Granulosa cells Granulosa cells Theca cells
Granulosa (autocrine) Theca, granulosa Theca, granulosa (auto/paracrine)
Cell differentiation
TGFβ
Theca cells Granulosa cells
Granulosa, theca (auto/paracrine)
Growth inhibition Cell differentiation
IGF-I IGF-II
Granulosa Theca
Granulosa, oocyte and theca (auto/paracrine)
Growth stimulation Cell differentiation
Bone morphogenic proteins (BMP)
Theca
Granulosa (paracrine)
Cell differentiation
Inhibins
Granulosa
Oocyte, theca, and granulosa (auto/paracrine)
Cell differentiation
Activins
Granulosa
Granulosa (autocrine)
Cell differentiation
Function
Estradiol
Growth Factors/Cytokines As Intraovarian Regulators Follicular development Inhibin Estradiol
Follistatin Activin
Mature follicle
Certain growth factors have been implicated in cellular communications within the ovary, including insulin-like growth factors IGF-I and IGF-II, epidermal growth factor (EGF), transforming growth factor-α (TGFα), basic fibroblast growth factor (bFGF), cytokines such as interleukins (IL-1 and IL-6), and tumor necrosis factor (TNFα). Growth factors and cytokines that are important as intraovarian regulators are outlined in Table 2-4.
Progesterone
Insulin-like Growth Factors Ovulation Corpus luteum
Figure 2-6 A diagrammatic presentation of the hypothalamic-pituitaryovarian axis. Developed follicles secrete steroid hormones (estradiol and progesterone) and peptide hormones (inhibin, activin, and follistatin); all collectively control secretion of gonadotropins. Estradiol and progesterone, depending on concentration, have either positive or negative feedback and can alter the frequency and/or amplitudes of pulses at the level of both the hypothalamus and pituitary.
follistatin being maintained. The membrane-anchored follistatin would be able to compete with activin receptors on nearby cells, thus modulating the biologic effects of activin. Once bound to activin, follistatin is able to accelerate the endocytotic internalization and lysosomal degradation of activin by pituitary cells.144 Follistatin levels as measured by sensitive and specific twosite enzyme immunoassay are significantly higher in women with PCOS in comparison to controls. Higher follistatin levels combined with lower activin levels in these patients suggest its role in the lack of pre-ovular follicle development and FSH suppression.125
IGF-I and IGF-II promote cellular mitosis and differentiation in a variety of systems and play an important role in modulating folliculogenesis in an autocrine/paracrine fashion.145–147 Insulin-like growth factors consist of two single-chain polypeptide growth factors that are structurally and functionally similar to proinsulin. The IGF autocrine/paracrine system includes IGFs, their specific receptors in target cells, and a family of IGF-binding proteins that regulate their bioavailability. Both IGF-I and IGF-II are produced in the ovary and augment the effects of the gonadotropins, although the main IGF in human follicles is IGF-II.148 In small antral follicles, both IGF-I and IGF-II are expressed but restricted to thecal cells. However, IGF-I receptor mRNA has been detected only in granulosa cells.146 It serves as an autocrine regulator in thecal cells and as a paracrine regulator in granulosa cells. In dominant follicles, however, no IGF-I mRNA has been detected either in thecal or in granulosa cells, and IGF-II expression is restricted to granulosa cells only. IGF-I receptors are present in granulosa cells only, and IGF-II receptors are expressed in both cell types.146 Thus, in the dominant follicle, IGF-I functions mainly as a paracrine regulator149,150 and IGF-II acts as an autocrine factor. This suggests that IGF-II has an important role in coordinating differential follicular development within the ovary.
27
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 28
Section 1 Basic Science Epidermal Growth Factor (EGF), Transforming Growth Factorα (TGFα), and Basic Fibroblast Growth Factor (bFGF)
A number of other peptide growth factors have been implicated as regulators of follicular development and steroidogenesis (see Table 2-4).151 These include EGF, TGFα, and bFGF. EGF is a single-chain polypeptide of 53 amino acids with three disulfide bonds and has mitogenic effects in a variety of ectodermal and mesodermal tissues. TGFα is a 50-amino acid peptide with 30% to 40% homology with EGF. The EGF receptor is a 170-kDa glycoprotein with tyrosine kinase activity. TGFα binds to EGF receptors with the same affinity as EGF. The presence of EGF/TGFα and bFGF as well as their receptors in the ovary has been shown both at the protein and mRNA levels. The presence of immunoreactive EGF as well as EGF receptors has been identified in the preovulatory follicles152 and corpus luteum.153,154 Furthermore, studies have shown the presence of TGFα155 and bFGF156 mRNAs in follicular cells; studies have also shown that the TGFα message is upregulated by FSH in vivo. FSH plus TGFα or FSH plus EGF resulted in significantly elevated progesterone and 20α-hydroxyprogesterone levels in granulosa cells in culture.157 The presence of TGFα message in cultured granulosa cells and the fact that it mediates its action via binding to EGF receptor all point to its autocrine role in granulosa cell differentiation, follicle development, and selection. Expression of bFGF and its receptor mRNA has been detected in fetal ovaries and in granulosa cells.158,159 bFGF has been shown to be mitogenic for granulosa cells and to cause an inhibitory action on granulosa cell differentiation and thecal cell steroidogenesis.160,161 It also has potent angiogenic activity.162 Cytokines
Cytokines primarily produced by white blood cells modulate various cellular functions. The cytokines in the ovary are secreted both by the immune cells that are recruited from the circulation in the ovarian stroma and by the thecal and granulosa cells. A number of cytokines have been linked to modulation of ovarian function, including interleukins IL-1 and IL-6 and TNFα. Both IL-1 and IL-6 have been found in significant amounts in follicular fluid.163,164 Granulosa cells accounted for the majority of immunostaining for IL-1 and IL-6 in follicular aspirates, which suggests that these cytokines are produced in granulosa cells164,165 and that they affect granulosa function.166 During folliculogenesis, IL-I promotes proliferation and suppresses differentiation. In the ovulatory process, it promotes ovulation by increasing production of chemokines, steroids, ecosanoids, and vasoactive substances.167 IL-6 demonstrates inhibitory effects on both estradiol and progesterone secretion by FSH-stimulated granulosa cells.168 Elevated IL-6 levels during genital infections may provide a possible link to reproductive dysfunction. TNFα expression has also been detected in granulosa cells of human antral and atretic follicles by immunohistochemistry.169 Also, in vitro treatment with TNFα enhanced steroidogenesis in both healthy and atretic follicles,170 suggesting that TNFα has a paracrine and/or autocrine role. Nonetheless, the physiologic implications of these actions remain unclear and require further investigation. Neuropeptides
28
Some evidence suggests that an independent ovarian-central nervous system axis exists.171,172 Electrical stimulation of the
hypothalamus in hypophysectomized and adrenalectomized rats produced a change in ovarian steroidal synthesis that was independent of changes in ovarian blood flow.173 In addition, murine thecal cells can produce androgens under adrenergic stimulation.174 Adrenergic innervation of the ovary acts primarily on the thecal-interstitial cells through β2 receptors, synergizing with the effects of gonadotropins in the production of ovarian androgens.174 This may in turn play a role in the regulation of estrogen production by granulosa cells, thereby influencing follicle recruitment and selection.
REGULATION OF OVARIAN HORMONES The hypothalamic-pituitary axis plays a key role in the regulation of hormonal synthesis by the ovaries. The hypothalamus is connected to the pituitary gland via a portal vascular system that allows transport of hypothalamic releasing factors from the brain to the pituitary (see Fig. 2-6). The hypothalamus, being the coordinating center, provides precise signals via pusatile release of GnRH to the gonadotrophs, which in turn secrete LH and FSH. Any interruption in this connection results in low gonadotropin levels, leading to failure of ovarian hormone secretion.
Hypothalamic Regulation Gonadotropin-releasing Hormone
The gonadotropin-releasing activity in hypothalamic extracts was first demonstrated in the late 1950s. In 1971, almost 15 years later, GnRH was first isolated and characterized from a hypothalamic extract. This was followed by its synthesis and its clinical availability. However, early clinical studies proved disappointing until the nature of its pulsatile secretion was recognized. In their classic experiment in the rhesus monkey, Knobil and colleagues showed that normal LH and FSH release required the pulsatile infusion of GnRH at approximately 60-minute intervals175 Furthermore, a change in pulse frequency (lesser or greater) or continuous infusion resulted in failure of LH and FSH secretion and release (Fig. 2-7).176 These observations were confirmed in humans. Pulsatile GnRH infusion reproduces appropriate patterns of hormonal changes, resulting in ovulation and fertility in women with hypothalamic amenorrhea. Physiologic Role of GnRH
GnRH is produced by secretory neurons located in the arcuate nucleus of the medial basal hypothalamus and the preoptic area of the anterior hypothalamus. The nerve terminals are found in the lateral portions of the external layer of the median eminence adjacent to the pituitary stalk.177 GnRH has an intrinsically pulsatile pattern of secretion, which is under the control of a hypothalamic pulse generator in the arcuate nucleus.178,179 The frequency and amplitude of the pulsatile rhythm of GnRH secretion are crucial in regulating gonadotropin secretion and hence gonadal activity.180,181 Physiologic frequency (approximately hourly pulses) tends to upregulate GnRH receptors, enhancing pituitary responsiveness to subsequent stimulation by GnRH. This leads to a “self-priming” effect, whereby LH levels have been shown to increase sequentially with sequential GnRH pulses. A longer frequency causes anovulation and amenorrhea; a shorter frequency or constant exposure to GnRH downregulates the GnRH receptors, inducing refractory gonadotropin responses.176,182–184
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 29
Chapter 2 Ovarian Hormones Continuous
including acetylcholine, catecholamines, serotonin, opioids, and γ-aminobutyric acid.185 Norepinephrine is believed to stimulate GnRH release whereas opioids exert inhibitory effects. Dopamine can produce both inhibitory and excitatory GnRH responses, depending on the physiologic state.186
Pulsatile 200
15
150
10
100
5
50
0
FSH (ng/ml)
LH (ng/ml)
Pulsatile 20
Biochemistry and Biosynthesis
GnRH is a linear decapeptide, derived from the post-translational processing of a large precursor molecule, prepro-GnRH. The prepro-GnRH molecule consists of 92 amino acids in a tripartite structure (Fig. 2-8). It begins with a signal peptide of 23 amino acids, which is followed by the decapeptide and then a Gly-LysArg sequence needed for proteolytic processing and C-terminal amidation of GnRH molecules. The last 56 amino acid residues are collectively known as the GnRH-associated peptide (GAP), which may have prolactin-inhibiting activity.187,188 Knowledge of GnRH structure led to the development of many clinically important long-acting GnRH agonists, including buserelin, leuprolide, and nafareline (see Fig. 2-8). Gonadotropin-releasing hormone is encoded from a single gene on the short arm of chromosome 8p21-p11. The human gene contains 4 exons; exon 2 encodes pro-GnRH, exon 3 and part of exon 2 and 4 encode the GAP protein, and exon 4 encodes a long 3′ untranslated region. Molecular processing occurs primarily in the nucleus of the cell body (soma). After transcription, the mRNA is transported to the cytoplasm where translation takes place and it is converted into the decapeptide. GnRH and its cleavage products, GAP and pro-GnRH, are then transported to the nerve terminals where they are secreted in tandem into the portal circulation.187,189,190
0 10
5
0
5
10
15 Days
20
25
30
35 40
Figure 2-7 Change in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in gonadotropin-releasing hormone (GnRH) deficient monkeys, according to the mode of delivery of GnRH. A continuous infusion decreased both LH and FSH levels, which are restored by pulsatile GnRH administration. (Data from Belchetz PE, et al: Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropinreleasing hormone. Science 202:631-633, 1978.)
The “pulse generator” is subject to modification by two main inputs: (1) hormone-mediated signals and (2) neural signals. Hormone signals include negative and positive feedback from the gonadal steroids (e.g., estrogen and progesterone) as well as gonadal protein hormones. Neural signals may come from a wide variety of sources and are mediated by neurotransmitters,
C terminal
Pre-pro-GnRH
1
2
3
4
5
6
7
8
9
10
Glu
His
Trp
Ser
Tyr
Gly
Leu
Arg
Pro
Gly
GnRH associated peptide (56aa) N terminal Native GnRH
1
2
3
4
5
6
7
8
9
10
pyroGlu
His
Trp
Ser
Tyr
Gly
Leu
Arg
Pro
Gly-amide
6 D-Ser
Leu
Buserelin (agonist)
1
2
3
4
5
pyroGlu
His
Trp
Ser
Tyr
(tertButly)
7
8
9
Arg Pro-ethylamide
Leuprolide (agonist)
Figure 2-8
1
2
3
4
5
6
7
pyroGlu
His
Trp
Ser
Tyr
D-Leu
Leu
8
9
Arg Pro-ethylamide
The structures of native gonadotropin-releasing hormone (GnRH) and some analogs currently in clinical use.
29
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 30
Section 1 Basic Science Measurement
GnRH has a short half-life (2–4 min) due to its degradation by peptidases in the hypothalamus and pituitary gland. These peptidases cleave the molecule at the Gly-Leu bond and at position 10. Due to the large dilutional effect, peripheral GnRH serum levels are too low for pulse characteristics to be determined reliably in humans. However, the simultaneous measurement of circulating levels of LH in hypophysial-portal and peripheral blood samples in other species has been shown to correlate closely with GnRH release.191,192 As such, frequent measurements of LH pulses can be used as an accurate indicator of GnRH secretion patterns. FSH also correlates with GnRH secretion, but is less useful due to its long half-life.
these cells responsive to LH and augmenting progesterone secretion. Progesterone then increases FSH release in midcycle. Biochemistry and Biosynthesis
The anterior pituitary produces three glycoprotein hormones: LH, FSH, and thyrotropin-stimulating hormone (TSH), all of which share a similar biochemical structure. Each consists of a heterodimer of two noncovalently linked protein subunits, αβ. Each subunit is cysteine-rich and contains multiple disulfide linkages (Fig. 2-9). There are also multiple carbohydrate moieties on both subunits that are important in the metabolism and biologic activity of the hormones.200,201 The α subunit is common to all three hormones, whereas the β subunit is unique.
Regulation by Pituitary Hormones As mentioned above, GnRH action on gonadotrophs stimulates gonadotropin production and release in a pulsatile fashion. In addition, LH and FSH release from the pituitary is also affected in both a positive and negative manner by estrogen and progesterone as well as by the protein hormones secretion by the ovaries (see Fig. 2-6). The positive effect of estrogen and the negative effect of progesterone on the gonadotropins depend on the level of steroid hormone and the duration of exposure to the gonadotrophs. On the other hand, both LH and FSH are required for ovarian estrogen synthesis and the level of estrogen production depends on the time of exposure and the level of gonadotropins.193,194 Nonetheless, a disordered signal from the pituitary gland may result in infrequent ovulation (oligo-ovulation) or absent ovulation (anovulation).
Glu56Ala LH
α 1
S
30
As discussed above, LH regulates ovarian steroidogenesis. The surge of LH in the middle of the menstrual cycle is also responsible for inducing ovulation. The surge occurs as a result of a dramatic rise in estradiol produced by the preovulatory follicle, which produces a positive feedback on LH. The midcycle surge stimulates the resumption of meiosis and the completion of reduction division in the oocyte with release of the first polar body. Proteolytic enzymes and prostaglandins are increased in response to LH, leading to a release of the oocyte from the ovary.195 Finally, the continued secretion of LH after ovulation converts the remaining follicular cells in the ovary to the corpus luteum and stimulates the corpus luteum to produce progesterone by enhancing the conversion of cholesterol to pregnenolone. Follicle-stimulating hormone regulates ovarian estrogen synthesis by binding to the FSH receptor on the surface of the granulosa cell and is required for follicular maturation and growth.196,197 This results in elevated cyclic adenosine monophosphate (cAMP) levels and the induction of aromatase, which converts androstenedione from the neighboring thecal cells to estrone. FSH also induces expression of 17βHSD type 1, which converts estrone to estradiol. Increased secretion of estradiol leads to further proliferation of granulosa cells and follicular growth and an increase in the number of estradiol receptors.196,198,199 In the mature follicle, FSH and estradiol increase the LH receptors’ expression in granulosa cells, making
Y 78 92
S Y 30
β 1
121
IIe15Thr
Glu54Arg
Ser102Gly
Trp8Arg FSH
α Regulation by Luteinizing Hormone and Follicle-stimulating Hormone Physiologic Role
Y 52
1
β
S Y
Y
7
24
Y
Y
62
78 92
S
1
110
Cys51Gly Val61Δ2bp stop87
Cys82Arg
hCG
α 1
S Y 13
β
Y
Y
52
78 92
S Y 30
0
0
0
0
122 127 132 137
1
145
Val79Met Figure 2-9 A schematic presentation of the gonadotropin subunits, showing the sizes, locations of carbohydrate side chains, and currently known mutations and polymorphisms: The symbols Y and O represent the locations of the N-linked and O-linked carbohydrate side chains, respectively. The symbol S represents disulfide bonds. The arrows indicate the positions of point mutations/polymorphisms. The numbers below the right end of the bars indicate the number of amino acids in the mature subunit protein. Cα, common α subunit; LHβ, luteinizing hormone β subunit; FSHβ, follicle-stimulating hormone β subunit; HCGβ, human chorionic gonadotropin β subunit. (Adapted from Huhtaniemi I: Functional consequences of mutations and polymorphisms in gonadotropin and gonadotropin resistant genes. In Leung PCK, Adashi E (eds): The Ovary, 2nd ed. London, Elsevier Academic Press, 2004, p 56.)
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 31
Chapter 2 Ovarian Hormones α Subunit
The human α subunit gene is located on chromosome 6p21.123 and is composed of 4 exons. The first exon is noncoding. The gene encodes a 14-kDa polypeptide that consists of a 24-amino acid signal peptide and the mature α subunit of 92 amino acids with 10 cysteine residues and two N-linked oligosaccharide groups.202 The cysteine residues participate in the intrasubunit disulfide linkages. The α subunit is more abundant than the β subunit, and unassociated, or “free,” α subunits are present in the serum and pituitary. They have little known biologic activity. Hence, only the αβ heterodimer possesses biologic activity.
Regulatory domain A/B
DNA binding domain C
Mutations in Gonadotropin Genes
Although rare, mutations in gonadotropin genes can result in clinical disorders, which have been described in the literature. In fact, the subject has been recently reviewed extensively.201,209 There are several reports of neutral polymorphisms, but no activating mutations have been reported so far in the α subunit gene.209 Examples of mutations in the LHβ subunit include a single amino acid substitution (Glu to Arg) at codon 54210 that is associated with hypogonadism in homozygous males and with a high incidence of infertility in heterozygotes. In addition two point mutations—Trp to Arg at codon 8 and Ile to Thr at codon 15—have been described in five women with immunologically anomalous LH but with hyperbioactivity.211 However the direct relationship of these mutations with a specific pathogenesis remained elusive. The other variant of LHβ (polymorphism) with substitution of Serine to Glycine at codon 102 in exon 3 has been found to be population-specific in 4% of women in Singapore with menstrual disorders. Several inactivating mutations have been described in the FSHβ subunit gene (see Fig. 2-9). The first mutation reported
Ligand binding domain E
A
mRNA
Nucleus
Pre-mRNA
β Subunit
The β subunits for LH and FSH are encoded by separate genes and are located on different chromosomes. The gene coding for the LHβ subunit consists of three exons and is present in a complex gene cluster on human chromosome 19q13.3.203 The cluster includes six chorionic gonadotropin β (CGβ) genes that are presumably derived from single ancestral LHβ gene by gene duplication.204 Both LHβ and CGβ proteins are structurally and functionally similar. They are approximately 80% homologous in amino acid sequence. Both propeptides contain a 20-amino acid signal sequence. The mature LHβ and CGβ subunits consist of 121 and 145 amino acids, respectively. The major difference between LHβ and CGβ proteins is the presence of a 24-amino acid C-terminal peptide in CGβ, which is heavily glycosylated, with four O-linked carbohydrate moieties (Fig. 2-10). The gene for the FSHβ subunit is located on the short arm of chromosome 11p13 and, like the gene for LH, it consists of three exons.205 The molecular size of FSH is 33 kDa, consisting of a signal peptide of 18 amino acids and the mature FSHβ protein of 111 amino acids. Like α subunits, both LHβ and FSHβ subunits contain 10 cysteines for disulfide formation. Compared to FSHβ and CGβ subunits, LH does not have a terminal sialic acid on its carbohydrate side chain. This results in a shorter metabolic clearance time for LH, compared to FSH and HCGβ subunits. HCGβ has the highest content of sialic acid and has the longest half-life.206,207 Deglycosylation of gonadotropins has no effect on receptor binding but abolishes signal transduction.208
Hinge region D
HRE C C
CA AB 1
Hormone binding
AB E
C
DNA binding
3
Dimerization
2
Dissociation of HSP90
E
AB Protein
4
E
HSP90 HSP90 Steroid hormone (estrogen)
Cytoplasm
B Figure 2-10 Basic structure and general mechanism of action for cytoplasmic/nuclear steroid hormone receptors. A, Basic structure of steroid hormone receptor. B, Mechanism of action involving steps 1–6 as described in the text. HSP90, heat shock protein; HRE, hormone response element; CA, coactivators.
was a homozygous 2bp deletion in a codon 61 (Valine) in a woman who presented with delayed puberty, amenorrhea, and infertility.212 The mutation was a nonsense mutation leading to altered amino acid sequence after codon 60, leading to a stop codon at residue 87. The mutated protein was altered and was thus unable to associate with the α subunit and was nonfunctional. The patient was treated with exogenous FSH, leading to follicle maturation and pregnancy. Another case report on FSH mutation with a similar phenotype was found to be heterozygote for two FSH mutations: the first was a nonsense mutation at codon 61 and the second was a substitution of Cysteine to Glycine at codon 51. The loss of the cysteine residue was likely responsible for the altered conformation change and loss of function leading to the phenotype.213 An inactivating mutation leading to the substitution of Cysteine to Arginine residue at codon 82 was described in an infertile man.214 Measurement of LH and FSH
It has been difficult to develop highly specific immunoassays for the gonadotropins due to the high homology of the glycoprotein
31
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 32
Section 1 Basic Science
32
hormones as well as the need to distinguish between free α subunits and intact hormones. Cross-reactivity with the α subunit has made it difficult to accurately measure LH and FSH with RIAs that use polyclonal antibodies.215–217 In addition, there is microheterogeneity in both pituitary and circulating gonadotropins due to the degree of glycosylation. Variation in oligosaccharide content and structure also causes charge microheterogeneity, resulting in serum isoforms that separate over the pH range of 6.5 to 10 on electrofocusing.218 Although the clinical significance of this microheterogeneity of circulating isoforms remains unknown, it affects immunoreactivity as detected by various antibodies, all of which lead to variability among different immunoassays. Microheterogeneity also affects the biologic activity and may be primarily responsible for the discrepant results generated by immunoassays versus bioassays. The other problem stems from a lack of a suitable reference preparation for both immunoassays and bioassays. The international reference preparation (IRP) of purified human urinary menopausal gonadotropins (2nd IRP-hMG) was established by the World Health Organization (WHO) and has been widely used in most immunoassays and bioassays. The unitage assigned to IRP was defined by bioassays and formed the basis of all subsequent purified pituitary preparations as, for example, the WHO international standard (2nd IS). Most commercial assays are calibrated against 2nd IS. Although the biologic potency estimates are given for the IRP or IS, the immunoreactivity varies in different immunoassays depending on the antibody specificity. In recent years, two-site directed immunoradiometric (IRMA) or immunochemiluminometric (ICMA) assays have been developed and are based on the use of two monoclonal antibodies. These have helped overcome most limitations of RIAs.219 These assays are automated and show exquisite sensitivity approaching 0.1 mIU/mL. Furthermore, these assays are not affected by the presence of free α subunits and correlate better with bioassays. The high sensitivity of these assays also allows detection of low levels seen in early puberty. Luteinizing hormone bioassays utilize dispersed mouse or rat Leydig cells or a Leydig cell tumor cell line (MA-10) in culture220,221 and measure testosterone production in vitro. These assays measure the biologic activity of circulating LH under physiologic conditions. This is important because the biologic activity of LH changes with alterations in glycosylation and the tertiary structure of the molecule. The combination of bioassay and RIA permits the calculation of bioactive/immunoreactive ratios, which can provide a useful index of qualitative changes of the LH molecule.219,222 Although the bioactive and immunoactive LH profiles are generally well correlated during physiologic changes, significant discrepancies can occur in some pathologic states. For example, inactivating mutations in the LHβ gene result in elevated levels of immunoreactive LH but a marked loss of bioactivity. In vitro bioassays for FSH activity using rat granulosa cells or Sertoli cells measure production of cAMP or aromatase activity in response to FSH. The sensitivity of these assays is about 2.5 mIU/mL. Alhough in vitro bioassays have been valuable in elucidating the physiology, they remain cumbersome and time consuming and are not practical for routine clinical use. Measurement of LH and FSH is useful in the diagnosis of gonadal function disorders (Table 2-5). Elevated levels of FSH generally indicate ovarian failure but may be seen in some
Table 2-5 Role of Pituitary Hormones in Assessment of Female Infertility Hormone
Hormone Levels
Interpretation
Prolactin
↑Prolactin
Evaluate for prolactinoma after excluding hypothyroidism, pregnancy, macroprolactinemia as cause.
LH and FSH
↓ LH, ↓ FSH
Hypothalamic or pituitary disease
↑ LH, ↑ FSH
Premature ovarian failure
↑ LH, ↓ or normal FSH
Polycystic ovary syndrome
patients with viable ovarian follicles.223 Although rare, high gonadotropin levels associated with gonadotropin-secreting pituitary tumors or ectopic gonadotropin-producing tumors. In an amenorrheic patient, an elevated LH level with normal FSH and LH-to-FSH ratio typically (but not invariably) of greater than 2 is suggestive of PCOS. Low levels of these hormones are indicative of pituitary or hypothalamic dysfunction and occur together with low serum estradiol levels. For further assessment of pituitary reserve, provocative GnRH testing is required. LH and FSH responses to intravenous injection of 100 μg GnRH are measured at 20 and 60 minutes. Lack of response may suggest the likely diagnosis of hypogonadotropic hypogonadism; however, its sensitivity and specificity are low in patients receiving exogenous sex steroids.224 Prolactin Physiologic Role of Prolactin
The main role of prolactin is the stimulation of lactation in the postpartum period. Its effect is blunted by estrogen and progesterone; the decrease in both these hormones after parturition allows lactation to occur. Prolactin also acts at the hypothalamus to suppress gonadotropin production, primarily by inhibiting the pulsatile secretion of GnRH. Thus, conditions associated with hyperprolactinemia can cause hypogonadism, which leads to shortened luteal phases, decreased numbers of granulosa cells, anovulation, and amenorrhea in women. In men, excess prolactin can lead to decreased spermatogenesis, decreased libido, impotence, and infertility. Biochemistry and Biosynthesis
Prolactin is a single polypeptide with a molecular weight of 22 kDa. It consists of 198 amino acids and is folded into a globular shape connected by disulfide bonds. It is remarkably homologous to human growth hormone (hGH) and human placental lactogen (hPL). The gene for prolactin is found on chromosome 6, and seems to have been evolutionarily derived from a common somatomammotropic (hGH-hPRL-hPL) precursor. It is produced by lactotrophs in the pituitary, which make up almost 50% of the total pituitary cell population. Its production is under tonic inhibition by dopamine, produced by the tuberoinfundibular cells, and the hypothalamic tuberohypophyseal dopaminergic system. Prolactin is extremely heterogeneous and exists in at least four different molecular forms225–227: (1) little prolactin, molecular weight (MW) 23 kDa, a nonglycosylated monomeric hormone with high receptor binding and bioactivity; (2) G, or glycosylated prolactin, MW 25 kDa, which has reduced immunoreactivity; (3) big prolactin, MW 50 kDa,
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 33
Chapter 2 Ovarian Hormones consisting of a mixture of both dimeric and trimeric forms of G prolactin; and (4) big-big prolactin, MW 100 kDa, consisting of G prolactin covalently coupled with an immunoglobulin, also known as macroprolactin. The big and big-big forms have lower receptor-binding affinity, but may be converted to little prolactin by reduction of the disulfide bonds. As such, discrepancies can exist between measured prolactin levels and the clinical effects. Measurement
Prolactin levels are measured by use of IRMA and ICMA. These methods give excellent reproducibility, sensitivity, and assay efficiency; however, they vary in their abilty to react with biologically inactive macroprolactin. Hence, a measured serum immunoreactive prolactin level often does not correlate with expected clinical effects. A polyethylene glycol precipitation method should be used to detect the macroprolactinemia.228 The other caveat is that these samples are usually assayed at a single dilution. As such, extremely high levels of prolactin (≈1000 ng/mL), such as those seen in macroprolactinomas, may saturate both capture and localizing antibodies, leading to a falsely low value in some one-step sandwich immunoassays. This has been known as the hook effect. Thus, in patients with macroadenomas, a 1:100 serial dilution should be performed if the assay is prone to this hook effect.
MECHANISMS OF ACTION OF HORMONES Ovarian/pituitary hormones circulate in very low concentrations in the extracellular fluid, generally in the range of 10–15 to 10–9 mol/L. To exert their biologic effects on the target cells, special recognition mechanisms are required. Target cells are able to discriminate between the different hormones at low concentrations by depending on cell-associated recognition molecules called receptors. Hormones exert their biologic effects by interacting with these high-affinity receptors, which in turn trigger one or more effector systems within the cell. The high affinity, specificity, and receptor expression level together define the nature and degree of biologic response of a hormone. All receptors have at least two functional domains, a recognition domain and a signal-generating domain. The recognition domain binds to the hormone, and the second domain generates a signal that couples hormone recognition to some intracellular function. This coupling of hormone binding to signal transduction, or receptor–effector coupling, provides the first step in the amplification of a hormonal response and distinguishes the target cell receptor from the plasma carrier proteins that bind hormone but do not generate a signal. Just on the basis of the location of the hormone receptor (i.e., intracellular/nuclear or cell surface), two distinct mechanisms of hormone actions can be classified. These mechanisms further differ by the nature of the signal transduction pathway or second messenger responsible for mediating hormone action (Table 2-6). Examples of nuclear receptors include steroid hormones that are lipophilic and pass through the cell membrane to interact with receptors located either within the cytoplasm or the nucleus. This in turn affects gene transcription within the nuclear compartment. Polypeptide hormones (i.e., LH, FSH, hCG, GnRH, inhibins, and activins) and growth factors that are hydrophilic interact with cell-surface receptors that are located
Table 2-6 Classification of Receptors for Steroid and Peptide Hormones Hormones that Bind to Intracellular/Nuclear Receptors
Hormones that Bind to Cell Surface Receptors
Type 1 receptor, classical steroid hormone receptor Requires ligand binding for activation Homodimerization pattern Estrogen receptor Progesterone receptor Androgen receptor Glucocorticoid receptor Mineralocorticoid receptor
Seven-transmembrane domain receptors Second messenger is cAMP LH FSH Second messenger is calcium and/or phosphatidylinositols GnRH TRH Second messenger is cGMP Nitric oxide Atrial natriuretic factor
Type 2 receptors
Single-transmembrane domain receptors Intrinsic kinase activity Second messenger is tyrosine kinase IGF Insulin EGF Second messenger is serine kinase Activin TGFβ Aquired kinase activity by interaction with transducer molecules Growth hormone Prolactin
Able to bind DNA in the absence of ligand, exerting repressive effect Heterodimerization pattern Thyroid Hormone Retinoic Acid Receptor Vitamin D receptor Retinoid X receptor Orphan receptor A. Ligand unknown
on the plasma membrane. They trigger a plethora of signaling activity in the membrane and cytoplasmic compartments as well as exerting parallel effects on the transcriptional apparatus in the nuclear compartment. These cell surface receptors can be further classified based on the second messenger into four major subgroups, as listed in Table 2-6.
Steroid Hormone Action Nuclear Receptors Superfamily
Steroid hormone nuclear receptors (estrogen receptor [ER], progesterone receptor, and androgen receptors) are ligandinducible transcription factors that regulate the expression of target genes involved in reproduction and metabolism. They belong to the superfamily of nuclear hormone receptors and share many structural and functional features.229 Other members of the superfamily include receptors for glucocorticoids, mineralocorticoids, thyroid hormones, 1,25-dihydroxy vitamin D3, retinoic acid, and an ever-increasing number of orphan receptors, which show structural similarity but for which ligands are not known. Within this nuclear receptor superfamily, three main groups have been identified based on the differences in their functional and recognition characteristics230: type 1, or steroid receptor subclass; type 2, or thyroid/retinoid/vitamin D3 receptor subclass; and a third subclass of orphan receptors. Type 1 (“Steroid” or “Classical”) Receptor Subfamily
This includes the ER as well as the progesterone, androgen, glucocorticoid, and mineralocorticoid receptors. These receptors cannot bind to DNA in the absence of ligand and thus remain functionally silent. They exist as cytoplasmic/nuclear, multimeric complexes that are in association with heat shock proteins (e.g., HSP90, HSP70, and HSP56). The association of the
33
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 34
Section 1 Basic Science ligand with the receptor and dissociation of the heat shock proteins are required for activation of the receptor.
ligand binding is responsible for interaction with coactivators or corepressors.
Type 2 Receptor Subfamily
Cellular Mechanism of Action of Steroid Hormones
This includes the thyroid hormone, vitamin D3, and retinoic acid receptors, as well as the retinoid X receptor. In the absence of ligand, these receptors can bind to DNA and exert the repressive effect or silence their respective promoters. Unlike steroid receptors, type 2 receptors bind constitutively to response elements and are capable of forming heterodimers with the retinoid X receptor. These interactions may serve to modulate the amplitude of the transcriptional response to the ligand. Most of the early knowledge about steroid hormone mechanism of action has been derived from in vitro and in vivo binding studies that used radiolabeled estradiol as a ligand.231 The role of ERs in the regulation of breast cancer growth has been well studied over the past four decades; it was the first steroid receptor to be discovered in the early 1960s. This led to the subsequent elucidation of a general pathway for steroid hormone action. In general, nuclear receptors share a common protein architecture consisting of five functional domains232 as illustrated in Figure 2-10A. Amino-Terminal Transactivation Domain (A/B Region)
This is the most variable domain in terms of sequence and length in the family of nuclear receptors. It can range in size from 20 amino acids in the vitamin D3 receptor to 600 amino acids in the mineralocorticoid receptor. It usually contains a transcription activation function (TAF-1), which interacts with other core transcriptional machinery (e.g., coactivators) to activate target gene transcription. Central DNA-binding Domain (C Region)
This region is essential for activation of transcription. It encodes two zinc finger motifs and has a very high degree of homology among all types of nuclear receptors. Hormone binding to the receptor induces specific conformational changes in this region, allowing receptor binding to the hormone-responsive element (HRE) of the target gene. The amino acid sequence that lies between the first and second zinc fingers (i.e., the recognition helix) is responsible for establishing specific contact with the DNA. The second zinc finger stabilizes the contact and increases the affinity of the receptor for the DNA. Hinge Region (D Region)
As the designation hinge indicates, this region is the site of rotation that allows the protein to alter its conformation after ligand binding. It provides the localization signal that is important for moving the recptor to the nucleus in the absence of ligand and contains a nuclear localization domain (glucocorticoid and progesterone receptors) and/or a transactivation domain (thyroid hormone or glucocorticoid receptors). Carboxy-Terminal Ligand-Binding Domain (E Region)
34
This region is responsible for binding of the relevant ligand and is responsible for receptor dimerization or heterodimerization. It also contains the binding site for heat shock proteins and has a transactivation function (TAF-2) that can drive transcriptional activity. Unlike TAF-1, its transcriptional activity depends on hormone binding. Conformational change that occurs after
The steroid hormone nuclear receptors are known as liganddependent transcription factors. Binding with their ligands is a necessary step for their function as transcriptional regulators. Unliganded receptors may be localized to either the cytoplasm (e.g., glucocorticoid receptor) or the nucleus (e.g., estrogen, progesterone, and thyroid hormone receptors). For most steroid hormones the unliganded receptors exist in the cell nucleus as large molecular weight oligomers (≈300K; 7-10S sedimentation rate)233 and can be isolated in cytosolic fraction from cells or tissues disrupted in hypotonic media. The oligomers are formed by noncovalent association of a monomeric receptor protein with a dimer of heat shock protein (HSP90, HSP70, or HSP56).234 The general features of the mechanism of action of these hormones are depicted in Figure 2-10B. Steroid hormones that freely diffuse through the cell membrane bind to the specific receptors in the nucleus. Ligand binding to receptor initiates the receptor transformation, or so-called activation process. During this process the receptor undergoes conformational changes that primarily occur as a result of its dissociation from HSP, which exposes the DNA-binding site. Nuclear translocation and dimerization of the activated receptor then occurs. Most evidence suggests that this process is thermodynamically irreversible. The hormone receptor complex then binds to a specific region of DNA, the HRE, which is located upstream of the gene. The first HRE was identified for the glucocorticoid receptor. Later the HREs for the progesterone, androgen, estrogen, and mineralocorticoid receptors were shown to be similar to that of the glucocorticoid receptor.235–237 The steroid HREs in the target genes are a palindromic (inverted-repeat) DNA sequence of 15 base pairs (Table 2-7). This interaction leads to the recruitment of a host of ancillary factors known as coregulators (coactivators or corepressors), creating a transcriptionally permissive or nonpermissive environment at the promoter, as well as communicating with other general transcription factors and RNA polymerase II. Coactivators function as adaptors in a signal transduction pathway. The binding of these coregulators modulates the resulting transcription (i.e., the activation and inactivation of specific genes). Hormone antagonists, for example, induce a different conformation in the TAF-2 that hinders the coactivator-binding site and recruits a corepressor instead, and inhibits gene expression. The availability of these coregulators in Table 2-7 Sequence of DNA Recognition Elements for Steroid Hormone Receptors Steroid Hormone Receptor
Element
DNA Recognition Sequence
Estrogen receptor
ERE
AGGTCAsssTGACCT
Progesterone receptor
HRE
AGAACAsssTGTTCT
Androgen receptor Glucocorticoid receptor Mineralocorticoid receptor Sequences read 5′-3′ direction indicated by arrows. S indicates spacer nucleotides (A, G, C, or T).
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 35
Chapter 2 Ovarian Hormones responsible for estrogenic effects in other tissues, including the uterus. 17β-estradiol binds to the estrogen receptor with a much higher affinity than estrone or estriol. In addition, the binding of estradiol to its receptor and its subsequent activation also enhances cooperativity, meaning that the action of estradiol binding to one site increases the affinity for it to bind to another site, enabling the receptors to respond to small changes in hormone concentration. Estrogen’s relatively long duration of action is also due in part to the high-affinity state achieved by its receptor. On the other hand, clomiphene exerts its antiestrogenic effects by negative cooperativity, preventing the transition of the estrogen receptor from its low-affinity state to its highaffinity state. The two receptors (ERα and ERβ) are differentially expressed in different tissues, leading to the differences in the response to the same hormone subtypes.243,244 The α receptors are predominantly expressed in breast cancer tissue, ovarian stroma, and endometrium. ERβ receptors, on the other hand, are expressed in several nonclassic target tissues, including the kidney, intestinal mucosa, lung, bone, brain, endothelial cells, and the prostate gland. 17β-estradiol and estrone have a higher affinity for α receptors and thus exert their effects predominantly on target tissue with α receptor expression. Phytoestrogens such as genistein and coumestrol, on the other hand, bind predominantly to β receptors245 and would be expected to exert their effects on target tissues expressing these receptors. The conformational change of the ligand-binding domain also differs in both α and β estrogen receptors, depending on which ligand has been bound to the receptor.244 This distinct conformational change is the major factor that determines the receptor’s ability to interact with coactivators or corepressors. For example, estradiol activates transcription when it binds to ERα but inhibits transcription when bound to ERβ. Raloxifene and tamoxifen, on the other hand, inhibit transcription when forming complexes with ERα and activate transcription when bound to ERβ. The differential expression of target tissue adaptor proteins and phosphorylation also affect gene transcription. A higher concentration of coactivators or corepressors in the target tissue can affect the cellular response of that tissue to the same ligand. Phosphorylation of the receptor by protein kinases increases the transcriptional activity of the receptor. For example, growth factors such as epidermal growth factor and IGF-I can stimulate
different tissues plays an important role in defining the biologic response to both steroid hormone agonists and antagonists.238 The biologic activity of a hormone is determined by at least four factors intimately related to the structure of the hormone receptor in question. The first factor is the affinity of the hormone for the hormone-binding domain of the receptor. The second factor is the differential expression of receptor subtypes in the target tissue, altering the response to the same hormone. The third factor is the conformational shape of the ligand–receptor complex and its consequent effects on dimerization and the modulation of adaptor proteins. The last factor is the differential expression of target tissue adaptor proteins and phosphorylation. A higher concentration of coactivators or corepressors in the target tissue can affect the cellular response of that tissue to the same ligand. Phosphorylation of the receptor by protein kinases increases the transcriptional activity of the receptor.
The Estrogen Receptor Structure and Function
The structure of ER (now known as ERα) was reported in 1986.239 It consists of five components or domains that are divided into six regions, referred to as A-F (Fig. 2-11), instead of the five regions seen in most steroid receptors. The F region is a C-terminal segment of 42 amino acids that influences the conformational changes that occur after estrogen/antiestrogen binding. Thus, it modulates the level of transcriptional activities, most likely by affecting the interaction with coregulator proteins. It has a molecular weight of 66,000 and contains 595 amino acids. ER mRNA is 6.8 kilobases and contains 8 exons derived from a gene located on the long arm of chromosome 6. More recently a second form of ER has been discovered and named ERβ; it is encoded by a gene located on chromosome 14240 and is in close proximity to the genes that are related to Alzheimer’s disease.241 The two receptors show a high degree of homology in the DNA-binding domain (97%) and ligand-binding domain (59%) but less so in hinge (30%), regulatory (17%), and F regions (17.9%)241,242 (see Fig. 2-11). Hence, the binding characteristics of these two receptors are similar, although they differ significantly in their ability to activate gene transcription by regulatory domain TAF-1, which is minimal or absent in ERβ. Both ERα and ERβ are required for normal ovarian function, as shown by specific receptor knockout studies in mice.16 ERα is primarily
The Estrogen Receptors
Nuclear localization
Transcription activation function-1 (TAF-1)
ER-α
NH2
A/B
Ligand binding, heatshock protein binding, transcription activation function-2 (TAF-2)
DNA binding, dimerization
C
E
D
Conformational influence
F
1
Regulatory domain ER-β
COOH 595
NH2
A/B 1
DNA binding domain C
Hinge
D
Hormone binding domain E
F region
F
COOH 485
Figure 2-11 A schematic diagram of two estrogen receptor (ER) isoforms. Different domains (A-F) and their corresponding functions are illustrated. ER-α, estrogen receptor α; ER-β, estrogen receptor β.
35
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 36
Section 1 Basic Science protein kinase phosphorylation, activating the estrogen receptor—even in the absence of estrogen. Somatic mutations in ERα are described and may be associated with certain disease states. A nonsense mutation (premature stop codon) in ERα has been described in a patient with decreased bone mineral density, increased bone turnover, and incomplete closure of bone epiphyses, which demonstrates the role of the ERα in bone growth and homeostasis.246 ER mutations have also been detected in patients with breast cancer. Such mutations include exon 5 deletion within the ligandbinding domain, leading to a constitutively active receptor, and exon 7 deletion, displaying dominant negative activity and inhibition of ER function.247 Antiestrogens and ER
Compounds with antiestrogenic activity can be classified into two categories: those with pure antiestrogenic activity and those with both agonist and antagonist properties. Tamoxifen—an antiestrogen that is used both as a chemopreventive agent and as a hormonal therapeutic agent for breast cancer—inhibits ER action.248 Paradoxically, tamoxifen acts as an estrogen in uterine tissue, and this tissue-specific estrogenic effect is the reason why prolonged tamoxifen therapy increases the risk of uterine cancer.249 Raloxifene, a related benzothiophene analog, retains its antiestrogenic effect in breast and uterine tissue. Both tamoxifen and raloxifene have estrogen-like effects on nonreproductive tissues such as bone and heart and lung tissue.250 Tamoxifen acts by competing with estrogen for receptor binding. Because estrogen-binding affinity is of higher magnitude than tamoxifen, severalfold higher concentrations of tamoxifen are required to inhibit estrogen action. The agonistic or antagonistic effect of tamoxifen is determined by the presence of different promoter elements in the specific cell type.251 Estrogen binding to receptors activates both transcription domains (i.e.,TAF-1 and TAF-2). Tamoxifen’s agonistic activity is due to activation of TAF-1, and its antagonistic activity is due to its ability to inhibit the estrogen-dependent activation of TAF-2. The ligand-binding sites for estrogen and antiestrogen are not identical, and tamoxifen binding on receptors induces conformational changes that alter interaction with estrogen-associated proteins and modulates transcriptional activity.251,252 Tamoxifen also activates ERmediated induction of promoters that are regulated by the
TAF-1 site, which explains why it has estrogenic effects on the endometrium—a tissue with significant TAF-1 transcription function. In other cell types, such as those in the breast, TAF-1 has weak transcriptional activity. Hence, antiestrogens have no effect on TAF-1 mediated transcription.253 Raloxifene, on the other hand, may activate estrogen-responsive genes through a response element that is distinct from HRE.254 Pure antiestrogens are derivatives of estradiol that have a long hydrophobic side chain at position 7. Examples of pure antiestrogens include ICI 164,384 and ICI 182,780 (Fulvestrant). Binding of pure antiestrogens may sterically interfere with the dimerization process and thus inhibit DNA binding. Furthermore, these compounds increase the rate of receptor degradation and also inhibit ER-mediated transcription by preferential binding to corepressors, which contributes to their antiestrogenic activity.255,256 Progesterone Receptor Structure and Function
As with the estrogen receptor, there are two major forms of progesterone receptors— PR-A and PR-B—which are derived from the same gene. PR-A and PR-B are identical except that PR-B contains an additional 164-amino acid sequence at the Nterminal end, which is referred to as the B-upstream segment (BUS) (Fig. 2-12). PR-A has a molecular weight of 94 kDa and contains 768 amino acids; PR-B is 114 kDa with 933 amino acids. The two forms derive from two distinct estrogenregulated promoters.257 The transcription function domain (TAF-1) in the progesterone receptor is located in the 91-amino acid segment of the regulatory region, and TAF-2 is located in the hormone-binding domain. In PR-B, the BUS contains a third activation domain, TAF-3, which can synergize the actions of other TAFs or autonomously activate transcription.258 TAF-3 recruits and allows a separate subset of coactivators to bind with PR-B that do not interact efficiently with PR-A. Thus, PR-A and PR-B display different transactivation properties that are both cell specific and target gene promoter specific.259 The two isoforms PR-A and PR-B have distinct cellular localization and in the absence of ligand binding, PR-A is predominantly localized in the nucleus and PR-B is present in the cytoplasm.260 The role of progesterone receptor isoforms is not yet fully elucidated. Selective ablation of PR-A expression in mice resulted in severe abnormalities in ovarian and uterine function that led to
Nuclear localization
The Progesterone Receptors Transcription activation function-1 (TAF-1)
PR-A
NH2
A/B
DNA binding, dimerization
C
Ligand binding, transcription activation function-2 (TAF-2)
D
E
1
B-upstream segment (BUS) PR-B
NH2
Regulatory domain A/B
1
COOH 769
DNA binding domain C
Hinge
D
Hormone binding domain E
COOH 933
Transcription activation function-3 (TAF-3)
36
Figure 2-12 A schematic diagram of progesterone receptors isoforms. Different domains (A-E) and their corresponding functions are shown. PR-A, progesterone receptor-A; PR-B, progesterone receptor-B.
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 37
Chapter 2 Ovarian Hormones terone, estrogen, glucocorticoid, and mineralocorticoid receptors) but is related most closely to the progesterone receptor.270 Progesterone shows cross-reactivity with androgen receptors, to a degree that becomes clinically relevant only at pharmacologic doses. In most tissues, testosterone is converted to DHT by the action of the enzyme 5α-reductase. DHT binds to the androgen receptor with a higher affinity than testosterone, leading to greater stabilization of the receptor and more efficient signaling, which amplifies the androgen action. Hence, the efficiency of local conversion of testosterone to DHT is an important intracellular step in the androgen response. A large number of androgen receptor mutations that can alter receptor function have also been described271,272; for example inactivating point mutations in the hormone-binding domain of the androgen receptor can generate different phenotypes that lead to partial to complete androgen insensitivity. A point mutation at residue 689 that substitutes Proline to Histidine may alter the conformation of the ligand-binding domain, which reduces the androgen receptor’s affinity for DHT and abolishes its ability to transactivate the HRE.273 A Serine to Proline substitution at residue 865 eliminates androgen binding and transactivation; thus it also causes complete androgen insensitivity.274 At residue 807, a substitution of Threonine for Methionine causes partial androgen insensitivity by reducing—but not abrogating—the androgen binding to the receptor. However, a Valine or Arginine substitution at the same site totally abrogates androgen binding and causes complete androgen insensitivity syndrome.275
infertility but did not affect progesterone responses in the mammary gland or thymus.261 In contrast PR-B ablation does not affect ovarian, uterine, and thymic responses to progesterone and manifests as reduced mammary ductal morphogenesis. Thus, PRA is essential for female fertility; in the absence of PR-A, PR-B functions in a tissue-specific manner and mediates some of the progesterone receptor actions in the mammary gland.261 However, transgenic mice carring an extra copy of the PR-A gene have abnormal mammary gland development, indicating that overexpression of PR-A may have physiologic significance. The relative levels of the two isoforms differ in the endometrium during the menstrual cycle.262 In the uterus, progesterone action downregulates cell-cycle arrest proteins but upregulates growth factors and their receptors and other regulators263 and is also essential for the initiation and maintenance of pregnancy. Progesterone antagonist RU-486 (mifepristone) initially was synthesized as a glucocorticoid receptor antagonist264 but later was found to display marked antiprogesterone activity.265 It binds to the glucocorticoid recptor with threefold higher affinity than dexamethasone and to the progesterone receptor with a fivefold higher affinity than natural progesterone.266 Unlike progesterone, the RU-486–progesterone receptor complex inhibits transcription because it has a slightly different conformational change in the TAF-2 domain.267 If implantation occurs, it downregulates progesterone-induced genes and results in decidual necrosis and detachment of the conception products.251,266 Androgen Receptor Structure and Function
The androgen receptor gene was cloned in 1988 and was localized on the human X chromosome between the centromere and q13.268 Like the progesterone receptor, the androgen receptor also exists in two forms: a full-length B form and a shorter A form (molecular weights ≈110 kDa and 87 kDa); both are encoded by the same gene.269 The 87-kDa isoform (AR-A) contains the intact C-terminus but lacks 188 amino acid residues in the N-terminus of the 110-kDa isoform (AR-B) (Fig. 2-13). The ratio of AR-B to AR-A in genital skin fibroblasts from healthy subjects is 10:1. It is not known whether there are functional differences between these isoforms.269 The DNA-binding domain or TAF-2 of the androgen receptor is similar to the TAF-2 regions of other steroid hormone receptors (proges-
Nongenomic Actions of Steroids Some steroid hormone actions are independent of their classic genomic actions, as mediated via nuclear receptors—these are called nongenomic actions.276 These effects are rapid, occur within seconds, and are not affected by inhibitors of gene transcription such as dactinomycin or inhibitors of protein synthesis such as cycloheximide. These rapid actions include sodium and calcium ion transport and some neural and cardiovascular effects.277 The messenger and effector system vary with the steroid and the cell type. Thus far, studies have suggested that specific binding sites or receptors are present on the cell membrane and that steroid binding triggers rapid changes in the electrolyte transport system.
Nuclear localization
The Androgen Receptors Transcription activation function-1 (TAF-1)
NH2
AR-A
A/B
DNA binding, dimerization
C
D
Ligand binding, transcription activation function-2 (TAF-2)
E
188
B-upstream segment (BUS) AR-B
Regulatory domain A/B
NH2 1(Met)
188 (Met)
COOH 917
DNA binding Hinge domain C
D
Hormone binding domain E
COOH 917
Transcription activation function-3 (TAF-3)
Figure 2-13 A schematic diagram of androgen receptor isoforms. The androgen receptor is very similar to the progesterone receptor and exists in a shorter A form and a full-length B form.
37
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 38
Section 1 Basic Science For example, estrogens have been shown to modulate some cardiovascular effects by inducing Ca2+ flux and vasodilation in the coronary artery.278 Furthermore, steroids can activate secondmessenger pathways, generating second messengers capable of altering gene transcription independently of their classical receptor-mediated gene transcription.279,280 Thus, steroid hormones have nongenomic effects as well as genomic effects that are mediated by both classical steroid receptor-mediated pathways and second-messenger pathways.
Tropic Hormone Action Tropic hormones (i.e., gonadotropins and GnRH) are primarily hydrophilic and depend on their interactions with receptors scattered on the plasma membrane at the cell surface. These receptors, in turn, can be classified into four groups based on their structural homology and type of intracellular messenger involved in activating the signal transduction pathway (see Table 2-6).
G Protein-Coupled Receptors
38
The gonadotropin and GnRH receptors belong to the large family of receptors that are known as serpentine or seven-transmembrane domain receptors because each contains three domains: an aminoterminal extracellular domain (ectodomain) followed by seven hydrophobic amino acid segments; the transmembrane domains, which span the membrane bilayer (or endodomain); and a hydrophilic carboxyl-terminal domain, which resides within the cytoplasmic compartment. Because they depend on G protein transducers to execute their biologic effects, they are also known as G protein-coupled receptors (GPCRs). G proteins are heterotrimeric proteins associated with these receptors and are socalled because they bind the guanine nucleotides guanosine diphosphate (GDP) and guanosine triphosphate (GTP). Each G protein consists of three subunits: α, β, and γ. They are a heterogeneous family, and at least 16 α subunit genes, 6 β subunit genes, and 12 γ subunit genes have been identified. Various combinations of these provide a large number of possible αβγ complexes. The identity of the individual G protein is determined by the nature of the α subunit. As such, G proteins can be divided into four subfamilies (Gs, Gi, Gq, and Gi2) based on their protein sequence homology. They act as transducers, linking the receptors with the effector proteins that are responsible for producing changes in cellular function. The large variety of G proteins allows for flexibility and diversity in the response of the target cell, depending on the level of G protein expression. There are many types of possible effector molecules, including adenylyl cyclase, calcium channels, potassium channels, cGMP, and phospholipase. Each effector molecule in turn produces a large quantity of second messengers such as cAMP, Ca2+, and phosphatidylinositols, which activate an even larger number of downstream molecules. This is an important factor that explains why the endocrine system is sensitive to such low concentrations of circulating ligand and why only a small percentage of cell membrane receptors need to be occupied to generate a response. Other examples of receptors and their ligands that fall into this family include the TSH receptor and ACTH receptor. The structure of the LH receptor and FSH receptor are similar to each other and show close homology with the TSH receptor. A comparison of the LH receptor with the FSH receptor shows
about 70% homology in the transmembrane domain, but only 42% in the ectodomain and 48% in the endodomain regions. Gonadotropin Receptors
The gonadotropin receptors are primarily expressed in the gonadal tissues and demonstrate a unique expression pattern that determines their cell-specific roles. LH receptors are present in ovarian thecal and luteal cells and in testicular Leydig cells. FSH receptors are found in ovarian granulosa cells and in testicular Sertoli cells. Furthermore, FSH induces LH receptors in the granulosa cells that are expressed in mature follicles. These receptors are essential in mediating the gonadotropin actions in steroidogenesis and in gonadal growth and differentiation. Their structure, function, and regulation as well as molecular biology have been extensively covered in recent reviews.281,282 Structure and Function
Genes for both LH and FSH receptors are located on chromosome 2p21. The LH receptor gene is about 70 kb and consists of 11 exons and 10 intervening introns.281 The FSH receptor gene is about 54 kb and contains 10 exons and 9 intervening introns.282 As shown in Figure 2-14, the structural similarities between the two receptors are remarkable with the exception of an additional exon in the LH receptor. The long exon 11 in LH receptor and exon 10 in FSH receptor encodes for the seven-transmembrane domains and the intracellular tail as well as the C-terminal end of the hinge region of ectodomain. The remaining 9 exons in the FSH receptor and 10 exons in the LH receptor encode for the entire ectodomain. Both receptors have multiple splice sites, leading to transcription of multiple mRNA splice variants and expression in the ovary and testis.281 The LH receptor protein contains a 24-amino acid signal peptide (17 in FSH receptor) and the mature protein consists of 675 amino acid residues (678 in FSH receptor) (see Fig. 2-14). The molecular mass is approximately 85 to 90 kDa for both glycosylated LH and FSH receptor proteins. The ectodomains of these receptors are composed of several leucine-rich repeats (LRRs) of about 24 amino acid residues each (9 in LH receptor and 10 in FSH receptor) that form a half donut-shaped structure and are essential for the binding of gonadotropins. The ectodomain is connected to the transmembrane region by the hinge region with conserved sequences. The transmembrane region consists of seven helical structures and is followed by the cytoplasmic C-terminal tail, both of which are important for interaction with intracellular proteins. The binding of LH and FSH to their specific receptors leads to receptor activation and downstream signaling. Mechanism of Action
The intracellular messenger for LH and FSH is cAMP, which is derived from adenosine triphosphate (ATP) through the action of the enzyme adenylate cyclase. The basic steps involved in the receptor-mediated action of gonadotropins are illustrated in Figure 2-15. The regulation of adenylate cyclase is mediated by a GTP-dependent regulatory G-protein, each of which is composed of three subunits—α, β, and γ—and is associated with the receptor in an inactive GDP-bound form. Gonadotropic binding to their respective receptors induces a conformational change
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 39
Chapter 2 Ovarian Hormones
A
FSH receptor mutations FSH receptor gene:
1
FSH receptor protein: NH2
2
3
1
4
5
6
7
8
9
10 TM
Ectodomain
Intracellular domain
Ile 160 Thr Ala 189 Val / Asn 191 Ile Inactivating mutation:
675
COOH
Asp 224 Val Pro 346 Arg/ Ala 419 Thr Arg 573 Cys/ Leu 601 Val Asp 567 Gly
Activating mutation:
B
LH receptor mutations LH receptor gene:
1
LH receptor protein: NH2
2 1
3
4
5
6
7
8
9
10
11 TM
Ectodomain
Intracellular domain
Cys 131 Arg Phe 194 Val Inactivating mutation:
678
Deletion of exons 8 and 10
COOH
Cys 343 Ser / Glu 354 Lys / Ile 374 Thr / Thr 392 Ile / Trp 491 Stp / Cys 543 Arg / Cys 545 Stp / Arg 554 Stp / Ala 593 Pro / ΔLeu 608 /Val 609 / Ser 616 Tyr / Ile 625 Lys Activating mutation:
Leu 368 Pro / Ala 373 Val /Met 398 Thr / Leu 457 Arg / Ile 542 Leu / Asp 564 Gly / Ala 568 Val / Met 571 Ile / Ala 572 Val / Ile 575 Leu / Thr 577 Ile / Asp 578 Tyr / Cys 581 Arg
Figure 2-14 A schematic representation of the FSH (A)/LH (B) receptor gene and localization of identified mutations. The structural organization of the FSH/LH receptor protein is provided below it. The extracellular domain of the protein is shown as a straight line, followed by the seven-transmembrane domains and the intracellular domain. In the FSH receptor gene exon 10 and in the LH receptor gene exon 11 codes for the seven-transmembrane signal transduction domains.
in the receptor and activation of the G-protein complex that leads to release of GDP and binding of the α subunit to GTP.283 Subsequently, the GTP-bound form of the α subunit disassociates from the receptor as well as from the stable β/γ dimer and activates the adenylate cyclase. This in turn leads to an increase in the levels of intracellular cAMP, which in turn activates protein kinase A (PKA) by binding to the inhibitory regulatory subunit of PKA and causing it to dissociate from the complex. Activated PKA phosphorylates many cellular substrates, including several nuclear transcription factors (e.g., cAMP response binding protein [CREB]).281 The binding of CREB to the cAMP response element activates many genes. The fact that PKA activation does not account for all the actions of gonadotropins and that LH can stimulate steroid hormone synthesis without significant changes in cAMP indicated that another pathway may be activated. There is now evidence that the phosphatidylinositol 3,4,5-triphosphate (IP3) pathway is also activated by the LH receptor284 as well as by the FSH receptor,285 although it is not clear whether the IP3 pathway activates the same or different responses in the target
cells. The third signaling pathway, the MAPK pathway, has also been shown to be activated by the LH receptor286 (see Fig. 2-15). Continuous stimulation of receptors can lead to a decrease in response, a phenomenon known as downregulation. For example, pulsatile LH secretion maintains LH receptors and steroidogenesis in the gonads. However, persistent endogenous elevation of LH or hCG levels downregulates LH receptors and leads to desensitization to the hormonal signal.287 This involves receptor phosphorylation, which uncouples the receptor from the G protein, ending the response. The LH/hCG receptor undergoes desensitization in response to LH or hCG by the phosphorylation of the C-terminal cytoplasmic tail of the receptor.288 Another mechanism of downregulation is the uncoupling of the regulatory and catalytic subunits of the adenylate cyclase enzymes. For example, LH stimulates steroidogenesis by coupling the stimulatory to the catalytic units of adenylate cyclase. Prostaglandin F2α, on the other hand, inhibits the action of LH by an inhibitory regulatory unit that uncouples the catalytic unit to interfere with gonadotropin action.
39
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 40
Section 1 Basic Science
FSH/LH receptor Adenylate cyclase
Insulin receptor
Cell membrane RAS Gβγ
P Shp-2
P
Gα
Grb-2
IRS
SOS
Gα
ATP
GTP RAF
GDP
cAMP P13K MAPK
P
Protein translation
PKA
P13K IRS
ERK
PIP2
IP3
PDK-1 AKT/P
KB
Gene response Activation of transcription factors Nucleus
Figure 2-15 A diagrammatic representation of the interlinked signaling pathways between FSH/LH G-protein coupled receptors (GPCRs) and insulin/IGF-I receptor tyrosine kinases in ovarian cells. Activation of GPCR by hormone binding stimulates the Gα subunit to bind guanosine triphosphate (GTP) instead of guanosine diphosphate (GDP), leading to its dissociation from β/γ subunits to activate downstream signaling factors such as adenylyl cyclase that synthesizes second-messenger cyclic adenosine monophosphate (cAMP). Binding of cAMP in turn activates protein kinase A (PKA), leading to DNA binding and downstream cellular response. Also illustrated here is the IGF-I receptor signaling pathway. IGF-I/Insulin binding to the receptor initiates autophosphorylation and tyrosine phosphorylation of insulin receptor substrates (IRS), leading to activation of phosphatidylinositol-3-kinase (PI3K) and generation of 3-phosphorylated-inositol (IP3) from phosphoinositol (PIP2), which activates PI-dependent protein kinase-1 (PDK-1). PDK-1 in turn activates Akt/protein kinase B (Akt/PKB), leading to biologic effects. The activation of the insulin receptor substrates (IRS) also allows the docking and activation of small adaptor molecules with SH-2 domains (e.g., growth factor receptor binding protein-2 [Grb-2[] and Shp2). Activated Grb-2 recruits SOS-1, which activates the RAS pathway and gene transcription. (Main pathways are in bold, interlinked signaling pathways are in broken lines). SOS-1, son-ofsevenless; ERK, extracellular signal regulated kinase; FSH, follicle stimulating hormone; LH, luteinizing hormone.
Mutations in Gonadotropin Receptors
40
Both activating and inactivating gene mutations have been described in LH and FSH receptors and have been the subject of recent review.209 Interestingly, the activating mutations in the LH receptor gene result in altered testosterone production, and these mutations are known to affect the phenotype of men only, whereas inactivating mutations affect sexual differentiation and fertility in both men and women. To date, a total of 15 activating mutations have been identified in the LH receptor, all localized in the transmembrane region or in the intracellular loops (see Fig. 2-14A). Transmembrane 6 and the third intracellular loop are recognized as mutational hot spots, and 10 of 14 mutations are localized to these regions. These gain-of-function mutations lead to male-limited precocious puberty characterized by Leydig cell hyperplasia, premature puberty, and onset of spermatogenesis in boys as young as age 3 years.289,290 These patients have blood testosterone levels in the pubertal range, with low or undetectable LH
levels. A novel activating LH receptor mutation associated with Leydig cell tumors and nonfamilial precocious puberty has also been described.291 An equal number of inactivating mutations in LHR that cause partial to complete inactivation of receptor have been described.209 These inactivating mutations in LH receptors cause Leydig cell hypoplasia in men and amenorrhea in women. In contrast, lossof-function mutations are scattered throughout the LH receptor protein. Depending on the mutation, the severity of the male phenotype varies from primary hypogonadism to male pseudohermaphroditism with sexual ambiguity. Conversely, activating mutations of the FSH receptor are rare. Only one mutation has been identified this far (located in the third intracellular domain of exon 10) in a hypophysectomized patient who was fertile despite the lack of FSH and LH production.292 Likewise, fewer inactivating mutations have been identified in the FSH receptor (see Fig. 2-14B). Most of these are located in the extracellular domain and show reduced ligand
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 41
Chapter 2 Ovarian Hormones binding and signal transduction. They are implicated in hypergonadotropic ovarian dysgenesis in females and variable degrees of spermatogenic failure in males. Recently, two heterozygous missense mutations in the exon 10 encoding the transmembrane region have been described, and both were associated with the familial spontaneous ovarian hyperstimulation syndrome. Although there were no significant differences in the cAMP responses between the wild-type and mutated receptor, the mutated receptor gained sensitivity to hCG.293,294 Low-affinity binding of hCG to the FSH receptor most likely triggered signal transduction that led to hyperstimulation of ovaries.
Ligand
Gq-coupled receptor Cell membrane GDP Gq
Activating mutation: Arg 262 Gln / Tyr 284 Cys GnRH receptor gene: 5' UTR GnRH receptor protein:
Activating mutation:
NH2
1 1
2
3
329
Asn 10 Lys / Thr 32 Ile / Gln 106 Arg Glu 90 Lys / Ala 129 Asp / Arg 139 His
Inactivating mutation:
Ser 168 Asp / Cys 200 Tyr / Ser 217 Arg Leu 266 Arg / Cys 279 Tyr / Leu 314 X
Figure 2-16 A schematic representation of the gonadotropin-releasing hormone (GnRH) receptor gene and localization of identified mutations. The structural organization of the GnRH receptor protein is provided below it. The short extracellular domain of the protein is indicated by the straight line, followed by the seven-transmembrane domains. The GnRH receptor lacks a carboxyterminal cytoplasmic tail. Exon 1 codes for transmembrane domains 1-3, exon 2 codes for transmembrane domains 4-5, and exon 3 codes for transmembrane domains 6-7. 5′UTR, 5′’ untranslated region.
GTP Gq
PIP2
DAG
GTP GDP
Ca2+
Gonadotropin-releasing Hormone (GnRH) Receptor GnRH binds
to specific membrane receptors in pituitary gonadotrophs and stimulates LH and FSH secretion (Fig. 2-16). Besides gonadotrophs, GnRH receptors have also been expressed on the gonads, placenta, and brain295–297 Specific GnRH receptors are also characterized in immortalized αT3-1 gonadotroph cells as well as in GnRH-secreting GT1 hypothalamic cells.296,298 In the ovary, GnRH receptors are expressed in granulosa and luteal cells. In the testis, these receptors are expressed in Leydig cells but not Sertoli cells.299 In cultured granulosa cells, the receptor activation stimulates progesterone and prostaglandin synthesis, oocyte maturation, and ovulation300,301 but inhibits FSHinduced steroidogenesis, follicular development, and maturation as well as inhibin secretion.302–304 In luteal cells, it inhibits LH receptor expression and thus LH action.305 The structure function and intracellular signaling pathways involved in GnRH action have been extensively reviewed in recent years.306–308 The GnRH receptor gene, located on chromosome 4q21.2, consists of three exons309 and encodes a
PLC
IP3 ER
PKC
Ca2+channel Ca2+
Nucleus
Figure 2-17 A schematic representation of GnRH signaling through GPCR. Binding of GnRH to its receptor acts through Gq protein. Activated Gq binds ATP and activates its downstream target phospholipase C (PLC) and hydrolyzes PIP2, producing IP3 and diacylglycerol (DAG). IP3 diffuses through the cytoplasm to the endoplasmic reticulum (ER) and opens a calcium channel releasing calcium stores. Calcium and DAG activate protein kinase C (PKC), leading to cellular response.
327-amino acid protein with an approximate molecular weight of 50 to 60 kDa. The receptor has the characteristic features of GPCRs (Fig. 2-17). It consists of an aminoterminal domain, followed by seven transmembrane domains that are connected by three extracellular and three intracellular loops. Unlike other GPCRs, the GnRH receptor lacks the characteristic C-terminal cytoplasmic domain. GnRH binds to the transmembrane domain and the extracellular loop in the hairpin structure and requires partial entry of its N- and C-terminal regions into the transmembrane core of the receptor.310 The nature of the intracellular signaling mechanism by the GnRH receptor has been primarily studied in a gonadotrophderived αT3-1 cell line, as depicted in Figure 2-18. The effector system in the GnRH receptor is the phospholipase C β (PLCβ) and the second messengers are IP3 and 1,2 diacylglycerol (DAG). Its mechanism of action is dependent on calcium. Activation of the receptor by ligand binding initiates a series of steps that lead to transduction of signals. The first step is G protein (Gq/11)mediated activation of enzyme PLCβ, leading to hydrolysis of phosphoinositides (PIP2) and resulting in the production of IP3 and DAG. The IP3 interacts with a receptor on the endoplasmic reticulum to promote the oscillatory or biphasic release of Ca2+ from intracellular stores, which is known to be an important trigger for gonadotropin secretion. The increased Ca2+ and DAG in turn activate a series of protein kinase C subspecies (PKC). PKC then induce various downstream signal transduction cascades, including the extracellular signal regulated kinase and Jun N-terminal kinase signaling pathways.
41
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 42
Section 1 Basic Science Ligand Type 1 receptor
Type 2 receptor
factors interact and complement the FSH/LH pathway to control follicular growth. Family of Receptors with Tyrosine Kinase Activity
Cell membrane P R-SMAD R-SMAD
P
Co-SMAD
brane ar mem Nucle DNA-binding partner
P
R-SMAD Co-SMAD
P
Target gene
R-SMAD Co-SMAD
Figure 2-18 The TGF-β/activin signaling pathway. Binding of a TGF-β family member (e.g., activin) to its type 2 receptor forms a ligand–receptor complex and activation of the type 1 receptor by phosphorylation. The activated type 1 receptor then phosphorylates receptor-regulated SMAD (R-SMAD). This allows R-SMAD to associate with Co-SMAD and move into the nucleus. In the nucleus, the SMAD complex associates with a DNA-binding partner, such as FAST-1. This complex then binds to specific enhancers in the target gene, activating gene transcription. (In the TGF-β/activin pathway, R-SMAD is formed by SMAD2 and SMAD3. Co-SMAD is formed from SMAD4.)
Mutations in GnRH Receptor Gene
A functional GnRH receptor is a prerequisite for normal LH and FSH production. Hence, it is critical for normal pubertal development and reproduction. Several inactivating mutations have been identified in the GnRH receptor gene that are associated with variable phenotypes ranging from modest to complete insensitivity to GnRH. These mutations are present in a number of patients with idiopathic hypogonadotropic hypogonadism (IHH) with an autosomal recessive pattern of inheritance as well as in some patients with sporadic IHH.311 Most identified mutations are heterozygous missense mutations and are scattered throughout the GnRH receptor gene. A total of 14 mutations have been identified to date308 and are listed in Figure 2-16. In vitro studies have shown that some of these mutations make the receptor totally nonfunctional; others have some ability to elicit a response to GnRH.
Peptide Hormone/Growth Factor Action
42
Pituitary gonadotropin signaling plays a key role in follicular growth, ovulation, and luteinization. However, it is increasingly recognized that their actions are also dependent on their interaction with peptide/growth factor signaling pathways, including IGFs, EGF, and members of the TGFβ family (see Fig. 2-15). Understanding these pathways provides insight into how these
Insulin, IGF, and EGF receptors belong to a distinct group of receptors and differ from the GPCRs both structurally and functionally. Unlike the GPCRs, they only span the membrane once and acquire their signaling ability through the activation of tyrosine kinase, which is intrinsic to these individual receptor molecules. Hence, they are known commonly as tyrosine kinases. Their main ligands include hormones such as insulin and IGF, as well as paracrine and autocrine regulators such as platelet-derived growth factor (PDGF), bFGF, and EGF. Thus, via tyrosine phosphorylation, a number of physiologic processes such as cell proliferation, cell migration, cell differentiation, and apoptosis are mediated by these receptors. This explains why this group of receptors has been the target of much oncogenic research. All tyrosine kinase receptors have a similar structure: an extracellular domain for ligand binding, a single transmembrane domain, and a cytoplasmic domain. Ligand specificity is determined by the unique amino acid sequences making up the extracellular domain, which determines the three-dimensional conformation of the receptor. The transmembrane domains are heterogeneous, whereas the cytoplasmic domains are fairly homologous. They respond to ligand binding by undergoing conformational changes and autophosphorylation. The structure of the IGF-I receptor is strikingly similar to that of the insulin receptor, with two transmembrane domains linked by disulfide bridges, formed by two α and β subunits.312 The IGF-I receptor gene is located on chromosome 15 at bands q25-26 and contains 21 exons.313 The steps involved in signal transduction by IGF-I/insulin have been extensively reviewed in recent years314,315 and are illustrated in Figure 2-15. The association of the ligand (e.g., insulin) with the receptor’s extracellular domain triggers receptor dimerization. This results in the phosphorylation of tyrosine residues on both the receptor and nonreceptor substrates. The phosphorylation of receptor tyrosine residues occurs at specific locations, which causes these sites to associate with a variety of accessory proteins that have independent signaling capabilities. These accessory proteins include phospholipase Cγ, PI3 kinase (PI3K), GAP, and growth factor receptor-bound protein-2 (GRB2). These interactions are mediated by the presence of highly conserved type 2 src homology domains (SH2) in each accessory molecule, thus named based on their sequence homology to the src protooncogene. Each SH2 domain is specific for the amino acids surrounding the phosphotyrosine residues in the receptor molecule. PI3K also produces a second messenger, such as IP3, which in turn activates kinase AKT, also known as protein kinase B (PKB). Proteins phosphorylated by PKB promote cell survival. Although these associations may trigger immediate signaling events, other accessory proteins (e.g., GRB2) may serve to construct the scaffolding for a more complex signaling apparatus, such as that seen in the RAS-RAF-MEK pathway, This pathway recruits multiple other proteins, resulting in the activation of nuclear transcription and protein synthesis (see Fig. 2-15). Growth hormone and prolactin fall into another group of receptors that also have a single transmembrane-spanning segment and a short cytoplasmic tail. However unlike IGF-I/insulin receptors they do not possess intrinsic tyrosine kinase activity
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 43
Chapter 2 Ovarian Hormones but interact with other soluble transducer molecules (e.g., Janus kinase 2) that do have tyrosine kinase activity. Mechanism of Action of Activins and Inhibins
Activins and inhibins are members of the TGFβ superfamily and use a common general mechanism for signal transduction through serine/threonine-specific protein kinases rather than tyrosine kinases. The mechanisms involved in signal transduction by the serine/threonine kinases has been extensively reviewed in recent years.316,317 The activin receptor was first to be cloned and was later followed by other receptors.318,319 They are glycoproteins of approximately 55 kDa and consist of a 500-amino acid sequence. Two types of activin membrane receptors have been identified: type I (ActR-I) and type II receptors (ActR-II). Each contains an intracytoplasmic serine/threonine kinase domain. The steps involved in the mechanism of action of activin are depicted in Figure 2-18. Activin directly interacts with and binds to the relatively short extracellular region of ActR-II when expressed alone or in concert with ActR-I. It can also bind to other TGFβ family members (e.g., bone morphogenic proteins [BMPs] 2, 4, and 7) in concert with BMP type I receptor, which suggests that these receptors have the ability to cross-talk. Activin binding brings together two type II receptors and two type I receptors, which form a receptor complex. One of the receptor kinases phosphorylates and activates the other, which in turn phosphorylates their substrates—the SMAD proteins [the term SMAD is derived from the combination of names of two genes, the C. elegans gene called Sma and the Drosiphila gene Mad]. SMADs are a novel family of signal transducers that can be divided into three groups that include receptor-regulated SMADs (R-SMAD) and a single common SMAD (C-SMAD or SMAD4). The third group includes inhibitory SMADS that antagonize signaling. In activin/TGFβ signaling, the activated type I receptor phosphorylates ligandspecific R-SMADs (SMAD2 and SMAD3), allowing these proteins to associate with SMAD4. The complex then translocates to the nucleus as transcription cofactor. In the nucleus, the action of SMAD complex is modulated by a variety of transcription factors (DNA-binding proteins) at target DNA promoters, which leads to gene transcription. Inhibin is a heterodimer formed between an inhibin α chain and an activin β chain, and its biologic activity is opposite that of activin. A separate receptor for inhibin has not been identified. The mechanisms by which inhibin antagonizes activin actions are not clearly understood. It has been shown that inhibin competes with activin for binding to the activin receptors but is unable to trigger signaling.320 This may be one of the mechanisms by which inhibins antagonize activin actions. Other actions of inhibin may be mediated by as-yet unidentified inhibin receptors.
such as cytodifferentiation, mitogenesis, and apoptosis in a variety of ways. They act in concert with LH/FSH via a complex network of intracellular signaling to mediate their actions. A functional hypothalamic-pituitary axis is essential for ovarian hormone production. GnRH secretion in a synchronized pulsatile fashion is a key feature in the control of LH/FSH secretion, and new insights have made it a prime drug target for the treatment of infertility. Both GnRH and gonadotropin actions are transmitted through G protein-coupled receptors to target cells via multiple signaling mechanisms. Several mutations and polymorphisms have been identified in their genes and their receptors. These mutations have deleterious effect on reproduction. Although rare, this study has allowed a better understanding of receptor structure and function relationships and helped clarify the molecular pathogenesis of conditions associated with altered gonadotropin secretion and actions. Steroid hormones play a central role in the reproductive system. Physiologic effects of steroid hormones are mediated via their nuclear receptors, which belong to a superfamily of liganddependent transcription factors. The two isoforms of ER and the progesterone receptor are differentially expressed in different tissues, leading to tissue-specific responses. Furthermore, the differences in gene expression depend on interactions with protein cofactors, the coactivators and corepressors. A better understanding of the effect that the cell environment has on nuclear receptors and their coregulators led to the discovery and understanding of the mechanism of action of antiestrogens and selective receptor modulators.
PEARLS ●
●
●
●
●
●
● ●
●
●
SUMMARY ●
The ovary is a dynamic endocrine organ. The follicle cells interact in a highly integrated manner to produce several steroid and peptide hormones. Steroidogenesis requires effective delivery, uptake, and use of sterol by an array of steroidogenic enzymes. Virtually all steps in steroid biosynthesis require the action of LH and FSH and are influenced by endocrine, autocrine, and paracrine actions of several intraovarian peptide hormones, growth factors, cytokines, and neuropeptides. In recent years, research has shown that these growth factors affect various cell processes,
●
●
●
There is a specific cellular location for many steroidogenic enzymes. Sex steroids can be produced thtough two pathways: Δ5(the 3β-hydroxysteroid pathway) or Δ4 (the 3-ketone pathway). Hydroxylases and aromatase enzymes belong to the cytochrome P450 family. The two-cell theory explains the production of steroid hormones of the ovary. Thecal cells respond to LH; granulosa cells respond to both FSH and LH. Theca cells produce androgens that are aromatized by the granulosa cells to estrogens. Estradiol is the main estrogen in premenopausal women. Progesterone and 17 OH-progesterone are produced mainly by the corpus luteum in the luteal phase. The majority of testosterone is derived from the peripheral metabolism of DHEA and androstenedione. Very little ovarian steroid hormone circulates free in the circulation but rather is bound to proteins. Inhibin A and B are heterodimers produced by the granulosa cells. Inhibin B is highest during the luteal–follicular transition and early follicular phase. Inhibin A rises in the luteal phase. Inhibin A is produced primarily by the fetoplacental unit during pregnancy. Activins are dimers of the inhibin β subunit and are produced by the granulosa cells. Follistatin is produced by the granulosa cells and acts mostly as as an antagonist of activin.
43
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 44
Section 1 Basic Science ●
Steroid hormones bind to intracellular receptors located within the cytoplasm or nucleus.
●
Polypeptide hormones and growth factors interact with cellsurface receptors located on the plasma membrane.
REFERENCES
44
1. McNatty KP, et al: The production of progesterone, androgens and oestrogens by human granulosa cells in vitro and in vivo. J Steroid Biochem 11:775–779, 1979. 2. Hsueh AJ, et al: Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 5:76–127, 1984. 3. Knight PG. Roles of inhibins, activins, and follistatin in the female reproductive system. Front Neuroendocrinol 17:476–509, 1996. 4. Gwynne JT, Strauss 3rd JF: The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. Endocr Rev 3:299–329, 1982. 5. O’Malley BW: Steroid hormones: Metabolism and mechanism of action. In Yen SSC, Jaffe RB, Barbieri RL (eds). Reproductive Endocrinology. Philadelphia, WB Saunders, 1999, pp 125–130. 6. Clark BJ, et al: The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 269:28314–28322, 1994. 7. Lin D, et al: Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267:1828–1831, 1995. 8. Sugawara T, et al: Human steroidogenic acute regulatory protein: Functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13. Proc Natl Acad Sci USA 92:4778–4782, 1995. 9. Yasui T, et al: Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 56:38–44, 2001. 10. Winter JS, et al: Gonadotrophins and steroid hormones in the blood and urine of prepubertal girls and other primates. Clin Endocrinol Metab 7:513–530, 1978. 11. Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291–303, 1969. 12. Mansfield, M.J., et al: Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab 66:3–9, 1988. 13. Boepple PA, et al: Impact of sex steroids and their suppression on skeletal growth and maturation. Am J Physiol 255:E559–E566, 1988. 14. Drummond AE, Findlay JK: The role of estrogen in folliculogenesis. Mol Cell Endocrinol 151:57–64, 1999. 15. Young JR, Jaffe RB: Strength–duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. II. Effects of varying concentrations of estradiol. J Clin Endocrinol Metab 42:432–442, 1976. 16. Couse JF, Korach KS: Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev 20:358–417, 1999. 17. Panay N, Studd JWW: Oestrogen and behaviour. In Genazzani AR, Purdy RH (eds). The Brain: Source and Target for Sex Steroid Hormones. UK, The Parthenon Publishing Group, 1996, pp 257–276. 18. Joffe H, Cohen LS: Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge? Biol Psychiatry 44:798–811, 1998. 19. Carlson MC, et al: Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 57:2210–2216, 2001. 20. Tang MX, et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348:429–432, 1996. 21. Henderson VW, et al: Estrogen for Alzheimer’s disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 54:295–301, 2000. 22. Shumaker SA, et al: The Women’s Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 19:604–621, 1998.
23. Mulnard RA, et al, for the Alzheimer’s Disease Cooperative Study. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA 283: 1007–1015, 2000. 24. Shumaker SA, et al, for the Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 291:2947–2958, 2004. 25. The Writing Group for the PEPI: Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389–1396, 1996. 26. Anderson G.L., et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712; 2004. 27. Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89:1943–1950, 1994. 28. Venkov CD, Rankin AB, Vaughan DE: Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 94:727–733, 1996. 29. Kim HP, et al: Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem Biophys Res Commun 263:257–262, 1999. 30. Kannel WB, et al: Menopause and risk of cardiovascular disease: The Framingham study. Ann Intern Med 85:447–452, 1976. 31. Hu FB, et al: Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 159:1061–1066, 1999. 32. Hulley S, et al for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613, 1998. 33. Le Guevel R, Pakdel F: Assessment of oestrogenic potency of chemicals used as growth promoter by in vitro methods. Hum Reprod 16:1030–1036, 2001. 34. O’Connell MB: Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 35(9 Suppl):18S-24S, 1995. 35. Thompson EA, Siiteri PK: Studies on the aromatization of C-19 androgens. Ann NY Acad Sci 212:378–391, 1973. 36. Kirschner MA, et al: Androgen–estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70:473–479, 1990. 37. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214, 1973. 38. Siiteri PK, MacDonald PC: Placental estrogen biosynthesis during human pregnancy. J Clin Endocrinol Metab 26:751–761, 1966. 39. Ruder HJ, Loriaux L, Lipsett MB: Estrone sulfate: Production rate and metabolism in man. J Clin Invest 51:1020–1033, 1972. 40. Loriaux DL, et al: Estrone sulfate, estrone, estradiol and estriol plasma levels in human pregnancy. J Clin Endocrinol Metab 35:887–891, 1972. 41. Barbieri R: Endocrine disorders in pregnancy. In Yen SC, Jaffe RB, Barbieri RL (eds): Reproductive Endocrinology. Philadelphia, WB Saunders, 1999, pp 785–811. 42. Goldfien A. Ovaries: In Greenspan FS (ed): Basic and Clinical Endocrinology. Philadelphia, McGraw-Hill, 2001, pp 453–508. 43. Franks S: Polycystic ovary syndrome. NEJM 333:853–861, 1995. 44. Abraham GE: Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 39:340–346, 1974.
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 45
Chapter 2 Ovarian Hormones 45. Anderson DC: Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 3:69–96, 1974. 46. Rosner W, Smith R: Isolation of human testosterone-estradiol-binding globulin. Methods Enzymol 36:109–120, 1975. 47. Berube D, et al: Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17p12p13). Cytogenet Cell Genet 54:65–67, 1990. 48. Hammond GL, Bocchinfuso WP: Sex hormone-binding globulin: Gene organization and structure/function analyses. Horm Res 45:197–201, 1996. 49. Dunn, JF, Nisula BC, Rodbard D: Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58–68, 1981. 50. Plymate SR, et al: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460–464, 1988. 51. Plymate SR, et al: Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 52:339–340, 1988. 52. Pardridge WM: Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 15:259–278, 1986. 53. Manni A, et al: Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 61:705–710, 1985. 54. Englebienne P: The serum steroid transport proteins: Biochemistry and clinical significance. Mol Aspects Med 7:313–396, 1984. 55. Rosenfield RL: Plasma testosterone binding globulin and indexes of the concentration of unbound plasma androgens in normal and hirsute subjects. J Clin Endocrinol Metab 32:717–728, 1971. 56. Rudd BT, Duignan NM, London DR: A rapid method for the measurement of sex hormone-binding globulin capacity of sera. Clin Chim Acta 55:165–178, 1974. 57. Cumming DC, Wall SR: Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J Clin Endocrinol Metab 61:873–876, 1985. 58. Yalow RS, Berson SA: Immunoassay of endogenous plasma insulin in man. J Clin Invest 39:1157–1175, 1960. 59. Niswender GD: Hapten-radioimmunoassay for steroid hormones. In Peron PG (ed): Immunologic Methods in Steroid Determination. New York, Appelton-Century-Crofts, 1970, pp 149–173. 60. Rao PN, et al: Synthesis of new steroid haptens for radioimmunoassay— part V. 19-O-carboxymethyl ether derivative of testosterone. A highly specific antiserum for immunoassay of testosterone from both male and female plasma without chromatography. J Steroid Biochem 9:539–545, 1978. 61. Gupta MK: Interference by luteal phase progesterone in a commercial kit for measurement of 17-α hydroxyprogesterone. Clin Chem 31:1246–1247, 1985. 62. Taieb J, et al: Limitations of steroid determination by direct immunoassay. Clin Chem 48:583–585, 2002. 63. Diver MJ, Nisbet JA: Warning on plasma oestradiol measurement. Lancet 2:1097, 1987. 64. Fuqua JS, et al: Assay of plasma testosterone during the first six months of life: Importance of chromatographic purification of steroids. Clin Chem 41:1146–1149, 1995. 65. Fanchin R, et al: Physiopathology of premature progesterone elevation. Fertil Steril 64:796–801, 1995. 66. Dighe AS, Sluss PM: Improved detection of serum estradiol after sample extraction procedure. Clin Chem 50:764–766, 2004. 67. Marquet P: Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther Drug Monit 24:255–276, 2002. 68. Griffiths WJ, et al: Electrospray and tandem mass spectrometry in biochemistry. Biochem J 355:545–561, 2001. 69. Nelson RE, et al: Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 50:373–384, 2004. 70. Valbuena D, et al: Ovarian stimulation and endometrial receptivity. Hum Reprod 14(Suppl 2):107–111, 1999.
71. Kligman I, Rosenwaks Z: Differentiating clinical profiles: Predicting good responders, poor responders, and hyperresponders. Fertil Steril 76:1185–1190, 2001. 72. Wright K, et al: A specific radioimmunoassay for estrone sulfate in plasma and urine without hydrolysis. J Clin Endocrinol Metab 47:1092–1098, 1978. 73. Ranadive GN, et al: Rapid, convenient radioimmunoassay of estrone sulfate. Clin Chem 44:244–249, 1998. 74. Gaskell SJ, Brownsey BG, Groom GV: Analyses for progesterone in serum by gas chromatography/mass spectrometry: Target data for external quality assessment of routine assays. Clin Chem 30:1696–1700, 1984. 75. Kubasik NP, Hallauer GD, Brodows RG: Evaluation of a direct solidphase radioimmunoassay for progesterone, useful for monitoring luteal function. Clin Chem 30:284–286, 1984. 76. De Boever J, et al: Solid-phase chemiluminescence immunoassay for progesterone in unextracted serum. Clin Chem 30:1637–1641, 1984. 77. Radwanska E, Hammond J, Smith P: Single midluteal progesterone assay in the management of ovulatory infertility. J Reprod Med 26:85–89, 1981. 78. Radwanska E, Frankenberg J, Allen EI: Plasma progesterone levels in normal and abnormal early human pregnancy. Fertil Steril 30:398–402, 1978. 79. Baxendale PM, Jacobs HS, James VH: Plasma and salivary androstenedione and dihydrotestosterone in women with hyperandrogenism. Clin Endocrinol (Oxf) 18:447–457, 1983. 80. Hummer L, Nielsen MD, Christiansen C: An easy and reliable radioimmunoassay of serum androstenedione: Age-related normal values in 252 females aged 2 to 70 years. Scand J Clin Lab Invest 43:301–306, 1983. 81. Putz Z, et al: A selective radioimmunoassay of androstenedione in plasma and saliva. J Clin Chem Clin Biochem 20:761–764, 1982. 82. Boots LR, et al: Measurement of total serum testosterone levels using commercially available kits: High degree of between-kit variability. Fertil Steril 69:286–292, 1998. 83. Vlahos I, et al: An improved ultrafiltration method for determining free testosterone in serum. Clin Chem 28:2286–2291, 1982. 84. Gupta MK: Androgen assessment in hirsutism and alopecia. Cleve Clin J Med 57:292–297, 1990. 85. Van Uytfanghe K, et al: Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Chem 50:2101–2110, 2004. 86. Winters SJ, Kelley DE, Goodpaster B: The analog free testosterone assay: Are the results in men clinically useful? Clin Chem 44:2178–2182, 1998. 87. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672, 1999. 88. Mathur RS, et al: Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35:29–35, 1981. 89. Carter GD, et al: Investigation of hirsutism: Testosterone is not enough. Ann Clin Biochem 20:262–263, 1983. 90. Davies R, et al: Indirect measurement of bioavailable testosterone with the Bayer Immuno 1 system. Clin Chem 48:388–390, 2002. 91. Riad-Fahmy D, et al: Steroids in saliva for assessing endocrine function. Endocr Rev 3:367–395, 1982. 92. Vining RF, McGinley RA, Symons RG: Hormones in saliva: Mode of entry and consequent implications for clinical interpretation. Clin Chem 29:1752–1756, 1983. 93. Lequin RM, et al: Progesterone in saliva: Pitfalls and consequent implications for accuracy of the determination. Clin Chem 32:831–834, 1986. 94. Vining, RF, McGinley R, Rice BV. Saliva estriol measurements: An alternative to the assay of serum unconjugated estriol in assessing fetoplacental function. J Clin Endocrinol Metab 56:454–460, 1983. 95. Sufi SB, et al: Multicenter evaluation of assays for estradiol and progesterone in saliva. Clin Chem 31:101–103, 1985.
45
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 46
Section 1 Basic Science
46
96. Tallon DF, et al: Direct solid-phase enzyme immunoassay of progesterone in saliva. Clin Chem 30:1507–1511, 1984. 97. Tamate K, et al: Direct colorimetric monoclonal antibody enzyme immunoassay for estradiol-17β in saliva. Clin Chem 43:1159–1164, 1997. 98. Mottram JC: On the general effects of exposure to radium on metabolism and tumour growth in the rat and the special effects on the testis and pituitary. Q J Exp Physiol Cogn Med Sci 12:209–229, 1923. 99. McCullagh D: Dual endocrine activity of testes. Science 76:19, 1932. 100. Rivier J, et al: Purification and partial characterization of inhibin from porcine follicular fluid. Biochem Biophys Res Commun 133:120–127, 1985. 101. Robertson DM, et al: Isolation of a 31 kDa form of inhibin from bovine follicular fluid. Mol Cell Endocrinol 44:271–277, 1986. 102. Ling N, et al: Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature 321:779–782, 1986. 103. Ueno N, et al: Isolation and partial characterization of follistatin: A single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 84:8282–8286, 1987. 104. Mason AJ, Niall HD, Seeburg PH: Structure of two human ovarian inhibins. Biochem Biophys Res Commun 135:957–964, 1986. 105. Lockwood GM, et al: Circulating inhibins and activin A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in vitro fertilization-embryo transfer. Clin Endocrinol (Oxf) 45:741–748, 1996. 106. Welt C, et al: Activins, inhibins, and follistatins: From endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) 227:724–752, 2002. 107. Burger HG: Evidence for a negative feedback role of inhibin in follicle stimulating hormone regulation in women. Hum Reprod 8(Suppl 2):129–132, 1993. 108. de Jong FH, et al: Effects of factors from ovarian follicular fluid and Sertoli cell culture medium on in vivo and in vitro release of pituitary gonadotrophins in the rat: An evaluation of systems for the assay of inhibin. J Reprod Fertil Suppl 26:47–59, 1979. 109. Attardi B, et al: Rapid and profound suppression of messenger ribonucleic acid encoding follicle-stimulating hormone β by inhibin from primate Sertoli cells. Mol Endocrinol 3:280–287, 1989. 110. Attardi B, Winters SJ: Decay of follicle-stimulating hormone-β messenger RNA in the presence of transcriptional inhibitors and/or inhibin, activin, or follistatin. Mol Endocrinol 7:668–680, 1993. 111. Burger HG, et al: Aspects of current and future inhibin research. Reprod Fertil Dev 7:997–1002, 1995. 112. Ireland JL, et al: Alterations in amounts of different forms of inhibin during follicular atresia. Biol Reprod 50:1265–1276, 1994. 113. Sugino K, et al: Purification and characterization of high molecular weight forms of inhibin from bovine follicular fluid. Endocrinology 130:789–796, 1992. 114. Robertson DM, et al: Isolation of inhibin α-subunit precursor proteins from bovine follicular fluid. Endocrinology 125:2141–2149, 1989. 115. Sugino K, et al: Inhibin α-subunit monomer is present in bovine follicular fluid. Biochem Biophys Res Commun 159:1323–1329, 1989. 116. Robertson DM, et al: Inhibin forms in human plasma. J Endocrinol 144:261–269, 1995. 117. Schneyer AL, et al: Immunoreactive inhibin α-subunit in human serum: Implications for radioimmunoassay. J Clin Endocrinol Metab 70:1208–1212, 1990. 118. McConnell DS, et al: Development of a two-site solid-phase immunochemiluminescent assay for measurement of dimeric inhibin-A in human serum and other biological fluids. Clin Chem 42:1159–1167, 1996. 119. Groome NP, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401–1405, 1996. 120. Welt CK, et al: Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. J Clin Endocrinol Metab 86:2531–2537, 2001.
121. Corson SL, et al: Inhibin-B as a test of ovarian reserve for infertile women. Hum Reprod 14:2818–2821, 1999. 122. Eldar-Geva T, et al: Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone. J Clin Endocrinol Metab 85:607–613, 2000. 123. Burger HG, et al: Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 48:809–813, 1998. 124. Lockwood GM, et al: Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 83:1730–1735, 1998. 125. Norman RJ, et al: Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod 16:668–672, 2001. 126. Illingworth PJ, et al: Measurement of circulating inhibin forms during the establishment of pregnancy. J Clin Endocrinol Metab 81:1471–1475, 1996. 127. Lambert-Messerlian GM, et al: Second trimester levels of maternal serum inhibin A, total inhibin, α inhibin precursor, and activin in Down’s syndrome pregnancy. J Med Screen 3:58–62, 1996. 128. Aitken DA, et al: Dimeric inhibin A as a marker for Down’s syndrome in early pregnancy. NEJM 334:1231–1236, 1996. 129. Ciris M, et al: Inhibin α and β expression in ovarian stromal tumors and their histological equivalences. Acta Obstet Gynecol Scand 83:491–496, 2004. 130. Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B: Inhibin A levels in cyst fluid from epithelial ovarian tumors. Acta Obstet Gynecol Scand 83:501–503, 2004. 131. Anderson RA, et al: Inhibin B in seminal plasma: Testicular origin and relationship to spermatogenesis. Hum Reprod 13:920–926, 1998. 132. Nachtigall LB, et al: Inhibin B secretion in males with gonadotropinreleasing hormone (GnRH) deficiency before and during long-term GnRH replacement: Relationship to spontaneous puberty, testicular volume, and prior treatment—a clinical research center study. J Clin Endocrinol Metab 81:3520–3525, 1996. 133. Jensen TK, et al: Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and folliclestimulating hormone levels. A study of 349 Danish men. J Clin Endocrinol Metab 82:4059–4063, 1997. 134. von Eckardstein S, et al: Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples. J Clin Endocrinol Metab 84:2496–2501, 1999. 135. Peng C, et al: Activin and follistatin as local regulators in the human ovary. Biol Signals 5:81–89, 1996. 136. Hasegawa Y, et al: Induction of follicle stimulating hormone receptor by erythroid differentiation factor on rat granulosa cell. Biochem Biophys Res Commun 156:668–674, 1988. 137. Miro F, Smyth CD, Hillier SG: Development-related effects of recombinant activin on steroid synthesis in rat granulosa cells. Endocrinology 129:3388–3894, 1991. 138. Demura R, et al: Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab 76:1080–1082, 1993. 139. Santoro N, Adel T, Skurnick JH: Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 71:658–662, 1999. 140. Lockwood GM: The role of inhibin in polycystic ovary syndrome. Hum Fertil (Camb) 3:86–92, 2000. 141. Hillier SG, Miro F: Inhibin, activin, and follistatin. Potential roles in ovarian physiology. Ann NY Acad Sci 687:29–38, 1993. 142. Schneyer AL, et al: Follistatin–activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 137:240–247, 1996. 143. Sugino H, et al: Follistatin and its role as an activin-binding protein. J Med Invest 44:1–14, 1997.
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 47
Chapter 2 Ovarian Hormones 144. Hashimoto O, et al: A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 272:13835–13842, 1997. 145. Adashi EY, et al: Insulin-like growth factors: The ovarian connection. Hum Reprod 6:1213–1219, 1991. 146. Giudice LC: Insulin-like growth factors and ovarian follicular development. Endocr Rev 13:641–669, 1992. 147. Monget P, Bondy C. Importance of the IGF system in early folliculogenesis. Mol Cell Endocrinol 163:89–93, 2000. 148. Geisthovel F, et al: Expression of insulin-like growth factor-II (IGFII) messenger ribonucleic acid (mRNA), but not IGF-I mRNA, in human preovulatory granulosa cells. Hum Reprod 4:899–902, 1989. 149. el-Roeiy A, et al: Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab 77:1411–1418, 1993. 150. el-Roeiy A, et al: Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 78:1488–1496, 1994. 151. Carson RS, et al: Growth factors in ovarian function. J Reprod Fertil 85:735–746, 1989. 152. Westergaard LG, Andersen CY: Epidermal growth factor (EGF) in human preovulatory follicles. Hum Reprod 4:257–260, 1989. 153. Khan-Dawood FS: Human corpus luteum: Immunocytochemical localization of epidermal growth factor. Fertil Steril 47:916–919, 1987. 154. Ayyagari RR, Khan-Dawood FS: Human corpus luteum: Presence of epidermal growth factor receptors and binding characteristics. Am J Obstet Gynecol 156:942–946, 1987. 155. Kudlow JE, et al: Ovarian transforming growth factor-α gene expression: Immunohistochemical localization to the theca-interstitial cells. Endocrinology 121:1577–1579, 1987. 156. Lobb DK, et al: Transforming growth factor-alpha in the adult bovine ovary: identification in growing ovarian follicles. Biol Reprod 40(5):1087–1093, 1989. 157. Yeh J, Lee GY, Anderson E: Presence of transforming growth factor-α messenger ribonucleic acid (mRNA) and absence of epidermal growth factor mRNA in rat ovarian granulosa cells, and the effects of these factors on steroidogenesis in vitro. Biol Reprod 48:1071–1081, 1993. 158. Yeh J, Osathanondh R: Expression of messenger ribonucleic acids encoding for basic fibroblast growth factor (FGF) and alternatively spliced FGF receptor in human fetal ovary and uterus. J Clin Endocrinol Metab 77:1367–1371, 1993. 159. Di Blasio AM, et al: Expression of the genes encoding basic fibroblast growth factor and its receptor in human granulosa cells. Mol Cell Endocrinol 96:R7–R11, 1993. 160. McAllister JM, Byrd W, Simpson ER: The effects of growth factors and phorbol esters on steroid biosynthesis in isolated human theca interna and granulosa-lutein cells in long term culture. J Clin Endocrinol Metab 79:106–112, 1994. 161. Adashi EY, et al: Basic fibroblast growth factor as a regulator of ovarian granulosa cell differentiation: A novel nonmitogenic role. Mol Cell Endocrinol 55:7–14, 1988. 162. Koos R. Ovarian angiogenesis, in Adashi EY (ed). The Ovary. New York, Raven Press, 1993, pp 433–453. 163. Khan SA, et al: Human testis cytosol and ovarian follicular fluid contain high amounts of interleukin-1-like factor(s). Mol Cell Endocrinol 58:221–230, 1988. 164. Machelon V, et al: Interleukin-6 biosynthesis in human preovulatory follicles: Some of its potential roles at ovulation. J Clin Endocrinol Metab 79:633–642, 1994. 165. Piquette GN, et al: Gene regulation of interleukin-1 beta, interleukin-1 receptor type I, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells. Fertil Steril 62:760–770, 1994. 166. Buscher U, et al: Cytokines in the follicular fluid of stimulated and nonstimulated human ovaries: Is ovulation a suppressed inflammatory reaction? Hum Reprod 14:162–166, 1999.
167. Brannstrom M: Potential role of cytokines in ovarian physiology: The case of interleukin-1. In: Leung PCK (ed). The Ovary, 2nd ed. London, Elsevier, 2004, pp 261–271. 168. Salmassi A, et al: Interaction of interleukin-6 on human granulosa cell steroid secretion. J Endocrinol 170:471–478, 2001. 169. Roby KF, et al: Immunological evidence for a human ovarian tumor necrosis factor-α. J Clin Endocrinol Metab 71:1096–1102, 1990. 170. Roby KF, Terranova PF: Effects of tumor necrosis factor-α in vitro on steroidogenesis of healthy and atretic follicles of the rat: Theca as a target. Endocrinology 126:2711–2718, 1990. 171. Marshall JM: Adrenergic innervation of the female reproductive tract: Anatomy, physiology and pharmacology. Ergeb Physiol 62:6–67, 1970. 172. Stefenson A, et al: Comparative study of the autonomic innervation of the mammalian ovary, with particular regard to the follicular system. Cell Tissue Res 215:47–62, 1981. 173. Kawakami M, et al: Involvement of ovarian innervation in steroid secretion. Endocrinology 109:136–145, 1981. 174. Dyer CA, Erickson GF: Norepinephrine amplifies human chorionic gonadotropin-stimulated androgen biosynthesis by ovarian thecainterstitial cells. Endocrinology 116:1645–1652, 1985. 175. Knobil E, et al: Control of the rhesus monkey menstrual cycle: Permissive role of hypothalamic gonadotropin-releasing hormone. Science 207:1371–1373, 1980. 176. Belchetz PE, et al: Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631–633, 1978. 177. Silverman AJ, Jhamandas J, Renaud LP: Localization of luteinizing hormone-releasing hormone (LHRH) neurons that project to the median eminence. J Neurosci 7:2312–2319, 1987. 178. Wetsel WC, et al: Intrinsic pulsatile secretory activity of immortalized luteinizing hormone-releasing hormone-secreting neurons. Proc Natl Acad Sci USA 89:4149–4153, 1992. 179. Rasmussen DD, et al: Pulsatile gonadotropin-releasing hormone release from the human mediobasal hypothalamus in vitro: Opiate receptormediated suppression. Neuroendocrinology 49:150–156, 1989. 180. Haisenleder DJ, et al: Influence of gonadotropin-releasing hormone pulse amplitude, frequency, and treatment duration on the regulation of luteinizing hormone (LH) subunit messenger ribonucleic acids and LH secretion. Mol Endocrinol 2:338–343, 1988. 181. Katt JA, et al: The frequency of gonadotropin-releasing hormone stimulation determines the number of pituitary gonadotropin-releasing hormone receptors. Endocrinology 116:2113–2115, 1985. 182. Clayton RN, Catt KJ: Gonadotropin-releasing hormone receptors: Characterization, physiological regulation, and relationship to reproductive function. Endocr Rev 2:186–209, 1981. 183. Yasin M, et al: Gonadotropin-releasing hormone (GnRH) pulse pattern regulates GnRH receptor gene expression: Augmentation by estradiol. Endocrinology 136:1559–1564, 1995. 184. Weiss J, et al: Divergent responses of gonadotropin subunit messenger RNAs to continuous versus pulsatile gonadotropin-releasing hormone in vitro. Mol Endocrinol 4:557–564, 1990. 185. Nazian SJ, et al: Opioid inhibition of adrenergic and dopaminergic but not serotonergic stimulation of luteinizing hormone releasing hormone release from immortalized hypothalamic neurons. Mol Cell Neurosci 5:642–648, 1994. 186. Yen SS, et al: Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obstet Gynecol 152:485–493, 1985. 187. Seeburg PH, et al: The mammalian GnRH gene and its pivotal role in reproduction. Recent Prog Horm Res 43:69–98, 1987. 188. Seeburg PH, Adelman JP: Characterization of cDNA for precursor of human luteinizing hormone releasing hormone. Nature 311:666–668, 1984. 189. Ronnekleiv OK, et al: Combined immunohistochemistry for gonadotropin-releasing hormone (GnRH) and pro-GnRH, and in situ hybridization for GnRH messenger ribonucleic acid in rat brain. Mol Endocrinol 3:363–371, 1989. 190. Ackland JF, et al: Molecular forms of gonadotropin-releasing hormone associated peptide (GAP): Changes within the rat hypothalamus and
47
Ch02-A03309.qxp
1/26/07
10:19 AM
Page 48
Section 1 Basic Science
191.
192.
193. 194.
195. 196. 197.
198.
199.
200. 201.
202.
203.
204. 205.
206. 207. 208.
209.
210.
211.
212.
213.
48
214.
release from hypothalamic cells in vitro. Neuroendocrinology 48:376–386, 1988. Levine JE, Ramirez VD: Luteinizing hormone-releasing hormone release during the rat estrous cycle and after ovariectomy, as estimated with push-pull cannulae. Endocrinology 111:1439–1448, 1982. Neill JD, et al: Luteinizing hormone releasing hormone (LHRH) in pituitary stalk blood of rhesus monkeys: Relationship to level of LH release. Endocrinology 101:430–434, 1977. Reiter EO, et al: A role for endogenous estrogen in normal ovarian development in the neonatal rat. Endocrinology 91:1537–1539, 1972. Goldenberg RL, et al: Interaction of FSH and hCG on follicle development in the ovarian augmentation reaction. Endocrinology 91:533–536, 1972. Espey LH: Ovulation. In Knobil E, Neill JD (eds): The Physiology of Reproduction. New York, Raven Press, 1994, p 725. Hseuh AJW, Jones PBC, et al: Hormonal regulation of the differentiation of cultured granulosa cells. Endocr Rev 5:127, 1984. Hsueh, AJ, et al: Granulosa cells as hormone targets: the role of biologically active follicle-stimulating hormone in reproduction. Recent Prog Horm Res 45:209–277, 1989. Tilly JL, LaPolt PS, Hsueh AJ: Hormonal regulation of folliclestimulating hormone receptor messenger ribonucleic acid levels in cultured rat granulosa cells. Endocrinology 130:1296–1302, 1992. LaPolt PS, et al: Gonadotropin-induced up- and down-regulation of ovarian follicle-stimulating hormone (FSH) receptor gene expression in immature rats: Effects of pregnant mare’s serum gonadotropin, human chorionic gonadotropin, and recombinant FSH. Endocrinology 130:1289–1295, 1992. Pierce JG, Parsons TF: Glycoprotein hormones: Structure and function. Annu Rev Biochem 50:465–495, 1981. Huhtaniemi I: Functional consequences of mutations and polymorphisms in gonadotropin and gonadotropin receptor genes. In Leung PCK (ed): The Ovary, 2nd ed. London, Elselvier Academic Press, 2004, pp 55–78. Fiddes JC, Goodman HM: The gene encoding the common α subunit of the four human glycoprotein hormones. J Mol Appl Genet 1:3–18, 1981. Naylor SL, et al: Chromosome assignment of genes encoding the α and β subunits of glycoprotein hormones in man and mouse. Somatic Cell Genet 9:757–770, 1983. Policastro PF, et al: A map of the hCG β-LH β gene cluster. J Biol Chem 261:5907–5916, 1986. Watkins PC, et al: DNA sequence and regional assignment of the human follicle-stimulating hormone β-subunit gene to the short arm of human chromosome 11. DNA 6:205–212, 1987. Ryan RJ, et al: Structure–function relationships of gonadotropins. Recent Prog Horm Res 43:383–429, 1987. Ryan RJ, et al: The glycoprotein hormones: Recent studies of structure–function relationships. Faseb J 2:2661–2669, 1988. Chen HC, et al: Characterization and biological properties of chemically deglycosylated human chorionic gonadotropin. Role of carbohydrate moieties in adenylate cyclase activation. J Biol Chem 257:14446–14452, 1982. Themmen APN, Huhtaniemi IT: Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21:551–583, 2000. Weiss J, et al: Hypogonadism caused by a single amino acid substitution in the β subunit of luteinizing hormone. NEJM 326:179–183, 1992. Suganuma N, et al: Effects of the mutations (Trp8→Arg and Ile15→Thr) in human luteinizing hormone (LH) β-subunit on LH bioactivity in vitro and in vivo. Endocrinology 137:831–838, 1996. Matthews CH, et al: Primary amenorrhoea and infertility due to a mutation in the β-subunit of follicle-stimulating hormone. Nat Genet 5:83–86, 1993. Layman LC, et al: Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. NEJM 337:607–611, 1997. Lindstedt G, et al: Follitropin (FSH) deficiency in an infertile male due to FSHβ gene mutation. A syndrome of normal puberty and
215.
216. 217. 218.
219.
220.
221. 222. 223. 224.
225.
226.
227. 228.
229. 230. 231. 232.
233. 234.
235.
236.
237.
238.
virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med 36:663–665, 1998. Midgley AR Jr: Radioimmunoassay: A method for human chorionic gonadotropin and human luteinizing hormone. Endocrinology 79:10–18, 1966. Faiman C, Ryan RJ: Radioimmunoassay for human follicle stimulating hormone. J Clin Endocrinol Metab 27:444–447, 1967. Faiman C, Ryan RJ: Radioimmunoassay for human luteinizing hormone. Proc Soc Exp Biol Med 125:1130–1133, 1967. Halvorson LM: Gonadotropic hormones: Biosynthesis, secretion, receptors and action. In Yen SSC, Barberi RL (eds): Reproductive Endocrinology. Philadelphia, WB Saunders, 1999, p 89. Jaakkola T, et al: The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin s